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Camplyobacter is a high priority food-born pathogen, as a low number of organisms can cause human 
illness. Poultry are a major source of Camplyobacter as it routinely colonises the chicken gut, where it 
can reach high numbers. Without effective on-farm control, there is potential for Camplyobacter to 
persist throughout the supply chain to contaminate the final product. This project builds on previously 
funded AgriFutures that seeks to develop an environmentally friendly biological control based on 
bacteriophages commonly found in commercial broiler farms that infect and kill Camplyobacter.  
This project demonstrated that a two-log reduction in Camplyobacter levels was achieved in both on-
farm and in-vitro experiments and created a broad understanding of potential phage candidates to 
target for future commercialisation. This will benefit the entire chicken meat supply chain from 
breeder flocks to the consumer through exploitation of a naturally occurring predator-prey 
relationship between bacteriophages (viruses) that infect and kill Camplyobacter. A 2-log reduction in 
Camplyobacter levels could reduce human infections by 90%. 
This project identified phage candidates with commercialisation potential by demonstrating their 
effectiveness on-farm with low levels (7%) of resistance as well as reducing surface contamination of 
chicken carcass during processing. Genomic sequencing of these candidate phages revealed no 
recognisable antibiotic or pathogenicity related genes, confirming their suitability for biocontrol 
applications. Importantly, this project generated the required data to facilitate regulatory of approval 
of these phages for biocontrol of Campylobacter in the Australian chicken meat industry. 
This project was funded by AgriFutures Chicken Meat Program, with co-funding provided by the 
Queensland Department of Agriculture and Fisheries, as part of the Objective 1 of the Chicken Meat 
Program RD&E Plan 2019-22 Improving the Food Safety of Australian chicken meat.  
This report is an addition to AgriFutures Australia’s diverse range of research publications and it 
forms part of our growing profitability arena, which aims to enhance the profitability and 
sustainability of our levied rural industries. The AgriFutures Chicken Meat Program seeks to grow the 
long-term prosperity of the Australian chicken meat industry.  
Most of AgriFutures Australia’s publications are available for viewing, free downloading or 
purchasing online at: www.agrifutures.com.au.  
Mr John Smith 




About the Authors 
Dr Nalini Chinivasagam – Principal Research Scientist, Department of Agriculture and 
Fisheries, Queensland, is a food microbiologist worked in the area of food-safety for more than 30 
years and has extensive experience working with food-borne pathogens, including Salmonella and 
Campylobacter, in the poultry, pig and seafood industries. Dr Chinivasagam has led a series of 
RIRDC and Poultry CRC funded projects that all delivered practical focused outcomes that have 
proven of value to the poultry industry. The projects include “ A proof of concept study for 
Campylobacter control”, “assessing Campylobacter dynamics in free-range and other farming 
systems” (RIRDC), “Evaluating food-borne pathogen transfer associated with partial and full re-use 
litter” (RIRDC), “Aerobiology around broiler sheds” (RIRDC), “Re-use of litter across farming 
systems” (CRC), Survey of Australian litter, (RIRDC) and a research summary that encompasses 
most of the above work titled “Food Safety Pathogens, Litter, and Aerosols – Summarising a Decade 
(2004 – 2014) of Research”. Dr Chinivasagam has also carried out work on composting of layer 
industry waste (AECL) as well as work on piggery effluent, composts, aerosols (APL) and seafood 
quality (FRDC).  
Professor Ian Connerton - Chair of Food Safety, Head of Division of Microbiology, Brewing and 
Biotechnology, School of Biosciences, University of Nottingham is the 2 Sisters Food Group Chair 
of Food Safety at the University of Nottingham where he leads the Food Microbiology and Safety 
Section. He has been involved in molecular biology research for more than 30 years which includes 
food-borne zoonotic pathogens. He is also involved in research on the influence and therapeutic use of 
bacteriophage against zoonotic pathogens in the human food chain, the synthesis and delivery 
pathogen products to host cells and their molecular responses, host protein interactions, enzyme 
technology in partnership with agri-food industries as well as making use of the traditional benefits of 
biological catalysts (chemical specificity, mild reaction conditions and low environmental loads) for 
food application. He is actively engaged in research on Campylobacter phages and has extensively 
published in this area of work. These include isolation, classification and genomics of Campylobacter 
bacteriophages. He has several publications and contributes to strategies in controlling Campylobacter 
in poultry in the UK.   
Dr. Craig Billington - Science Leader in the Risk and Response Group at the Institute for 
Environmental Science and Research (ESR), Christchurch, New Zealand, has more than 19-
year’s research experience in food safety. The focus of his research has been the control of pathogenic 
and spoilage organisms in foods, food processing environments and on livestock. Craig is an 
internationally recognised expert in bacteriophages (phages; viruses of bacteria) and developed New 
Zealand’s first registered phage product, STECleanz®, released in 2014 for the control of E. coli 
O157. This product was approved for use in both New Zealand and the USA. Craig’s other interests 
include active packaging, new methods for pathogen detection, metagenomics, antimicrobial 
resistance, food traceability/authenticity and the development of pathogen mimics. He is a regular 
peer reviewer for international journals and overseas funding agencies. He is a founding member of 
the International Phage Research Centre based in Nanjing, currently sitting on its academic 







Sincere thanks to the following for making a study of this nature possible enabling the progression of 
a bio-control option to control Campylobacter in meat chickens using bacteriophages 
• Dr Margaret A MacKenzie, (former Group Executive General Manager Technical Services, 
Ingham’s Enterprises Pty Ltd.) for her support across studies including access to farms and plant  
• Ms Kelly McTavish, Ingham’s Enterprises Pty Ltd. for assistance with all farm work 
• The farmers who allowed free access and provided samples that supported both original studies 
that made the current study possible 
• Agrifutures for providing the funding for the current study that facilitated a detailed 
understanding of the phages via international collaboration with both the University of 
Nottingham and Environmental Sciences Research, New Zealand 
• The Poultry CRC for funding the “proof of concept study” that provided the opportunities to 
narrow down these phages to cocktail candidates that enabled the progression of two on-farm 
trials in collaboration with the University of Nottingham 
• The RIRDC (AgriFutures) for funding the “Campylobacter dynamics…” study that resulted in 
acquiring a large collection of Campylobacter bacteriophages to progress to phage biocontrol 






Foreword .................................................................................................................................. iii 
About the Authors ................................................................................................................... iv 
Acknowledgments .................................................................................................................... v 
Introduction ............................................................................................................................ 17 
Objectives................................................................................................................................ 20 
Chapter 1 ................................................................................................................................ 21 
Assessing the relationship between the phages and farm Campylobacter isolates via a 
series of logical and targeted laboratory based studies ...................................................... 21 
1.0 Background ................................................................................................................. 21 
1.2 Methodologies ............................................................................................................. 21 
1.2.1 Campylobacter isolation .................................................................................... 21 
1.2.2 Campylobacter phage isolation .......................................................................... 21 
1.2.3 Enrichment for phage isolation .......................................................................... 22 
1.2.4 Phage purification and plate lysate stocks ......................................................... 22 
1.2.5 Determination of lytic profiles ........................................................................... 23 
1.2.6 Examples of screening of host Campylobacter against phage (filtrate) ............. 23 
1.3 Results ......................................................................................................................... 24 
1.3.1 Increased numbers and diversity of Campylobacter isolates ............................. 24 
1.3.2 Isolation of phages by spot testing from NSW poultry environments using host 
Campylobacter jejuni PT14 ........................................................................................ 24 
1.3.3 Isolation of phages by spot testing from NSW poultry environments using 
Queensland hosts ........................................................................................................ 26 
1.3.4 Using Campylobacter jejuni PT14 host for farm PU filtrates ............................ 27 
1.3.5 Phage isolation from Farm PU caeca using both multi-host enrichment and 
isolation ....................................................................................................................... 28 
1.3.6 Phage isolation from Farm PT caeca using multi-host for both enrichment and 
isolation ....................................................................................................................... 29 
1.3.7 Phage isolation from Farm SH farm caeca following both multi-host enrichment 
and isolation ................................................................................................................ 30 
1.3.8 Summary of phages isolated to progress candidate selection ............................ 30 
1.4 Lytic profile for phages isolated .................................................................................. 31 
1.5 Narrowing down isolated phages from Queensland and NSW ................................... 32 
1.5.1 The Campylobacter screening panel .................................................................. 32 
1.5.2 The two step screening process .......................................................................... 33 
1.5.3 The final selection to be added to the candidate panel....................................... 34 
1.6 Summary, phage isolations and Campylobacter farm hosts ........................................ 34 
Chapter 2 ................................................................................................................................ 35 
Evaluate selected phages that may form a cocktail for their suitability based on simple 
lytic profiles and detailed molecular studies ........................................................................ 35 
2.1 Background ................................................................................................................. 35 
2.2 Methodologies adopted ............................................................................................... 35 
2.2.1 Phage genome size determination using PFGE ................................................. 35 
 
vii 
2.2.2 Restriction endonuclease digests ....................................................................... 35 
2.2.3 Phage morphology (Transmission Electron Microscopy) .................................. 36 
2.2.4 Genome sequencing ........................................................................................... 36 
2.3 Distribution of phages ................................................................................................. 37 
2.4 Analysis of farm screening data .................................................................................. 39 
2.4.1 Farm PG against – 19 member panel ................................................................. 39 
2.4.2 Farm AK against – 19 member panel ................................................................ 40 
2.4.3 Farm QN against – 19 member panel ................................................................ 41 
2.4.4 Farm SN against – 19 member panel ................................................................. 41 
2.4.5 Farm PT against – 19 member panel ................................................................. 42 
2.4.6 Farm CW against – 19 member panel ................................................................ 43 
2.4.7 Farm SH against – 19 member panel ................................................................. 44 
2.4.8 Farm RD against – 19 member panel................................................................. 45 
2.4.9 Farm DK against – 19 member panel ................................................................ 46 
2.4.10 Summary of farm screening data ..................................................................... 47 
2.5 Combined analysis – 19 member panel ....................................................................... 47 
2.6 Statistical analysis of candidate performance – 19 member panel .............................. 48 
2.7 Expanded set of Campylobacter isolates to assess 23-member panel phage cocktail 
panel performance ............................................................................................................. 49 
2.8 Campylobacter log reduction ...................................................................................... 51 
2.8.1 Methodology for log reduction .......................................................................... 51 
2.8.2 Results of log reduction studies ......................................................................... 52 
2.8.3 Outcome of the above trial and its relevance to in-vivo bird trials .................... 52 
2.9 Phage resistance – in vitro studies ............................................................................... 53 
2.9.1 Methodology adopted to evaluate in-vitro resistance – University of Nottingham 
methodology ............................................................................................................... 54 
2.9.2 Step 1 Comparison of growth media for isolating mutants ................................ 54 
2.9.3 Step 2 Growth studies ........................................................................................ 55 
2.9.4 Resistance testing ............................................................................................... 56 
2.9.5 Methodology adopted to evaluate in-vitro resistance – ESR methodology ....... 57 
2.9.6 Outcome ............................................................................................................. 57 
2.9.7 Evaluation of the outcomes of the screening: .................................................... 62 
2.9.8 Implications to future farm trials: ...................................................................... 62 
2.10 Overall summary – in-vitro log reductions and resistance studies ............................ 63 
2.11 Transmission Electron Microscopy (TEM) of phage images .................................... 66 
2.12 Phage genome sequences .......................................................................................... 67 
Chapter 3 ................................................................................................................................ 68 
Achieve a suitable log reduction of Campylobacter with the possible inclusion of either 
“active” or “passive” phage therapy strategy, which is assessed in-vitro (micro titre 
plates) ...................................................................................................................................... 68 
3.1 Background ................................................................................................................. 68 
3.2 Material and methods .................................................................................................. 69 
3.2.1 Passive therapy experiments .............................................................................. 69 
3.2.2 Active therapy experiments ............................................................................... 69 
3.3 Results ......................................................................................................................... 70 
3.3.1 Passive therapy................................................................................................... 70 
3.3.2 Active therapy .................................................................................................... 72 
3.4 Conclusion ................................................................................................................... 73 
 
viii 
Chapter 4 ................................................................................................................................ 74 
Based on the knowledge of all of the above develop a cocktail of phages ......................... 74 
4.0 Background ................................................................................................................. 74 
4.1 Preliminary work undertaken towards progressing cocktail formulation, Stage 1 ...... 74 
4.1.1. High throughput screen initial data ................................................................... 77 
4.1.2 Conclusion ......................................................................................................... 77 
4.2 ESR Campylobacter phage characterisation (stage 2 cocktail optimisation) .............. 78 
4.2.1 Modify existing phage kinetic methods to work with Campylobacter (A)........ 78 
4.2.2 Testing of Campylobacter phage cocktails – (B) ............................................... 79 
4.2.3 Testing of Campylobacter phage cocktails – combination of Australian and 
New Zealand isolated phages (C) ............................................................................... 82 
4.2.4 Overall trend analysis of phage cocktail performance (D) ................................ 84 
4.2.5 Conclusions ........................................................................................................ 85 
Chapter 5 ................................................................................................................................ 86 
Generate data to support necessary Australian regulatory frame work for the use of 
phages as bio-control agents by the Australian Poultry Industry – .................................. 86 
Provide the Australian Poultry Industry an efficacious environmentally friendly option 
to control Campylobacter that will benefit the poultry industry and the consumer. ........ 86 
5.0 Background ................................................................................................................. 86 
5.1 Conclusions from the “proof of concept trial” with consequences to application in 
Australia ............................................................................................................................ 87 
5.1.1 Campylobacter reduction in treated birds .......................................................... 87 
5.1.2 Co-contribution of inherent phages to log reduction ......................................... 87 
5.1.3 Phage resistance ................................................................................................. 88 
5.1.4 Absence of phage in processed carcass – prior chlorination .............................. 88 
5.2 Campylobacter phages only occur in litter only in the presence in the bird ............... 89 
5.3 Survival in water.......................................................................................................... 90 
5.4 Additional outcomes from current study ..................................................................... 91 
5.5 Future needs to address commercialisation ................................................................. 91 
Implications ............................................................................................................................ 93 
Recommendations .................................................................................................................. 94 
Appendix 1 Variation to project ........................................................................................... 95 
Appendix 2 Phage genome sequences................................................................................... 97 
PH 181 ............................................................................................................................... 97 
PH 1 ................................................................................................................................. 115 
PH 2 ................................................................................................................................. 134 
Appendix 3 – Abstract – conference presentation ............................................................ 155 





List of Tables 
Table 1 Initial and supporting studies to current study ......................................................................... 19 
Table 2 Sample preparation for enrichment .......................................................................................... 22 
Table 3 Campylobacter isolation from chicken ileum and caeca ......................................................... 24 
Table 4 Source of phage isolation from NSW samples (using Campylobacter jejuni PT14 as host) ... 25 
Table 5 Purified phages (and phage collection numbers) sourced from caeca and ileum from Farm PU
 .............................................................................................................................................................. 27 
Table 6 Isolation of phages from Farm PU caeca following “multi- host enrichment and isolation” .. 28 
Table 7 Isolation of phages from Farm PT caeca, following both multi-host enrichment and isolation
 .............................................................................................................................................................. 29 
Table 8 A breakdown of purified Campylobacter phages (with allocated phage numbers) and phage 
punches ................................................................................................................................................. 30 
Table 9 Details of phage final panel of 23 phage cocktail candidates .................................................. 38 
Table 10 Multiplicity of infections used for growth study ................................................................... 55 
Table 11 Resistance testing via spot test MOI 0.1 ................................................................................ 56 
Table 12 Description of phage cocktail candidates used ...................................................................... 57 
Table 13 Details of Campylobacter isolates and phages used and outcome following testing for 
resistance ............................................................................................................................................... 61 
Table 14 screening of isolates against phage concentrations 106 to 102 ............................................... 64 
Table 15 Overall summary of the assessment of in-vitro resistance ..................................................... 65 
Table 16 Mean decline in Campylobacter count (log10 CFU/cm2) on broiler chicken skin (n=10) ... 71 
Table 17 Replication parameters for phage on C. jejuni PT14 ............................................................. 72 
Table 18 Phage candidates .................................................................................................................... 79 
Table 19 Phage cocktail composition ................................................................................................... 79 
Table 20 Campylobacter testing panel .................................................................................................. 80 





List of Figures 
Figure 1 Examples of screening done (in triplicate) for a single culture .............................................. 23 
Figure 2 Screening of Queensland farm Campylobacter isolates against NSW farm filtrates ............. 26 
Figure 3 Lytic profile of a select group of Campylobacter phages screened against a select panel of 
Campylobacter isolates (as used to develop cocktail for the CRC phage study) .................................. 31 
Figure 4  Campylobacter screening panel (inclusive of isolates that demonstrated good lysis to NSW 
phages) .................................................................................................................................................. 32 
Figure 5 Lytic profile of phages against most sensitive isolates from original Campylobacter panel . 33 
Figure 6 Lytic profile of isolates screened against Campylobacter isolates most sensitive to NSW 
phages ................................................................................................................................................... 34 
Figure 7  Source of phages from Queensland farms ............................................................................. 37 
Figure 8 An example of a lytic profile of the 19 phage cocktail candidates’ against a single farm 
Campylobacter isolate (scored from 0 -3 based on activity) ................................................................ 39 
Figure 9 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm PG ......... 39 
Figure 10 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm AK 
(2012) .................................................................................................................................................... 40 
Figure 11 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm AK 
(2013) .................................................................................................................................................... 40 
Figure 12 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm QN ...... 41 
Figure 13 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm SN ....... 41 
Figure 14 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm PT (2012)
 .............................................................................................................................................................. 42 
Figure 15 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm PT (2013)
 .............................................................................................................................................................. 42 
Figure 16 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm CW 
(2012) .................................................................................................................................................... 43 
Figure 17 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm CW, score 
- 3 only (2013) ...................................................................................................................................... 43 
Figure 18 Activity of candidate phage panel (PH 1- 19) against selected isolates (all C. jejuni) from 
Farm SH, across sheds 1, 5, 9 and 14 (all isolates taken on the same day) .......................................... 44 
Figure 19 Activity of candidate phage panel (PH 1- 19) against selected isolates (all C. jejuni) from 
Farm RD, across sheds 5, 6 and 7 (all isolates taken on the same day) ................................................ 45 
Figure 20 Activity of candidate phage panel (PH 1- 19) against selected isolates (all C. jejuni) from 
Farm DK, across sheds 2, 3 and B (all isolates taken on the same day) ............................................... 46 
Figure 21 Combined analysis of 241 farm Campylobacter isolates against the 19 member phage 
cocktail candidate panel representing scores 0 - 3 based on their lytic profiles ................................... 47 
Figure 22 Analysis of the lytic scores (0 -3) of a group of C. jejuni and C. coli isolates (241) for their 
activity against the 19 member phage cocktail panel. ........................................................................... 48 
Figure 23 Number of isolates with a score of 3 against the panel of 23 members (and the number of 
farms that represent those isolates) ....................................................................................................... 49 
Figure 24 Number of Campylobacter isolates lysed (score 3) from the total logical selection of 
Campylobacter isolates (74 number) .................................................................................................... 50 
Figure 25 Growth studies demonstrating log reduction using C. jejuni PT14 and phage PH 19.......... 52 
Figure 26 Comparison of using HBA and CCDA as potential media for growth studies .................... 54 
Figure 27 Growth curves generated for selecting and isolating phage resistant mutants ..................... 55 
Figure 28 Illustration of a spotted isolate from MOI 0.1 ...................................................................... 56 
Figure 29 Category 1 - Bacterial growth inside lysed area (phage plaques) - indicative of resistant 
growth following lysis .......................................................................................................................... 58 
Figure 30 Category 2 – isolated bacterial colonies on a lysed lawn (compared to control) ................. 59 
Figure 31 Category 3: Grainy areas (no colonies) ................................................................................ 60 
Figure 32 Screening for resistance combination NC2975 – PH18 ....................................................... 65 
Figure 33 PH2 phage (head diameter 91 nm, tail 110 nm) ................................................................... 66 
Figure 34 PH19 phage (head 95 nm diameter, tail 112 nm) ................................................................. 66 
Figure 35 C. jejuni levels with log10 8 PH 13 phage ........................................................................... 70 
 
xi 
Figure 36 C. jejuni levels with log10 8 PH 19 phage ............................................................................. 70 
Figure 37 C. jejuni levels with log10 8 PH 2 phage ............................................................................... 71 
Figure 38 Initial testing of shipped frozen stocks ................................................................................. 74 
Figure 39 Full screening of Queensland phages ................................................................................... 75 
Figure 40 Narrowed down phages (with DAF, NC hosts) .................................................................... 75 
Figure 41 Testing 10 hosts with a 3 phage cocktail .............................................................................. 76 
Figure 42 outcome when BHI, 42oC, 10% CO2 – combination was used ............................................ 76 
Figure 43 outcome when No2, 42oC, CampyGen (MGS), 100 rpm was used ...................................... 76 
Figure 44 Lytic activity of cocktail on NC 2981 at 42oC in BHI .......................................................... 77 
Figure 45 Lytic activity of 3 phage Campylobacter cocktail on NC 3037 at 42oC in BHI .................. 77 
Figure 46 Comparison of growth of Campylobacter in different media - 10 ml tubes ......................... 78 
Figure 47 Comparison of growth of Campylobacter in different media – microtitre plate .................. 78 
Figure 48 Comparison of phage cocktails A-C ..................................................................................... 80 
Figure 49 Comparison of phage cocktails C-E ..................................................................................... 81 
Figure 50 Comparison of phage cocktails I-K ...................................................................................... 81 
Figure 51 Combined AU-NZ phage cocktails L-N ............................................................................... 82 
Figure 52 Combined AU-NZ phage cocktails P-S ................................................................................ 83 
Figure 53 Combined AU-NZ phage cocktails M and O compared to AU cocktail D .......................... 83 
Figure 54 Overall relative effectiveness of phage cocktails against Campylobacter strains ................ 84 
Figure 55 Overall relative susceptibility of Campylobacter strains to phage cocktails ........................ 85 
Figure 56 Levels of Campylobacter (CFU/g) and phages (PFU/g) in caeca of chickens from four 24 
farm ....................................................................................................................................................... 89 
Figure 57 Storage studies PH18 in tap water and SM buffer at room temperature and 4oC ................. 90 





Poultry are a major source of Campylobacter with the organism having no impact on the bird. 
Irrespective of this situation, the important single source of campylobacteriosis is considered to be 
broiler meat (European Food Safety Authority 2016). The reported number of cases of 
campylobacteriosis in Australia in 2015 was 22,573 (Communicable Disease Intelligence 2019). 
Studies have suggested that a reduction in Campylobacter levels by greater than 2-log10 units would 
contribute to the reduction of the public health risk by more than 90% (European Food Safety 
Authority 2011). Overseas models have suggested that bacteriophage treatment has the greatest 
potential of all known/potential methods to reduce Campylobacter levels in the live chicken (Havelaar 
et al. 2007).  
Campylobacter naturally colonises the chicken gut, where it can reach high numbers and potentially 
contaminate the marketed product. A low number of organisms can cause human illness. This study is 
exploring a biocontrol option using bacteriophages (phages) to reduce Campylobacter numbers in 
chickens. Bacteriophages are viruses that infect and kill the target bacteria. These specific, 
Campylobacter-killing phages occur naturally in farm chickens, where they are already in a 
‘predator–prey relationship’ with Campylobacter. The aim of this study is to better the outcome of 
this natural phenomenon. The study builds upon data from previous studies to progress the option of 
using Campylobacter bacteriophages to control Campylobacter levels in poultry. 
The report is targeted at the Australian Poultry Industry, those with a role of food-safety at an industry 
level and also have a regulatory role. 
Background 
Risk assessment studies predict that a reduction of Campylobacter levels on chicken meat can 
contribute to significantly less human illness (Rosenquist et al. 2006). A 1.0-log reduction in faecal 
count supported by a 1.0-log reduction in contamination of the exterior of chickens, during processing 
would result in a 90% reduction of human infections (Havelaar et al. 2007). Hence, the development 
and validation of on-farm control options for reducing Campylobacter levels by 1.0 to 2.0 logs can 
realistically result in a lowering of human infections from 50,000 to 5,000 cases per year. 
Australian on-farm studies have addressed Campylobacter levels in the caeca of the bird across litter 
practices, including free-range across four years (Chinivasagam et al. 2015, Chinivasagam et al. 2016) 
compared three litter practices (including re-use) over a two year period on two farms and across six 
sequential farming cycles (Chinivasagam et al. 2016). During this extensive study, Campylobacter 
levels varied little across litter practices and were high and in the range of log 8.0–9.0 CFU/g in caeca 
(Chinivasagam et al. 2016). These factors highlight the need for options to reduce Campylobacter 
levels on-farm. The bacteriophage – bacteria (Campylobacter) interaction is a natural and on-going 
interaction that occurs in the gut of the bird and are found in commercial broiler farm environments 
and the bird. A study assessing UK broiler chicken flock (n=205) have demonstrated a significant 
reduction (P < 0.001) of Campylobacter jejuni counts in caeca in the chickens with a presence of 
Campylobacter-specific bacteriophages, with mean counts of log10 5.1 CFU/g Vs 6.9 CFU/g in 
chickens in the absence of Campylobacter phages (Atterbury et al. 2005). The ability to harness this 
natural reaction offers opportunities for a natural bio-control option.  
A range of phage products are currently available against other food-borne pathogens such as 
Salmonella, Listeria and E. coli (EHEC), but there are none against Campylobacter, to date. The use 
of phages as bio-control agents (or processing aids) is fast gaining interest internationally, driven by 
consumer demands for natural alternatives. The bio-control of Campylobacter using phages is an 
environmentally friendly option, with potential for positive market acceptance and the delivery of a 
safer product to the consumer.   
 
xiii 
This study is built upon and continues from two prior studies on Campylobacter. A previous study on 
on-farm Campylobacter dynamics in 2011 – 2015, comparing four litter practices, (Chinivasagam et 
al. 2015) provided the opportunity to isolate Campylobacter phages from Australian farming 
environments, which formed a large collection. A second short 1.5 year study 2015 – 2016 
(Chinivasagam et al. 2017), via addressing a “proof of concept” provided the opportunity to create a 
panel of phages and carry-out two targeted trials on a small number of farmed birds, within the 
commercial farming framework. More specifically, this study created a broad understanding of the 
phage candidates to enable progression to the next stage. 
 
Aims/objectives 
• Assess the relationship between the phages and farm Campylobacter isolates via a series of 
logical and targeted laboratory-based studies 
• Evaluate selected phages that may form a cocktail for their suitability based on simple lytic 
profiles and detailed molecular studies 
• Achieve a suitable log reduction of Campylobacter with the possible inclusion of either “active” 
or “passive” phage therapy strategy, which is assessed in-vitro (micro titre plates) 
• Based on the knowledge of all the above develop a cocktail of phages  
• Carry out trials on farm raised birds (farm) and on processed carcasses (lab) (not undertaken due 
to variation) – Appendix 1 
• Generate data to support necessary Australian regulatory framework for the use of phages as bio-
control agents by the Australian Poultry Industry  
• Provide the Australian Poultry Industry an efficacious environmentally friendly option to control 
Campylobacter that will benefit the poultry industry and the consumer 
 
Methods used  
• A logical representation of Campylobacter hosts were used to expand a previously available 
Campylobacter phage candidate panel from 19 - 23 candidates. This included backyard and NSW 
source material (in addition to Queensland). This included both C. jejuni and C. coli  
• The activity of the candidate panel was assessed on a farm by farm basis based on previously 
available screening data and the overall candidate panel performance was statistically analysed 
• The expanded candidate panel was assessed against a broader group of Campylobacter isolates 
based on year sourced, origin on farm, litter practice and species 
• In-vitro log reduction studies were undertaken to assess efficiency of reduction afforded by host 
and phage via in-vitro studies and compared with on-farm reductions (former CRC study) 
• In-vitro resistance studies were undertaken to assess the potential development of resistance 
during application. The outcomes were compared with the outcomes from the CRC farm trial 
• Cocktail formulation was undertaken using both Australian and New Zealand Campylobacter 
hosts and the resultant outcomes were compared as to best performers 
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• Detailed molecular studies on a small number of candidate phages were undertaken to 
demonstrate the use of this approach as a pathway to intelligent cocktail formulation, address 
safety and required regulatory needs 
• Finally, all outcomes across the present and previous studies were summarised to demonstrate 
phage bio-control as a safe option that can be adopted by the industry within a framework of 
regulatory requirements as generated across all relevant studies  
 
Results/key findings 
• The original phage candidate panel was found to be optimum by analysing previously generated 
farm Campylobacter and phage data. An additional four candidates made up the panel to 23 
phages, which followed the use of diverse source samples for screening 
• Selected phage candidates (PH 16, 17, 18, 19) that showed better activity over others were 
apparent when analysing individual farm data (241 isolates across various farms) or when 
comparing species. The phage activity pattern against Campylobacter isolates present at the time 
naturally varied on the same farm when comparing sequential years (due to different populations). 
In general, the sheds across a single farm at a particular time had a similar Campylobacter – 
cocktail candidate activity  
• Lytic profiles using a panel of 19 phage cocktail candidates was carried across a random selection 
of Campylobacter (241) isolates sourced from 2012 – 2016 from 11 Queensland farms. The 
outcomes were statistically analysed and involved using 23 shed/year combinations which 
commonly had C. jejuni or C. coli on a single farm. For the initial screening of activity scores 
across farms, generalised linear mixed models (GLMM) were used with restricted maximum 
likelihood (REML) in GenStat (2016). From an overall perspective representative phage activity 
of phage cocktail candidates was observed across both C. jejuni and C. coli (241 farm isolates 
were analysed) 
• The 23-panel candidate panel was re-analysed against an expanded group of Campylobacter 
isolates (74) that considered year of isolation (2003 – 2016), litter practice, species and source of 
isolation. From an overall perspective phages PH 4, 5, 11, 16, 17, 18 and 19 dominated compared 
to the rest of the panel members. Generally, over five farms showed sensitivity to each individual 
phage cocktail candidate. The total number of Campylobacter isolates lysed by each phage (PH 1 
– 23) is also presented in showing an overall good representation of the 23 member phage cocktail 
candidate panel with phages PH 18 and 19 lysing around 50 Campylobacter isolates among the 
total of 74 Campylobacter isolates that formed this special group. The other lysed around 15 
Campylobacter isolates (and some over that number) 
• In-vitro studies using the universal international host C. jejuni PT 14 and PH 19, demonstrated a 
2-log reduction, this was compared with the log reductions achieved during the CRC farm trials  
• In-vitro studies using farm campylobacters and selected phage candidates demonstrated only a 7% 
resistance, which is comparable to published work. This aspect is discussed in detail along with 
the inconsistencies that prevail over extrapolating in-vitro resistance outcomes with what occurs 
within the bird. (i.e. the resistant form is non-motile and cannot prevail for long in the chicken gut 
the flagella is required for colonisation) 
• The application of phages isolated in this study can reduce the contamination of surface deposited 
campylobacters and those on chicken carcass surfaces at refrigeration temperatures by 1-2 log10 
CFU (passive therapy application) 
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• Phage isolated in the course of this project from farm sources in Australia are typical of group 3 
phage isolated from farm environments elsewhere in the world. Phage treatment of host bacteria 
at or over the phage proliferation threshold of 7 log10 CFU /ml achieved a reduction of 2 log10 
CFU/ml (active therapy application)  
• Genomic DNA sequences of phage isolated in Australia and included in the phage cocktails 
contain no recognisable antibiotic or pathogenicity related genes making them suitable for 
biocontrol applications  
• Demonstrated how detailed genomic analysis can provide a greater understanding of phage – 
Campylobacter binding (in addition to other factors assessed within the project) to enable 
intelligence-based refinement of the phage cocktails, which address both safety and efficiency. 
• Based on the knowledge of the above, phage cocktails were formulated in New Zealand where 
there exists previous expertise for the phages to move to commercialisation. Both Australian and 
New Zealand hosts were used for the purpose 
• A total of eleven cocktails were created using Australian phages. Some of the Australian phage 
cocktails were further tested by addition of New Zealand isolated phages to determine if there was 
any added benefit. The combined formulations performed the best and are active against AU and 
NZ Campylobacter isolates 
• Work to optimise phage cocktail formulations will be guided by this data 
• Finally, all outcomes across the present and previous studies were combined to address the final 
objective i.e. generate data necessary to support Australian regulatory frame work for bio-control 
and provide the Australian poultry industry an officious environmentally friendly option to 
control Campylobacter was addressed drawing the key elements across the previous Poultry CRC 
and current study 
• This included the demonstration of the achieved 2-log reduction (both on-farm and in-vitro), the 
identification of the future need to exploit the co-contribution of the natural phage population that 
became apparent during the Poultry CRC farm trials, the demonstration that resistance being not 
deterrent to phage bio-control, as demonstrated, which also can be managed by targeting the 
treatment period, the demonstration of phage free-carcasses based on the previously performed 
farm trials (for consumer acceptance), the existence of phages in litter only in the presence of 
phage positive birds when assessed across 2 –years and 24 farms (outcomes from a previous study 
on Campylobacter dynamics), and the optimum survival of phage candidates in tap water that 
ensures a simple and easy delivery option on-farm 
• This work has been presented as an invited presentation at the international conference “Tropical 
Agriculture” held in Brisbane 11th – 13th November 2019 (Appendix 3) 
 
Implications for relevant stakeholders 
Poultry are a major source of Campylobacter, although a zoonotic pathogen the organism has minimal 
impact on birds. Campylobacteriosis is the most common form of bacterial foodborne disease 
worldwide, and the single most important source of Campylobacter is broiler meat (European Food 
Safety Authority 2016). European studies indicate that on-farm interventions can exert effective 
control, with a 2.0 log reduction in faecal Campylobacter counts predicted to reduce human infections 
by 75% or a 1.0 log reduction in faecal count supported by a 1.0 log reduction in contamination of the 
exterior of processed chicken meat a 90% reduction of human infection (Havelaar et al. 2007). Hence, 
the development of an on-farm intervention to control Campylobacter levels by 1.0 to 2.0 logs is of 
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significance to industry and policymakers to bring about reductions in human infections from 50,000 
to 5,000 case per year.  
This study represents progress towards delivering a sustainable and low environmental impact option, 
which is likely to gain consumer acceptance for the control of one the key foodborne pathogens 
responsible for human illness. 
In summary: 
• Poultry are a major source of Campylobacter, with the most important single source of 
campylobacteriosis considered to be broiler meat  
• Modelling indicates that on-farm poultry interventions can be very effective in reducing human 
infections  
• Development and validation of on-farm control options for reducing Campylobacter levels by 1.0 
to 2.0 logs can realistically result in a 90% reduction of human infections 
• This study is progressing towards delivering an environmentally compatible option for the 
industry to achieve these reductions in Campylobacter on-farm 
 
Recommendations 
The research undertaken to date developing a Campylobacter bio-control solution for the poultry 
industry has been significantly advanced in this work. This work now needs to be capitalised upon to 
bring this closer to a commercial reality.  
Based on these outcomes there is need for future work with respect to the following: 
There is a need to continue sequence annotation for the rest of the cocktail candidates as demonstrated 
in this section 
Co-contribution of the natural phage – Campylobacter interaction which can be harnessed to enhance 
cocktail contribution  
There is need to formulate and address selection of cocktails from a scale up perspective to ensure a 
viable commercialisation pathway to market 
There is need to seek potential commercial entities to understand the way forward in providing a 






Poultry are a major source of Campylobacter with the organism having no impact on the bird. 
Irrespective of this situation, the important single source of campylobacteriosis is considered to be 
broiler meat (European Food Safety Authority 2016). Risk assessment studies predict that a reduction 
of Campylobacter levels on chicken meat can contribute to significantly less human illness 
(Rosenquist et al. 2006). European studies indicate that on-farm interventions can be very effective, 
i.e. a 2.0 log reduction in faecal Campylobacter counts will reduce human infections by 75%. 
Similarly, a 1.0 log reduction in faecal count supported by a 1.0 log reduction in contamination of the 
exterior of chickens, during processing would result in a 90% reduction of human infections 
(Havelaar et al. 2007). Hence, the development and validation of on-farm control options for reducing 
Campylobacter levels by 1.0 to 2.0 logs can realistically result in a lowering of human infections from 
50,000 to 5,000 case per year. 
There are limited options to control Campylobacter in farmed poultry. In the UK, due to both the 
disease and economic burden attributed to infectious intestinal diseases, Campylobacter (along with 
norovirus and rotavirus) have been classified as a high priority pathogen by the food standard 
agency’s food-borne disease strategy (Tam and O’Brien 2016). A recent review on the global 
epidemiology of Campylobacter, places focus on the poultry sector and highlights the need for a 
worldwide campaign to encourage interventions within the sector (Kaakoush et al. 2015). Overseas 
models have suggested that phage treatment has the greatest potential of all known/potential methods 
to reduce Campylobacter levels in the live chicken (Havelaar et al. 2007). The proposed study is a 
step in that direction and is designed to develop a biological process to control Campylobacter using 
phages. 
The use of phages as bio-control agents (or processing aids) is fast gaining interest internationally, 
driven by consumer demands for natural alternatives. The bio-control of Campylobacter using phages 
is an environmentally friendly option, with potential for positive market acceptance and the delivery 
of a safer product to the consumer. Though well used in Eastern Europe where there is a history of 
active research and use, the concerns on the use of phages elsewhere are mostly driven due to the 
scarcity of strong scientific evidence generated through fully controlled trials, supported by ethical 
standards of the West (Sillankorva et al. 2012). Further when compared to other treatments such as 
the used of electrolysed oxidizing water, phage therapy has been shown to have a higher cost benefit 
effect (Gellynck et al. 2008). The first phage-based pesticide on the market was against Erwinia 
amylovora, which causes fire blight in apples (Meczker et al. 2014). The Environmental Protection 
Agency (in 2002) approved the use of phages to control bacterial spot (rot) of tomatoes and peppers 
i.e. plant pathogens Xanthomonas campestris subsp vesicatoria and Pseudomonas syringae 
(Goodridge and Bisha 2011). The United States Food and Drug Administration (USDA) has 
supported the use of E. coli 0157 and Salmonella based “hide sprays” on cattle prior to slaughter plus 
approved products are available for red-meat parts and trims (Goodridge and Bisha 2011). Phage-
preparations are also being used on ‘post-harvest’ product with Food and Drug Administration, USA 
(FDA) and USDA approval against Listeria (Goodridge and Bisha 2011).  
Phages have potential to reduce on-farm Campylobacter in poultry (Connerton et al. 2011). The phage 
– bacteria (Campylobacter) interaction is a natural and on-going interaction that occurs in the gut of 
the bird. Phages isolated from commercial broiler house environments between successive flocks have 
shown relationships/variations across successive flocks reflecting the diversity that occurs across 
poultry farming environments, (Connerton et al. 2004). Phages have also been isolated across 
Australian broiler farming environments (Estella et al. 2015). A study assessing UK broiler chicken 
flock (n=205) have demonstrated a significant reduction (P < 0.001) of Campylobacter jejuni counts 
in caeca in the chickens with a presence of Campylobacter-specific phages, with mean counts of log10 
5.1 CFU/g Vs 6.9 CFU/g in chickens in the absence of Campylobacter Phages (Atterbury et al. 2005). 
The ability to harness this natural reaction offers opportunities for a natural bio-control option. Studies 
have also demonstrated that Campylobacter levels decreased between 0.5 and 5 log CFU/g in the 
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caeca of C. jejuni-colonised birds compared to untreated birds over 5-days, with such reductions 
depending on the phage-Campylobacter combinations, doses administered and post treatment time, 
(Carrillo et al. 2005).  
A range of products are already available against food-safety pathogens. The availability of such 
products has demonstrated the economic viability of phage-based options with no limitations in 
uptake mainly for food-safety organism such as Listeria, Salmonella and Escherichia coli 0157. 
Commercial phage products are already marketed against these organisms by various companies in 
Europe and USA. These phage products are largely marketed as “processing aids”. Listed below are 
some examples of products from selected companies. New Zealand has commercialised the countries 
first phage product against EHEC to be used for cattle hides (Dr. Billington, personal 
communication). 
Listeria - Listex P100 produced by Micreos (Netherlands). This is the first phage product to be 
permitted to be used in Australasia as a food processing aid and has Food Standards Australia New 
Zealand (FSANZ) approval to be used in Australia (http://www.foodproductiondaily.com/Safety-
Regulation/Listeria-killing-phage-product-gets-FSANZ-approval). This product has organic and halal 
certification. 
Listeria, (Listshield), E. coli 0157 (Ecoshield) and Salmonella (Salmofresh) are all products registered 
for use by “Intralytix (http://www.intralytix.com/Intral_Food.htm. 
Salmonella (Salmonellex) is approved for use by the FDA and USDA as a GRAS (Generally 
Recognised As Safe), and produced by Micreos. This company is going further to seek approval by 
the Organic Material Review Institute (OMRI) to enable the product to be used in organic products 
These few examples of companies are listed here to reiterate the fact that international companies are 
actively producing and marketing products. This activity in the market clearly indicates there is 
uptake and active use of phage-based products due to the nature of such products and their ability to 
control food-safety pathogens. To date, there are no commercial phage products against 
Campylobacter. Australian on-farm studies (Chinivasagam et al. 2016, Chinivasagam et al. 2015) 
have addressed Campylobacter levels in the caeca of the bird, from varying litter practices including 
free-range. The 2016 study (Chinivasagam et al. 2016) compared three litter practices (including re-
use) over a two-year period on two farms and across six sequential farming cycles. During this 
extensive study, Campylobacter levels varied little across litter practices and were high and in the 
range of log 8.0–9.0 CFU/g in caeca (Chinivasagam et al. 2016). These factors point to the need for 
an option to reduce Campylobacter levels on-farm.   
The current study is built upon and continues from two prior studies on Campylobacter 
(Chinivasagam et al. 2015, Chinivasagam et al. 2017). A previous study (Chinivasagam et al. 2015) 
on on-farm Campylobacter dynamics (when comparing four litter practices) provided the opportunity 
isolate Campylobacter phages from Australian farming environments, which formed a large 
collection. A second short 1.5 year study (Chinivasagam 2017, Chinivasagam 2020), via addressing a 
“proof of concept” provided the opportunity to create a panel of phages and carry-out two targeted 
trials on a small number of farmed birds, within the commercial farming framework. The sequence 
and previous contributions from which the current study follows are presented in Table 1. 
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Table 1 Initial and supporting studies to current study 
 Study details Key contributions of relevant studies 
1 RIRDC (Agrifutures) 
“Campylobacter dynamics in free-
range and conventional farming 
systems”.  2011-2014; - PRJ-006238 
(Chinivasagam et al. 2015) – 3 years 
(1) A collection of 500 phages isolated across diverse broiler 
farming environments (and litter practices) in Queensland 
over a two-year period 
(2) An understanding phage isolation pattern across farms 
(including caeca and litter) that supports necessary Australian 
regulatory framework for the use of phages as bio-control 
agents. 
(3) Invited peer review publication in progress 
2 Poultry CRC  
“A “proof of concept” study to control 
Campylobacter using phages”. Sub-
Project No: 3.1.6; - 2015 -2016; 




University of Nottingham, UK 
(1) A well screened 19-member phage cocktail candidate 
panel for cocktail preparation, following extensive screening 
against a range of farm Campylobacter isolates 
(2) Targeted farm trial based on: that a week before final 
pick-up (time of treatment) (a) the flock be phage negative 
(b) have a high Campylobacter levels (c) be sensitive to two 
or more candidates 
(3) Testing was done on-farm, during transport and at the 
plant 
(4) On Farm A, a 2-log reduction was achieved on-farm 
(5) On Farm B, log reductions were achieved in both test and 
controls but a phage inherent in the system interfered with 
assessing the cocktail phage outcome 
(6) This study provided the main candidate panel, 
demonstrated log reduction and the need for future work on 
including the co-contribution of inherent phages to cocktails 
(not addressed in the current study) 
(7) Publication and presentation: Chinivasagam, H.N., 
Estella, W., Maddock, L., Mayer, D.G., Weyand, C., 
Connerton, P.L. and Connerton, I.F. (2020) Bacteriophages to 
Control Campylobacter in Commercially Farmed Broiler 
Chickens, in Australia. Frontiers in Microbiology 11. 
https://www.frontiersin.org/article/10.3389/fmicb.2020.00632 
3 Agrifutures  
Concept to control ….(Chinivasagam et 
al. 2020, current study),  
PRJ-010208; - 2016 - 2019 
 
Collaboration:  
(1) University of Nottingham, UK 
(2) Environmental Sciences 
Research, NZ 
(1) Analysed previously unanalysed CRC data to have a 
better understanding of cocktail performance 
(2) Increased the panel form 19 – 23 candidates 
(3) Created a detailed understanding of candidate phages 
(including demonstration of selected cocktail performance) to 
supports necessary Australian regulatory framework for the 
use of phages as bio-control agents. 
(4) Peer review publications, planned 
 
Thus, the relevant outcomes of previous studies have been combined to address selected objectives of 
the current study as is relevant. 
More specifically the current study progressed to expand and analyse the candidate panel for 
performance against farm campylobacters, undertook in-vitro log reduction and resistance studies 
include cocktail formulation and analysis against collective set of isolates to address performance and 
detailed molecular studies to gain an overall perspective. The outcomes were targeted at delivering a 
safe biocontrol option that has a marketable potential and backed by data to advance regulatory 
support. All these options leading to providing an environmentally friendly biocontrol option to 




• Assess the relationship between the phages and farm Campylobacter isolates via a series of 
logical and targeted laboratory-based studies 
• Evaluate selected phages that may form a cocktail for their suitability based on simple lytic 
profiles and detailed molecular studies 
• Achieve a suitable log reduction of Campylobacter with the possible inclusion of either “active” 
or “passive” phage therapy strategy, which is assessed in-vitro (micro titre plates) 
• Based on the knowledge of all the above develop a cocktail of phages  
• Carryout trials on farm raised birds (farm) and on processed carcasses (lab) (not undertaken due 
to variation) – Appendix 1 
• Generate data to support necessary Australian regulatory framework for the use of phages as bio-
control agents by the Australian Poultry Industry  
• Provide the Australian Poultry Industry an efficacious environmentally friendly option to control 
Campylobacter that will benefit the poultry industry and the consumer.  
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Chapter 1: Assessing the relationship 
between the phages and farm 
Campylobacter isolates via a series of 
logical and targeted laboratory based 
studies  
1.0 Background 
This section reports the methodologies adopted for phage isolation and diversification using farm 
samples and farm Campylobacter hosts. Additional phages were isolated to expand the original CRC 
candidate panel of 19 candidates. Since that panel was created for the purpose of fulfilling the 
requirements of the farm trials required for the proof of concept and the overall study period was short 
(1.5 year) time spent on the panel work was limited. This section of work used previously unused 
approaches to try to diversify phages that may have potential to be included in the original panel. For 
this purpose the following were undertaken; 
• Use of NSW samples to diversify the source of phage isolation 
• Sourcing of new Campylobacter (2016) isolates from six Queensland farms to use additional 
screening and use of samples from those farms  
• Expanding candidate panel based on outcomes  
 
1.2 Methodologies 
This section reports phage isolation (with the inclusion of enrichment), phage purification and phage 
spotting technique used for screening of isolates.  
 
1.2.1 Campylobacter isolation  
This is described in (Chinivasagam et al. 2016). 
 
1.2.2 Campylobacter phage isolation 
This following was carried as per methodology of Atterbury et al. (2003) with slight modifications to 
the original methodology. The methodologies for Campylobacter phage isolation (and purification) 
was also based on the published methodologies of Frost et al. (1999), El-Shibiny et al. (2005) and 
Sambrook et al. (1989). 
Ten grams of litter and caeca were weighed into ninety millilitre of SM buffer then stomached using a 
stomacher for one minute for caeca. Litter and soil samples were shaken for 15 minutes. Following 
this initial preparation all samples were gently shaken at 4oC overnight on a platform shaker. The 
samples were distributed into micro centrifuge tubes and centrifuged at 15,000g for 5 minutes, chilled 
for 5 minutes then centrifuge again at 15,000g for 5 minutes. The supernatant was removed to a new 
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tube and filtered using membrane filtration with a 0.22 micrometre pore size filter (low DNA 
binding). The levels of phage were enumerated using direct plating. For this a mixture of 100 µl 
sample plus 200 µl of 108 cfu/ml C. jejuni PT 14 host was incubated aerobically at 42oC for 30 min. 
This mixture was then added to 5 ml of 0.6% overlay agar, which was poured on top of a 1% agar 
base plate and allowed to settle for around 30 minutes. The plates were incubated at 42oC for 24 hours 
under micro anaerobic condition. Plaques were observed and counted. A representative single plaque 
was punched and stored in SM buffer for purification. 
 
1.2.3 Enrichment for phage isolation 
Hosts used were the universal international strain C. jejuni PT14 QC Strain (NC3163) or strain 
/strains relevant to this study (i.e. hosts from farms PU, PT and SH) based on the three farms that 
were part of this work. 
The relevant samples (caeca, litter or soil) were prepared for enrichment and sampled as listed.in 
Table 2. 
Table 2 Sample preparation for enrichment 
Sample Weight/Volume Preston Broth Supplemented with 
Mg2+, Ca2+ 
Caeca 10g 40 ml     (1:4) 
Litter 17.5g 105 ml   (1:6) 
Soil 35g 105 ml   (1:3) 
 
The samples were mixed for 60 seconds in a stomacher and 100 µl of each culture of each overnight 
culture was added and incubated at 42oC under micro aerobic conditions overnight. Following 
incubation 10ml of the supernatant was dispensed into 15 ml centrifuge tubes and centrifuged at 
4,000xg for 10 minutes. The supernatant was centrifuged at 13,000xg for 5 minutes twice after brief 
storage on ice and filtered through a 0.22 µm membrane filter, following which it was tested for 
phages.  
 
1.2.4 Phage purification and plate lysate stocks 
This was carried out based on the method of Sambrook et al. (1989). The selected phage was grown at 
an appropriate dilution after which a single selected plaque was punched and plated again. This was 
carried two more times leading to a plaque being purified three times to ensure purity. After this the 
purified phage was grown as a confluent plate by adding 100ul of serial dilution of pure phage into 
200ul PT14 incubate aerobically at 42oC for 30 min, then mixed with 5 ml of 0.5% overlay agar and 
poured on top of a 1% agar base plate. Incubation was carried out at 42oC for 24 hours under micro 
anaerobic condition. From this plating, a suitable plate was selected where the plaques just touched 
one another with bacterial growth webbing that marked the junction between adjacent plaques. The 
top agar layer was gently crushed using a sterile spreader to which 5 ml SM buffer was added and 
allowed to stand for 30 min. Then the agar was scraped with liquid into sterile centrifuge tube. The 
base plate was washed a few times with SM buffer and all the liquid was collected into a tube. The 
mixture was centrifuge at 15,000g for 5 minutes at 4oC. The supernatant was recovered by filtering 
using a 0.22µm pore size filter membrane. The phage stock was stored in SM buffer with 25% 
glycerol at 4oC and -80oC. 
 
23 
1.2.5 Determination of lytic profiles 
The determination of Campylobacter host range was carried out as per Connerton and Timms (2015). 
Briefly Campylobacter overlays were prepared as previously described and the relevant phage was 
spotted in 10 µl aliquots (at log 107 PFU/ml) on the surface of the overlay. The well dried plates were 
incubated overnight at 42oC and scored as 0 = no lysis; 1 = poor lysis; 2 = medium lysis; 3 = very 
good lysis. The activity of a phage against a particular strain was assessed in this manner. 
 
1.2.6 Examples of screening of host Campylobacter against phage (filtrate) 
The following is an example of screening isolate NC 4096 against 16 phages (done in triplicate). The 
clear areas on the host depict areas of lysis, which were also scored as previously described. 
 





1.3 Results  
The sequential steps that resulted in increasing the original candidate panel of 19 members to 23 
members to diversify phage isolation is described. This was largely based on adopting multi-culture 
enrichment. This is followed by describing the “Campylobacter panel” created previously to 
accelerate screening. The original Campylobacter screening panel was expanded with new 
Campylobacter isolates (as a separate group) that were sensitive to NSW phages. Finally, four new 
candidates were added to the original panel of 19 to form a 23-member phage candidate panel. This 
panel was a focus of the rest of the reported studies. 
 
1.3.1 Increased numbers and diversity of Campylobacter isolates 
A total of 162 Campylobacter isolates (Table 3) that were isolated in 2016 (during the CRC study) 
were included to create hosts diversity. They were sourced across six farms. The farms were Farms R 
(sampled twice), SN, PU, CH and GH with isolates coming across multiple sheds during a single 
cycle, Table 3. The majority were C. jejuni with the rest C. coli as is normally seen on-farm. 
Table 3 Campylobacter isolation from chicken ileum and caeca 
Date Farm No. of culture Culture No. Strain 
12/07/2016 Farm R Shed 5 5 NC4059-4063 C. coli 
12/07/2016 Farm R Shed 6 5 NC4064-4068 C. coli 
12/07/2016 Farm R Shed 7 5 NC4069-4073 C. coli 
12/07/2016 Farm SN Shed 1 5 NC4074-4079 C. jejuni 
12/07/2016 Farm SN Shed 5 5 NC4080-4083 C. jejuni 
12/07/2016 Farm SN Shed 9 5 NC4084-4088 C. jejuni 
12/07/2016 Farm SN Shed 14 5 NC4089-4093 C. jejuni 
4/09/2016 Farm PU Shed 1 8 NC4094-4101 C. jejuni 
4/09/2016 Farm PU Shed 3 14 NC4102-4115 C. jejuni 
4/09/2016 Farm PU Shed 5 10 NC4116-4125 C. jejuni 
7/09/2016 Farm P Shed 1 15 NC4126-4140 C. jejuni 
31/10/2016 Farm R Shed 1 10 NC4144-4153 C. jejuni 
31/10/2016 Farm R Shed 2 10 NC4154-4163 C. jejuni 
31/10/2016 Farm R Shed 7 10 NC4164-4173 C. jejuni 
31/10/2016 Farm CH shed 1 10 NC4174-4183 C. jejuni 
31/10/2016 Farm CH shed 2 10 NC4184-4193 C. jejuni 
31/10/2016 Farm GH Shed 3 10 NC4194-4203 C. jejuni 
31/10/2016 Farm GH Shed 7 10 NC4204-4213 C. jejuni 
31/10/2016 Farm GH Shed 8 10 NC4214-4223 C. jejuni 
 
1.3.2 Isolation of phages by spot testing from NSW poultry environments using 
host Campylobacter jejuni PT14  
A diverse set of samples, that included both backyard and commercial chicken farming facilities were 
sourced from Armidale and Northern NSW. Table 3 presents the diverse environments sampled, 
which for the first time included backyard chickens with the aim for phage diversity. However, 
phages were only isolated from environment C (i.e. C1, C2, C3, C4, C5 and C6) and B which were 
commercial free-range broiler farms. Eighteen phages (PH761-778) were isolated using the 
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Campylobacter PT14 as host (the commonly used host to isolate phages). These phages were isolated 
from the caeca. It is also worth noting that the non-commercial farm environments (backyard farming) 
all litter and soil along with the single farm environment B soil did not yield phages (in comparison 
for caeca, commercial farm) which was positive for Campylobacter phages. 
 
Table 4 Source of phage isolation from NSW samples (using Campylobacter jejuni PT14 as host) 
Code Source Type Phage +/- 
B1 back yard hens location A Shed litter - 
B2 back yard hens location A Shed soil - 
B3 back yard hens location A Shed litter - 
B4 back yard hens location A Hen faeces - 
B5 back yard hens location B Outer shed litter - 
B6 back yard hens location B Outer shed soil 15cm deep - 
B7 back yard hens location B Inner shed dry litter - 
B8 back yard hens location B Inner shed dry litter - 
B9 back yard hens location B Hen faeces + soil - 
B10 back yard hens location B Outdoor Moist soil - 
B11 back yard hens location B Back hen shed bedding litter - 
B12 back yard hens location B Litter composite - 
B13 back yard hens location B Litter composite - 
B14 back yard hens location A Soil inner shed 15cm - 
B15 back yard hens location A Surface litter outer shed - 
B16 back yard hens location A Outdoor 15cm deep - 
B17 back yard hens location A Surface litter inner shed - 
B30 free range hens location C1 Soil inner shed 15cm - 
B31 free range hens location C1 Soil inner shed 15cm - 
B32 broiler shed location D Soil outside shed 15cm - 
B33 broiler shed location D Soil outside shed 15cm - 
B34 broiler farm location E Soil outside shed 15cm - 
B35 broiler farm location E Soil outside shed 15cm - 
B36 broiler facility location F  Caecum samples - 
C1 free range hens location C2 Caecum samples + 
C2 free range hens location C3 Caecum samples + 
C3 free range hens location C4 Caecum samples + 
C4 free range hens location C5 Caecum samples + 
C5 free range hens location C6 Caecum samples + 





1.3.3 Isolation of phages by spot testing from NSW poultry environments using 
Queensland hosts  
A total of 79 Campylobacter farm isolates (from Table 3) were used to screen 42 NSW phage filtrates 
by spot testing as this method enables the easy screening to a larger number of samples. A total of 95 
phages were isolated. Figure 2 illustrates the outcome of the extensive screening. The “shaded areas” 
represent phage positive isolations for a given Campylobacter isolate (left) and the various NSW 
sample filtrates (top). In summary, higher numbers of phages were isolated from the NSW samples 
using Queensland farm hosts rather than the routinely used international strain, Campylobacter jejuni 
PT14 as host (as reported in section 1.3.2).   
 
 
Figure 2 Screening of Queensland farm Campylobacter isolates against NSW farm filtrates 
In summary, a total of 101 phages were isolated using both the above approaches (i.e. using either 
Campylobacter jejuni PT14 (international host) or Queensland farm hosts from the diverse range of 
NSW samples. This approach ensured phage diversity with potential to enhance the candidate panel. 
  
Positive phage isolation 
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1.3.4 Using Campylobacter jejuni PT14 host for farm PU filtrates 
Farm PU was a Queensland farm sampled in 2016 and the approach adopted for Farm PU is reported 
in this section. 
Both caeca and ileum samples sourced from three sheds were used. Campylobacter jejuni PT14 was 
used as host. A total of 37 phages (PH779 - 815) were isolated, Table 5. 
Table 5 Purified phages (and phage collection numbers) sourced from caeca and ileum from Farm PU 
Date  
Phage 
no. Sample Date  
Phage 
no. Sample 
4.10.16 779 caeca shed 5 4.10.16 798 Ileum shed 5 
4.10.16 780 caeca shed 5 4.10.16 799 Ileum shed 5 
4.10.16 781 caeca shed 5 4.10.16 800 Ileum shed 5 
4.10.16 782 caeca shed 5 4.10.16 801 Ileum shed 5 
4.10.16 783 caeca shed 5 4.10.16 802 Ileum shed 5 
4.10.16 784 caeca shed 5 4.10.16 803 Ileum shed 5 
4.10.16 785 caeca shed 5 4.10.16 804 caeca shed 1 
4.10.16 786 caeca shed 5 4.10.16 805 caeca shed 1 
4.10.16 787 caeca shed 5 4.10.16 806 caeca shed 3 
4.10.16 788 caeca shed 5 4.10.16 807 caeca shed 3 
4.10.16 789 caeca shed 5 4.10.16 808 caeca shed 5 
4.10.16 790 caeca shed 5 4.10.16 809 caeca shed 5 
4.10.16 791 caeca shed 5 4.10.16 810 Ileum shed 1 
4.10.16 792 Ileum shed 5 4.10.16 811 Ileum shed 1 
4.10.16 793 Ileum shed 5 4.10.16 812 Ileum shed 3 
4.10.16 794 Ileum shed 5 4.10.16 813 Ileum shed 3 
4.10.16 795 Ileum shed 5 4.10.16 814 Ileum shed 5 
4.10.16 796 Ileum shed 5 4.10.16 815 Ileum shed 5 





1.3.5 Phage isolation from Farm PU caeca using both multi-host enrichment and 
isolation 
Farm PU caeca was used as source sample. Multi-host enrichment was adopted here. In this instance 
Farm PU isolates, NC 4094 – NC 4125 were used together in the enrichment process following which 
testing was done on individual Farm PU isolates, NC 4094 – NC 4125, Table 6. 
 
Table 6 Isolation of phages from Farm PU caeca following “multi- host enrichment and isolation” 
Isolate 
No Shed 
Caeca Shed 1 
(C1) 




NC4094 1 - - - 
NC4095 1 - - +++ 
NC4096 1 - - +++ 
NC4097 1 - - - 
NC4098 1 - - +++ 
NC4099 1 - - - 
NC4100 1 - - +++ 
NC4101 1 - - - 
NC4102 3 - - - 
NC4103 3 - +++ +++ 
NC4104 3 - - +++ 
NC4105 3 - - - 
NC4106 3 +++ +++ +++ 
NC4107 3 - - +++ 
NC4108 3 +++ +++ +++ 
NC4109 3 +++ +++ +++ 
NC4110 3 +++ - - 
NC4111 3 +++ +++ +++ 
NC4112 3 +++ +++ +++ 
NC4113 3 +++ +++ +++ 
NC4114 3 +++ +++ +++ 
NC4115 3 +++ +++ +++ 
NC4116 5 +++ +++ +++ 
NC4117 5 +++ +++ +++ 
NC4118 5 - - - 
NC4119 5 +++ +++ +++ 
NC4120 5 - - - 
NC4121 5 +++ +++ +++ 
NC4122 5 +++ +++ +++ 
NC4123 5 +++ +++ +++ 
NC4124 5 +++ +++ +++ 





1.3.6 Phage isolation from Farm PT caeca using multi-host for both enrichment 
and isolation  
In this instance phages were isolated from Farm PT caeca using multi-host enrichment with Farm PU 
isolates NC 4094 – NC 4125 plus Farm PT isolates NC 4126 – 4140. Following enrichment testing 
was carried out on individual host isolates from Farm PU (NC4094 – NC 4125) and individual host 
isolates form Farm PT (NC 4126 – 4140), Table 7. 
 
Table 7 Isolation of phages from Farm PT caeca, following both multi-host enrichment and isolation 
Isolate No. Shed Caeca shed 1 
(C1) 
Caeca shed 5 
(C5) 
Caeca shed 6 
(C6) 
Caeca shed 7 
(C7) 
NC4094 1 FL FL FL FL 
NC4095 1 FL FL FL FL 
NC4096 1 FL FL FL FL 
NC4097 1 FL FL FL FL 
NC4098 1 FL FL FL FL 
NC4099 1 FL FL FL FL 
NC4100 1 - - +++ - 
NC4101 1 FL - - - 
NC4102 3 - - +++ +++ 
NC4103 3 ? ? +++ +++ 
NC4104 3 +++ +++ +++ +++ 
NC4105 3 FL - - - 
NC4106 3 ? ? ? ? 
NC4107 3 +++ +++ +++ +++ 
NC4108 3 - - - - 
NC4109 5 +++ +++ +++ +++ 
NC4110 5 +++ +++ +++ +++ 
NC4111 5 ?? - +++ +++ 
NC4112 5 +++ +++ +++ +++ 
NC4113 5 +++ +++ +++ +++ 
NC4114 5 +++ +++ +++ +++ 
NC4115 5 +++ +++ +++ +++ 
NC4116 5 +++ +++ +++ +++ 
NC4117 5 +++ +++ +++ +++ 
NC4118 5 - - - - 
NC4119 5 +++ +++ +++ +++ 
NC4120 5 - - +++ - 
NC4121 5 +++ +++ +++ +++ 
NC4122 5 +++ +++ +++ +++ 
NC4123 5 +++ +++ +++ +++ 
NC4124 5 +++ +++ +++ +++ 
NC4125 5 +++ +++ +++ +++ 
FL – Fully lysed  +++ Clear lysis  ? Uncertain  (NC 4126 – NC 4140 negative)  
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1.3.7 Phage isolation from Farm SH farm caeca following both multi-host 
enrichment and isolation  
Screening for phages was done via “multi- host enrichment” using Campylobacter isolates from Farm 
SH (NC 4074-4093) and phage sensitive Campylobacter, from Farm PU (NC4096, 4098, 4100, 4102, 
4110, 4116, 4125 & PT14). This was followed by screening Farm SH against individual Farm SH 
isolates and Farm PU isolates (NC4096, 4098, 4100, 4102, 4110, 4116, 4125 & PT14) 
No phages were isolated from Farm SH caeca. 
 
1.3.8 Summary of phages isolated to progress candidate selection 
A total of 215 additional phages were isolated (Table 8) to enable progress phage candidate selection.  
There was a need to use both C. jejuni PT14 the universal host and Queensland farm hosts to isolate 
phages from both NSW samples and Queensland farms PU and PT. Thus, host diversity was used to 
ensure phage diversity. 
Table 8 A breakdown of purified Campylobacter phages (with allocated phage numbers) and phage punches  
Source Phage number. Number of 
phage 
Punched 
NSW (PT14) PH761-778 18  
NSW (using farm host) - - 77 
Farm PU(Using PT14) PH779-815 37  
Farm PU and Farm PT (using farm host) - - 138 





1.4 Lytic profile for phages isolated  
A total of 38 purified phages (from Table 7) were screened against the 39 Campylobacter screening 
panel (created during the Poultry CRC study). The phages we used were from NSW (18 phages) and 
Farm PU, (20 phages). The Campylobacter screening panel contains “hard”, “medium” and “easy” to 
lyse phages and was the basis for the selection of the 19-member candidate panel (Poultry CRC) 
Based on this screening, 17 phages from NSW and 1 phage from Farm PU are able to lyse 5 
Campylobacter reference panel isolates (NC3209, 3210, 3217, 3223, and 3234), as illustrated by the 
yellow shading (very good lysis, Figure 3) and pink (medium lysis, Figure 3). This approach was 
using to narrow down potential candidate phages. 
 
 
Figure 3 Lytic profile of a select group of Campylobacter phages screened against a select panel of Campylobacter isolates 
(as used to develop cocktail for the CRC phage study) 
 
  
Score of 3 – very good lysis 




1.5 Narrowing down isolated phages from Queensland and NSW  
During the CRC study a 19-member phage cocktail candidate panel was created in a manner similar 
to that reported. The aim with this study was to further diversify this panel with phages sourced from 
farms that were potential candidate farms for the Poultry CRC farm trials along with those isolated 
from NSW poultry environments (including broiler chicken caeca). 
The following path was undertaken to select the optimum candidates, which ultimately all came from 
Queensland farm environments.   
 
1.5.1 The Campylobacter screening panel 
As previously described the Campylobacter screening panel made of hard to lyse, medium and easy 
candidates is illustrated in Figure 4. 
 
Figure 4  Campylobacter screening panel (inclusive of isolates that demonstrated good lysis to NSW phages) 
The difficult to lyse isolates (orange), those that lysed 4 – 5 isolates (blue) are followed by those 
isolates that were able to lyse NSW phages (pink) and the overall isolates with good lysis 
(Queensland in light blue) are displayed in Figure 4. 
  
Difficult to lyse 
Lysed 4 to 5 isolates 
Variable 
Good lysis 
Good lysis, NSW phage 
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1.5.2 The two-step screening process 
A two-step screening process was adopted to identify the optimum candidates as follows: 
− The phages described in this section were initially screened against the sensitive Campylobacter 
isolates from the original Campylobacter screening panel, Figure 5. 
− The phages described in this section were then screened against the Campylobacter isolates that 
were more sensitive to NSW phages, Figure 6.  
 
 






Figure 6 Lytic profile of isolates screened against Campylobacter isolates most sensitive to NSW phages 
 
1.5.3 The final selection to be added to the candidate panel 
Following analysis of the overall screening, four additional candidates were selected and added to the 
panel of 19 candidates. The diversification work carried out as reported resulted in the recently 
isolated phages PH 726, 769, 782, and 793 being added to the panel to final phage cocktail candidate 
panel of 23 members. From this point onwards the phages would be coded from 1 - 23 as PH 1 – 23 
(which are also inclusive of these four phages which formed the 23-member phage cocktail panel). 
 
1.6 Summary, phage isolations and Campylobacter farm hosts 
A diverse set of samples (previously not tested) from both NSW and QLD poultry/poultry 
environments were used for both Campylobacter and phage isolation. A total of 160 diverse 
Campylobacter isolates from poultry ileum (never tested before) and caeca collected from a cluster of 
QLD farms were used. Phage diversity was achieved by using these this set of new Campylobacter 
isolates for screening both via direct and enrichment techniques (as described in this section).   
A lytic profile using the Poultry CRC - 39 member Campylobacter screening panel isolates and a 
selection of Campylobacter isolates that were sensitive to NSW screening were used to narrow down 
candidates as panel members. Based on the outcomes and analysis an additional 4 candidates were 







Chapter 2: Evaluate selected phages that 
may form a cocktail for their suitability 
based on simple lytic profiles and detailed 
molecular studies 
2.1 Background  
This section combines outcomes of the work undertaken under the current study and previously 
unanalysed Poultry CRC study data. Thus, this section provides comprehensive analysis of phages 
(including host – phage relationships). It summarises the host and phage sources, their lytic spectra 
against selected farm Campylobacter isolates, resistant profiles including Pulse Field Gel 
Electrophoresis along with DNA sequencing of phages.  
Whilst the Poultry CRC study undertook extensive screening to narrow down to cocktail candidates to 
enable the facilitation of the proof of concept farm trials, detailed analysis of the phage-host data 
remained un-analysed due to the short duration of that project (i.e. 1.5 years). This was undertaken 
during the current study. In summary the following are described in this section: 
• Analysed the extensive screening data generated by the poultry CRC to gain a broader 
understanding in relation to the 19-phage cocktail candidate panel and farm Campylobacter 
isolates on a farm to farm basis and subsequent overall summary of panel activity 
• The activity of the 23-member cocktail panel against an expanded set of host Campylobacter 
sourced from 2004 – 2016 to understand broader activity 
• One-step log reductions to understand performance of selected phage cocktail candidates 
• In-vitro resistance studies to support the in-vivo resistance observations (no resistance during the 
poultry CRC farm trials following phage introduction to birds) 
• Detailed analysis of phages via both PFGE and DNA analysis 
 
2.2 Methodologies adopted 
The Phage screening methodologies are as described in Chapter 1.  
 
2.2.1 Phage genome size determination using Pulse Field Gel Electrophoresis 
(PFGE)  
This method was based on Atterbury et al. (2003) and Loc Carrillo et al.(2007).  
 
2.2.2 Restriction endonuclease digests  
This method was based on Loc Carrillo et al. (2007). 
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2.2.3 Phage morphology (Transmission Electron Microscopy)   
This was undertaken as per Atterbury et al. (2003). 
 
2.2.4 Genome sequencing 
High titer phage stocks (>109 PFU/ml) were prepared as described previously using C. jejuni PT14 as 
the host. Phage preparations were treated with proteinase K (100 μg/ml in 10 mM EDTA [pH 8]) to 
remove the capsid and DNA extracted using the DNA Wizard Kit (Promega, UK) according to the 
manufacturer's instructions. Library preparations of genomic DNAs followed the Illumina NexteraTM 
tagmentation protocol (Illumina, Cambridge, UK) and the library sequenced using the Illumina v3 
sequence cassette for 600 cycles on the MiSeq platform to produce paired-end sequence reads of 
250 bp. De novo assembly of sequence reads was performed using CLC Genomics Workbench 
version 11.0.1 (Qiagen, Aarhus, Denmark). Assembled reads yielded a complete dsDNA genomes. 
Gene predictions were made using PHASTER (Arndt et al. 2016) to identify putative open reading 
frames (ORFs), followed by manual curation using BLAST (non-reductive databases) with the 





2.3 Distribution of phages 
The bacteriophages that formed the basis of the candidate panel were all isolated across Queensland 
farms from widely distributed locations across the north and south of the areas around Brisbane 
(Figure 6). This included commercial 21 farms and two commercial piggeries. 
 
Figure 7  Source of phages from Queensland farms 
The phage cocktail candidates originated from Queensland meat chicken farms from two integrator 
companies and two commercial piggeries. The details of the phage cocktail candidates and their 
method of isolation (direct isolation or enrichment) and source sample (caeca, litter or soil) and hosts 
used (universal host C. jejuni PT 14 with or without farm hosts) and year isolated is presented in 
Table 9. 
Chicken farms      
Piggery      
 
South East Queensland 
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Table 9 Details of phage final panel of 23 phage cocktail candidates 
Phage 
Number 
Date  Farm, location Source and isolation; Direct – (with C. jejuni PT 14 only) or 
Enriched with farm hosts C. coli (NC2934), C. jejuni (NC3142) and 
C. jejuni PT 14) 
1 2012 Redland bay area- free-
range re-use 
Farm Soil - Enriched 
2 2012 Beaudesert area, free-range 
full clean-out 
Farm Soil - Enriched 
3 2012 Redland bay, re-use Carcass rinse - Enriched 
4 2012 Caboolture area, re-use Litter No re-use - Enriched 
5 2012 Caboolture area, re-use Litter No re-use - Enriched 
6 2012 Carbrook area, free-range 
litter re-use 
Caeca, free range - Enriched 
7 2012 Carbrook area, free-range 
litter re-use 
Farm Soil - Enriched 
8 2013 Carbrook area, free-range 
litter re-use 
Caeca, free-range – Direct  
9 2013 Carbrook area, free-range 
litter re-use 
Re-used Litter practice - Direct 
10 2013 Carbrook area, free-range 
litter re-use 
Farm Soil, free-range - Direct 
11 2013 Carbrook area, free-range 
litter re-use 
Carcass rinse, free-range - Direct 
12 2013 Ipswich, full-cleanout Litter, No re-use - Direct 
13 2013 Redland bay area, litter re-
use 
Caeca - Direct 
14 2013 Redland bay area, litter re-
use 
Litter, - Direct 
15 2013 Redland bay area, litter re-
use 
Caeca, - Direct 
16 2013 Redland bay area, full 
clean-out 
Caeca, - Direct 
17 2013 Redland bay area full 
clean-out 
Caeca, - Direct 
18 2015 Piggery, commercial Pig Effluent, enrich C. jejuni PT14  only 
19 2015 Piggery, commercial Pig Effluent, enrich C. jejuni PT14 only 
20 2015 Redland bay area, full 
clean-out 
Litter, Direct 
21 2016 Beaudesert area, re-use Caeca, - Direct 
22 2016 Caboolture area, litter re-
use 
Caeca, - Direct 
23 2016 Caboolture area, litter re-
use  





2.4 Analysis of farm screening data 
The phage – farm activity screening data was part of the cocktail candidate selection process during 
the CRC study to enable progression to farm trials. This was a short 1.5-year study hence detailed 
analysis of that data remained unanalysed on progression to the current study. This data was analysed 
to enable a better understanding of farm – Campylobacter activity. The available screening data on 
farm by farm basis has been addressed in this section. In summary, the then available 19-candidates 
were screened against the Campylobacter hosts and based on the lytic profile were scores as 
illustrated in Figure 8. 
 
Figure 8 An example of a lytic profile of the 19 phage cocktail candidates’ against a single farm Campylobacter isolate 
(scored from 0 -3 based on activity) 
2.4.1 Farm PG against – 19-member panel 
The isolates from this farm was sourced in 2012 and were linked to Company 1. The farm was a 
conventional litter re-use farm, the isolates were sourced on day 41 (pick-up day 51). A total of three 
isolates were tested against the panel, they were all C. jejuni. The best phages (score 3) are PH 5, 9, 
12, 16, 17, Figure 9. 
 




2.4.2 Farm AK against – 19-member panel 
The isolates for this farm were sourced over two years (2012 and 2013) and were linked to Company 
1. The farm was a free-range litter re-use farm. The isolates were sourced on day 43 (pick-up day 48 
in 2012) and day 39 (pick-up day 41 in 2013). A total of 25 isolates were sourced in 2012 and three in 
2013. In 2012, the overall best phages (score 3) are PH 6, 9, 12, 18, 19. In 2012 there was a mix of C. 
jejuni and C. coli among the 25 isolates tested and all these isolates were sensitive to the latter two 
phages PH 18 and 19. The others had a score of 2 against select candidates, Figure 10. 
 
 
Figure 10 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm AK (2012) 
Three isolates sourced in 2013 presented a different picture as illustrated in Figure 11. Phages PH 5, 
16 and 17 gave a lytic score of 3 against these isolates. All these three isolates were C. jejuni. 
 




2.4.3 Farm QN against – 19-member panel 
This farm was tested in 2013 only and three isolates were chosen to carry out lytic profile. The farm 
was a conventional litter re-use farm and the isolates were sourced on day 48 (final pick-up day 54). 
The farm was linked to company 1. Two of the isolates were C. coli and the other C. jejuni. Both C. 
coli isolates presented a lytic score of 3 against phages PH 18 and 19 (but not the C. jejuni isolate, 
lytic against PH 5), Figure 12. 
 
 
Figure 12 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm QN 
 
2.4.4 Farm SN against – 19-member panel 
This farm was tested in 2013 and was linked to Company 2. This was a conventional full clean-out 
farm. The isolates were sourced on day 53 (pick-up day 54). There was a mix of two C. jejuni and two 
C. coli isolates. Both C. coli isolates had a lytic score of 3, against phages PH 18 and 19, Figure 13. 
 




2.4.5 Farm PT against – 19-member panel 
This farm was tested both in 2012 and 2013 and was linked to company 1. This was a farm that 
phages were not isolated originally, thus a large number of isolates were tested. 
The farm was a conventional litter re-use farm. The isolates were sourced on day 48 (pick-up day 49) 
in 2012 and day 47 (pick-up day 50) in 2013. A total of 39 isolates were sourced in 2012 and a total of 
19 isolates were sourced in 2013. Among the isolates sourced in 2012, eight were C. coli and the C. 
jejuni with one having no species identity.  In 2012, seven isolates sourced were C. coli and nine C. 
jejuni. 
In this instance a “cluster of C. jejuni isolates, had a score of 3 only reacting against PH 19. None of 
the C. coli isolates in this instance presented a score of 3 against PH 19 (as in some previous 
instances. Overall, the representation of isolates lysing the 2012 Campylobacter were low, Figure 14. 
 
Figure 14 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm PT (2012) 
In 2013, there was a different pattern of phage lysis based on the isolates at the time. Majority of 2013 
Farm PT isolates reacted against many of the cocktail candidates. A better lysis pattern in general was 
obtained in 2013 compared to 2012 (also being a farm with poor phage isolation). C. coli (as in most 
cases) presented a score of 3 for phages PH 18, 19 and C. jejuni a score of 3 against phages PH 16, 7 
(in addition to 5) and a few reacted against PH 6 and 8, Figure 15. 
 
Figure 15 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm PT (2013) 
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2.4.6 Farm CW against – 19-member panel 
Isolates from this farm were tested both in 2012 and 2013. This was a conventional full clean-out 
farm and was linked to Company 1. The isolates were sourced on day 46 (pick-up 49) in 2012 and on 
day 53 (pick up not available) in 2013. A total of 20 isolates were tested in 2012 (all isolates were C. 
jejuni). A wide lysis profile against a range of candidates was apparent across all candidates except 
phage PH 7, Figure 16. This was in contrast to the rest of the farms tested. More specifically, all 
candidates had a score of 3, with the exceptions of phages PH 7, 13 and 14, Figure 17. 
 
Figure 16 Activity of candidate phage panel (PH 1- 19) against selected isolates from Farm CW (2012) 
During 2013, as in 2012, a broad lytic profile was presented with good activity across isolates sourced 
during both sequential years. All isolates in 2013 were also C. jejuni as was in 2012. Due to the 
optimum activity across these set of isolates Figure 17 is presented only on the basis of those isolates 
that scored 3. 
 




2.4.7 Farm SH against – 19-member panel 
This farm is linked to Company 1 and four sheds were sampled on the same day. In total a random 
selection of eights isolates were drawn from shed 1, six each from sheds 5 and 9 and five from shed 
14. Selected C. jejuni isolates presented a score of three for all candidates (Figure 18). 
There seems to be a common C. jejuni strain across all sheds (except Shed 9) that that had good lysis 
(score 3) across all cocktail candidates. 
 
 
Figure 18 Activity of candidate phage panel (PH 1- 19) against selected isolates (all C. jejuni) from Farm SH, across sheds 







2.4.8 Farm RD against – 19 member panel 
This farm is linked to company 1 and as in the previous instance multiple sheds were sampled on the 
same day. A total of five isolates were tested against the 19 member cocktail candidate panel. All 
isolates lysed, two phages PH 18 and 19, (Figure 19) which was also commonly lysed by other farm 
Campylobacter isolates as previously described. 
 
Figure 19 Activity of candidate phage panel (PH 1- 19) against selected isolates (all C. jejuni) from Farm RD, across sheds 








2.4.9 Farm DK against – 19-member panel 
Farm DK is a conventional re-use farm and belongs to company 1. The isolates were sourced on the 
same day across sheds 2, 3 and B on the same day. A total of 10 isolates per shed was sourced for 
carrying out lytic profiles. All isolates were C. jejuni. In this instance phages PH 18 and 19 were 
sensitive to the Campylobacter isolates across the three sheds. 
 
Figure 20 Activity of candidate phage panel (PH 1- 19) against selected isolates (all C. jejuni) from Farm DK, across sheds 







2.4.10 Summary of farm screening data 
This data was generated during the previous study to select candidates but the farm to farm details 
remained unanalysed. The analysis was undertaken during the current study to compare the activity of 
the 19-member (where data was available) (a) across farms (b) across years (c) across sheds on the 
same farm on the same day. Selected phage candidates such as PH 16, PH 17, PH 18 and PH 19 
showed activity across most farms and both species. The pattern naturally varied on the same farm 
across sequential years due to different populations that appeared, whilst in general the sheds across a 
single farm at a particular time had a similar Campylobacter – cocktail candidate activity 
2.5 Combined analysis – 19-member panel 
Overall analysis of a group of 241 isolates against the cocktail candidates is presented in Figure 21, 
displaying good coverage across the candidate panel. More isolates were lysed by phages PH 18 and 
19. This analysis is based on the screening done with the data generated during the Poultry CRC 
study. 
 
Figure 21 Combined analysis of 241 farm Campylobacter isolates against the 19 member phage cocktail candidate panel 




2.6 Statistical analysis of candidate performance – 19-member 
panel 
Lytic profiles using a panel of 19 phage cocktail candidates was carried across a random selection of 
Campylobacter (241) isolates sourced from 2012 – 2016 from 11 Queensland farms. The outcomes 
were statistically analysed and involved using 23 shed/year combinations which commonly had C. 
jejuni or C. coli on a single farm. Lytic profiles were carried as in Carrillo et al. (2005) following the 
scoring (i.e. 0 – 3 with 3 representing clear lysis and 0 no lysis). Data that represented trial farms 
(CRC) R (prior to the trial) and D (during the trial) were included. 
For the initial screening of activity scores across farms, generalised linear mixed models (GLMM) 
were used with restricted maximum likelihood (REML) in (GenStat 2016). The fixed effects were 
species, year and phage, along with their interactions. The random effects were the farms, years, 
cultures within farm/year, and the position of the phages on each culture. These effects were restricted 
to not permit negative estimated variance components for comparing the test and control chickens. 
From an overall perspective representative phage activity of phage cocktail candidates was observed 
across both C. jejuni and C. coli 241 farm isolates analysed, Figure 22. 
 
 
Figure 22 Analysis of the lytic scores (0 -3) of a group of C. jejuni and C. coli isolates (241) for their activity against the 19 

















C. coli C. jejuni LSD (P=0.05)
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2.7 Expanded set of Campylobacter isolates to assess 23-member 
panel phage cocktail panel performance 
Whilst the analysis just described in section 2 was presented via the detailed analysis of data 
generated by the Poultry CRC study, the current analysis was undertaken to both build upon those 
outcome/understandings and also include the recently added for cocktail candidates that completed 
the panel from 19 – 23 members. 
A representative sub-set of Campylobacter isolates were created from our 2000 Campylobacter 
collection (2003 – 2016, RIRDC / CRC projects). The grouping followed four sequential (and logical) 
steps for selection which included year sourced, farm/location, origin (i.e. litter of caeca) and species. 
Thus, based on the former the overall group consisted of a total of 74 Campylobacter isolates.  
Of these 47%, 12% and 39% were sourced from caeca, carcass rinses and litter respectively. The 
remaining 2% of isolates had no recorded source sample. In total, the source samples were taken from 
11 different farms and included varying litter practices.   
Among the total, 27% of the isolates were sourced from farms using the conventional practice (i.e. 
new litter utilised) and 54% with either partial reuse or full litter re-use. It is worth mentioning that the 
full litter re-use practice was adopted specifically for our RIRDC funded study (which compared three 
litter practices under commercial farming conditions).  
Amongst the isolates (with a known species recorded), 29% are C. coli with the remaining 71% being 
identified at C. jejuni. This is comparable to the overall ratio for the species identity (of known 
isolates), which in the entire collection is 25:75 (C. coli: C. jejuni).  
From an overall perspective phages PH 4, 5, 11, 16, 17, 18 and 19 dominated compared to the rest of 
the panel members, Figure 23. Generally, over five farms showed sensitivity to each individual phage 
cocktail candidate. 
 
Figure 23 Number of isolates with a score of 3 against the panel of 23 members (and the number of farms that represent those 
isolates) 
The total number of Campylobacter isolates lysed by each phage (PH 1 – 23) is also presented in 










2.8 Campylobacter log reduction 
European studies indicate that on-farm interventions (such as phage therapy) can be very effective, 
with a 2-log reduction in faecal Campylobacter counts contributing to a 75% reduction in human 
infections. Similarly, a 1-log reduction in faecal count supported by a 1-log reduction in 
contamination of the exterior of chickens, during processing is predicted to result in a 90% reduction 
of human infections (Havelaar et al. 2007). Additionally, a 3-log reduction in Campylobacter numbers 
in the intestines of infected birds at slaughter, can contribute to a 90% reduction in public health risks 
(Crotta et al. 2017). 
Thus, achieving a two-log reduction on-farm can contribute to a reduction in human illness. A two-log 
reduction was achieved on-farm during the CRC trial. The following section describes the work 
undertaken to assess in-vitro log reduction.  
The aim to demonstrate in-vitro log reduction of Campylobacter following phage application was to 
validate the concept of using a phage cocktail (as a biocontrol agent) to reduce Campylobacter levels 
in the caeca of commercially farmed chickens. The achievement of log reductions of Campylobacter 
in the laboratory was an indication of that ability to be transferred on-farm and hence be able to 
progress to chicken trials, though this has already been demonstrated by the CRC farm trials. 
 
2.8.1 Methodology for log reduction 
An appropriate Campylobacter host and phage were used for the purpose and are listed as follows: 
Host: Campylobacter jejuni PT14    Phage: PH 19 
The basis for the selection of Campylobacter jejuni PT14 and Phage: PH 19 for log reduction studies 
is as follows 
Campylobacter jejuni PT14 is a universal international host commonly used to isolate Campylobacter 
phages from poultry (Atterbury et al. 2003). This host was thus used to isolate all phages (750 
numbers) in our collection. This was possibly due to the common receptor recognition between C. 
jejuni PT 14 (host) and the phages which were isolated (including the cocktail candidates). Based on 
this common link, (i.e. between our cocktail phages and PT14), C. jejuni PT 14 was used as host to 
assess in-vitro log reduction.   
The phage selected was PH 19 and was a member of our 19 panel phage cocktail candidates. PH 19 
was also one of the candidates of a “two-phage cocktail” used during farm trial 2 (CRC – Proof of 
concept study). Whilst a combination of four other phage cocktail candidates successfully contributed 
to a 2-log reduction in the caeca of chicken during Farm trial 1 (of the CRC study). Whereas PH 19 
had the potential to lyse Campylobacter prior to the trial at day 40 (a requirement to address the proof 
of concept), log reduction attributed to the combined cocktail (i.e. PH 19 and PH 18) did not occur, 
during farm trial 2 as a reduction in Campylobacter levels were also observed in the control birds. As 
a result, there were no statistically significant differences between the test and control birds. This was 
due to the incursion of a native – competing phage that was present in both the test and control birds 
at the time. Thus, this was not potentially a reflection of phages PH 18 and 19. Thus, PH 19 was 
chosen for the present in-vitro study to be able to better understand phage – bacteria relationships (a) 
as it potential further use in cocktails and (b) try better understanding the activity of this phage in-
vitro. 
An overnight culture of C. jejuni PT14 (in logarithmic phase) was standardised to around log 6.00 
cfu/ml and set up ready for incubation (at 42oC for 24 hours) with shaking. To this phage PH 19 (a 
standardised concentration of around log 3.0 pfu/ml) was added. Phage and Campylobacter levels 
were assessed every 2h for 24h. Figure 25, presents the growth curve. 
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Campylobacter: Campylobacter (test and control) was introduced at log 6.4 cfu/ml (at time 0). These 
levels increased to log 8.0 cfu/ml, following which a drop in the phage infected Campylobacter host 
occurred at 8h (to log 5.9 cfu/ml, almost two logs) and difference to controls is even greater (3.3 
logs).   
 
2.8.2 Results of log reduction studies  
The control Campylobacter continued to increase to log 10.0 cfu/ml. The infected Campylobacter 
host continued to gradually increase (to 20h). The levels of both control and infected Campylobacter 
reached log 10 cfu/ml almost 12h later at 25h.   
 
 
Figure 25 Growth studies demonstrating log reduction using C. jejuni PT14 and phage PH 19 
In conclusion, this study has demonstrated in-vitro 2 log reduction in Campylobacter levels within 5h 
of infection with phage. 
 
2.8.3 Outcome of the above trial and its relevance to in-vivo bird trials   
PH 19 has demonstrated its potential to reduce Campylobacter levels in-vitro and is thus worthy as a 
phage cocktail candidate. However, when used as a cocktail candidate (along with a partner phage) 
and in the presence of native phages in the chickens, no statistically significant differences between 
the test and the control were observed during the farm trial. There may have been some cross-
interference under the circumstances that prevailed at the time. The fact that there was cross 





2.9 Phage resistance – in vitro studies 
The “phage-Campylobacter dynamics” in the chicken caeca is an on-going natural phenomena that 
supports both the survival of the phage and the bacteria. The genetic diversity in Campylobacter in 
chickens is naturally caused by the presence of phages in the gut. This is an on-going process, 
irrespective of whether options for bio-control are adopted. Campylobacter temporarily develops 
resistance in the presence of the phage, but reverts to a sensitive form in the absence of the phage. The 
sensitive form is an active coloniser of the chicken gut, thus the trend for Campylobacter to revert to a 
form that allows it to successfully “exploit” this “niche” which is favourable for its on-going survival. 
Published studies (Loc Carrillo et al. 2005, Scott et al. 2007, Hammerl et al. 2014 and Fischer et al. 
2013) have demonstrated the proportion of resistant campylobacters in the chicken caeca to be small 
and the rapid reversal of those resistant forms to sensitivity (in the absence of the phage). This is 
simply due to the fitness cost associated with maintaining resistance traits (i.e. the loss of flagella) 
required to continuously colonise the chicken gut. 
This aspect is addressed by Loc Carrillo et al. (2005). The study shows that “campylobacters resistant 
to phage infection were recovered from phage-treated chickens at a frequency of <4%. These resistant 
types were compromised in their ability to colonize experimental chickens and rapidly reverted to a 
phage-sensitive phenotype, in vivo. The selection of appropriate phage and their dose optimization are 
key elements for the success of phage therapy to reduce campylobacters in broiler chickens”. C. jejuni 
populations that survive phage predation in broiler chicken display genomic re-arrangements resulting 
in resistance to phages as well as inefficient colonisation of the broiler chicken intestine (Scott et al. 
2007). When these strains were reintroduced into chickens in the absence of bacteriophage further 
genomic rearrangements at the same locations resulted in, reversion to bacteriophage sensitivity and 
colonisation proficiency (Scott et al. 2007). The resistance phonotype is of temporary nature with a 
high potential to revert to a sensitive phenotype. Thus, genomic instability of C. jejuni in the avian gut 
has been adopted as a mechanism to temporarily survive phage predation and subsequent competition 
for resources in order to survive local environmental pressures.  
Based on this evidence, we predict that if any Campylobacter survive phage bio-control treatments via 
resistance they will readily revert to sensitivity, and therefore there will not be any net increase in 
phage resistance in the Campylobacter population on farm. Nevertheless, this prediction needs to be 
validated. These in-vitro studies are a step in that direction. However, the following needs to be noted 
in relation to in-vitro studies. 
During active therapy the phage will be required to replicate in the host bacteria which can select 
phage resistant escape mutants. These mutants can rapidly overtake a laboratory culture under ideal 
host growth conditions, but phage-sensitive cells are out-competed far less frequently in chickens. 
This is because many of the useful phage have requirement for a functional flagella apparatus. In 
culture, losing motility has little or no penalty and in-vitro, the outcome is quite different to that what 
occurs in the chicken gut. Non-motile campylobacters (in the chicken gut) do not colonise chickens, 
do not efficiently adhere or invade human cells and cannot compete with motile campylobacters that 
remain phage sensitive. Thus, the outcome of in-vitro studies may not reflect as to what may occur in 
the chicken. Nevertheless, this was explored in the current section. 
The poultry CRC farm trials have demonstrated a log-reduction (and an absence of resistance post 
phage treatment in isolates sourced from the chicken gut). Thus, there can be differences in in-vivo 
and in-vitro testing of phage resistance.  
In summary, the concerns of phage resistance on-farm can be addressed by the following practices  
− The use of cocktails and not single phages to treat the birds 
− The introduction of phage to chickens around 24h prior removal for slaughter (to prevent the 
development of resistance). 
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These measures were adopted during the CRC trial which yielded no resistance and a demonstrated a 
2-log reduction in the caeca of the commercially farmed bird (on-farm). 
In-vitro resistance studies were addressed using two basic approaches,  
• Using Campylobacter – phage growth experiments in liquid media – University of Nottingham 
method 
• Using a stipulated MOI (multiplicity of infection) – ESR method 
 
2.9.1 Methodology adopted to evaluate in-vitro resistance – University of 
Nottingham methodology 
Basis: The levels of both phage and bacteria were assessed over time (i.e. via a “growth experiment”) 
using liquid media. The time series nature of the study enables the assessment of frequency at which 
resistant mutants may arise, following a crash in Campylobacter population (as a consequence of 
phage infiltration). 
Approach: Growth experiments were carried out using a chosen farm hosts and phages. 
Campylobacter and phage levels were assessed at time chosen time intervals (from 0 – 24h). Colonies 
were picked from the enumeration plates of a growth experiment when the Campylobacter 
populations started to increase post phage induced crash. 
 
2.9.2 Step 1 Comparison of growth media for isolating mutants  
Both CCDA and Horse Blood Agar (HBA) were compared for their suitability for use as plating 
media for growth studies and both media were found suitable. 
 
Figure 26 Comparison of using HBA and CCDA as potential media for growth studies 
In summary, there was no difference in the recovery of Campylobacter (colonies) following growth 
experiments using either CCDA or HBA (Figure 25). HBA was used. 
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2.9.3 Step 2 Growth studies 
Three trials were carried out with the following phage - Campylobacter combinations (i.e. NC 3351 – 
PH 21, NC 3330 – PH 20 and NC 3037 – PH 22). All three Campylobacter isolates were farm isolates 
and phages used were new cocktail candidates. We were only able to see a small drop (and thus try 
isolate resistant mutants) from a single combination which is described below. 
Methodology: 
• Campylobacter NC3037 – farm isolate 
• Phage 22 – New cocktail candidate  
• Two multiplicity of infections (i.e. Campylobacter – phage ratio) were used (Table 9) 
Table 10 Multiplicity of infections used for growth study 
Campylobacter NC 3330 Phage 726 (non-cocktail phage) 
MOI 1 
105 CFU/ml 105 PFU/ml 
MOI 0.1 
105 CFU/ml 104CFU/ml 
 
Figure 4 presents the Campylobacter – phage growth curve when subjected to two MOI’s i.e. 0.1 and 
1.0. 
More specifically,  
• There was a drop in Campylobacter levels for both MOI 1 at 5h (log 0.2 when compared with 
the control) and occurred at 5h (Figure 3). 
• This was followed a small rise (log 5.50 to log 5.60). We isolated colonies at this stage for 
MOI 1 
• The drop in Campylobacter levels for MOI 0.1 was also 0.2 and occurred at 6h (Figure 3). 
• Unfortunately we did not pursue the experiment beyond 6h to see any potential rise that may 
have occurred as with MOI 1. No colonies were sourced. 
• Generating resistance in-vitro was challenging 
 
Figure 27 Growth curves generated for selecting and isolating phage resistant mutants 
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2.9.4 Resistance testing  
The cultures were tested against phage stocks 103 to 106 pfu/ml which were used to do spot tests. 
Essentially both test cultures and the parental strain showed full lysis at the highest phage 
concentration of 106 pfu/ml, Table 11 and Figure 28. There was a lack of resistance. 
There could be two reasons: 
1. The drop obtained was not sufficient to be indicative of a “crash” but we tested nevertheless to try 
to understand. 
2. As a result, the colonies isolated (post “crash”) were not indicative of resistance and remained 
sensitive. 
Table 11 Resistance testing via spot test MOI 0.1 
Phage concentrations 106 105 104 103 
culture     
1 FL FL FL TNTC grainy 
2 FL FL FL 41 
3 FL FL ~100 6 
4 FL FL ~65 7 
5 FL FL FL 30 
parental FL FL FL TNTC grainy 
FL = fully lysed  TNTC – too numerous to count 
 





2.9.5 Methodology adopted to evaluate in-vitro resistance – ESR methodology 
Table 12 presents the description of the phage cocktail candidates used. The source of some of 
Campylobacter isolates chosen originated from our Campylobacter screening panel developed for the 
CRC study. The Campylobacter screening panel was created using a diversity of Campylobacter 
isolates sourced across farms and screening them against select groups of phages, and then grouped 
(based on the resultant lytic profiles). Finally, select representatives from each group formed the 
Campylobacter screening panel. The panel included campylobacters that had a good, medium and 
difficult lytic potential. 
Table 12 Description of phage cocktail candidates used 
Candidate used Farm RD, 
CRC – farm trial 
Candidate used for DK, 
Farm, CRC – farm trial 
New Candidates 
PH 5 PH 18 PH 20 
PH 8 PH 19 PH 21 
PH 11  PH 22 
PH 13  PH 23 
 
The second set of Campylobacter isolates used originated from a CRC farm trial. These campylobacters 
were isolated from chicken caeca representative of birds that demonstrated a successful log reduction 
following treatment with a cocktail. These isolates remained sensitive to the phage used to treat the 
chickens. The caeca of chickens treated with the cocktail also demonstrated successful log reduction 
and were the source of the isolates. All details are presented in Table 13. 
 
2.9.6 Outcome 
The resultant infected plates were compared with the controls. Three general categories were apparent 
as listed below.  
The lysis patterns were categorised as follows: 
Category 1 – Clear plaques visible with bacterial growth inside the plaque (only 1 combination had 
this pattern) Figure 29. Bacterial growth emerged within a clear plaque, indicative of the emergence 
of a resistant population following lysis. 
Category 2 - Isolated colonies in a partially lysed lawn (when compared with control). Intermittent 
and isolated single colonies were visible; but were not indicative of emerging against previous 
bacterial lysis (plaque) representative of a true mutant Figure 30. 
Category 3 – Just grainy i.e. some area lysed some not (merged colony growth), no isolated colonies 
Figure 31. 
Only Category 1 was typical of a resistant mutant. Some colonies were also picked from Category 2. 
No colonies were visible in the Category 3, which had grainy lawns with joined colonies. 





















Table 13 Details of Campylobacter isolates and phages used and outcome following testing for resistance 
NC number Source Details Description on plate Colony ID Resistance  
3330 – PH 20 Caeca Redland farm 2012 Campy panel isolated colonies in a partially lysed lawn   17 Not typical 
3351 - PH 21 Carcase Redland farm 2012 Campy panel Looked like control nothing to see No lysis?? Not 
used 
Not typical 
3037 - PH 22 Litter Redland farm 2011 Campy panel isolated colonies in a partially lysed lawn   8, 9 Not typical 
2482 - PH 2 Caeca Carbrook 2009 Campy panel isolated colonies in a partially lysed lawn   15 Not typical 
3333 - PH 5 Caeca Redland 2012 Campy panel Did not pick control contamination Not used Not typical 
3217 – PH 11 Caeca Redland 2012 Campy panel isolated colonies in a partially lysed lawn   13 Not typical 
2992 – PH 13 Caeca Redland 2011 Campy panel isolated colonies in a partially lysed lawn   10,11 Not typical 
2975 – PH 18 Caeca Redland 2011 Campy panel Very good, typical outcome of resistance 1,2,3,18,19,16,24 5% plate 
Typical  
4164 - PH 19 Caeca Redcliffe 2016 Redcliffe shed 7 
before trial 
Grainy nothing to pick Not used Not typical 
4346 – PH 8 Caeca farm test Redcliffe 2016 Redcliffe  
Trial    TEST 
No indication 12 Not typical 
4347 – PH 19 Caeca farm test Redcliffe 2016 Redcliffe  
Trial    TEST 
Some isolated colonies 14 Not typical 
4349 - PH 5 Caeca farm test Redcliffe 2016 Redcliffe  
Trial    TEST 
Grainy nothing to pick (no resistance good result for 
cocktail??) 
Not used Not typical 
4352 - PH 5 Caeca farm test Redcliffe 2016 Redcliffe  
Trial    TEST 
Is a Redcliffe combination, isolated colonies in 
partially lysed lawn (joint plaque, very faint) 
6, 7,20 Not typical 
4356 – PH 8 Caeca plant control Redcliffe 
2016 
Redcliffe  
Trial    control 
isolated colonies in a partially lysed lawn   4,5,21,22,23 Not typical 
4377 – PH 5 Caeca plant test Redcliffe 2016 Redcliffe  
Trial     TEST 
Grainy nothing to pick (no resistance good result for 
cocktail??) 
Not used Not typical 
In bold – Farm Redcliffe cocktail phage Highlighted – Farm DK cocktail phage  The rest – New cocktail member 
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2.9.7 Evaluation of the outcomes of the screening: 
A total of fifteen phage – Campylobacter combinations were screened (Table 13), the isolates selected 
in a manner to cover both Campylobacter panel and farm trial isolates. The Campylobacter isolates 
were paired with cocktail phages that were used to reduce Campylobacter on-farm (Redcliffe farm 
trial phages) and others were from the cocktail member panel. 
Table 14 presents the detailed screening of the phage bacteria combinations that yielded colonies and 
Table 15 presents a summary of the different patterns. Only one combination was truly representative 
of demonstrating “typical resistance” NC 2975 (which was a normal farm isolate) and PH 18 which 
was used during Farm trial 2 (Farm DK), Table 14, Figure 32.  
Thus, based on the total isolates tested only 7% resistance was observed during in-vitro testing. 
Among those which presented dispersed colonies across partially lysed lawns 42% of the 
combinations yielded resistant and 21% sensitive isolates. Among those that remained sensitive, were 
two isolates from the Campylobacter panel and one farm isolate that originated from the Redcliffe 
farm trial. The rest, (21%) simply had grainy lawns (i.e. joined bacterial colonies among areas of 
clearing with no visible colonies as described under Category 3). 
Interestingly three of the Redcliffe farm Campylobacter isolates – post phage (which were tested with 
phages used in cocktail during both farm trials i.e. PH 5 at Redcliffe and PH 19 at Farm DK) did not 
yield any resistance colonies, only grainy lawns. PH 5 was among a combination that demonstrated 
successful in-vivo log reduction on-farm. Maybe this approach can be adopted to further narrow down 
and select suitable cocktail candidates. 
 
2.9.8 Implications to future farm trials:   
This has been discussed at the beginning on the differences between in-vitro and in-vivo resistance. 
Whilst among the carefully selected phage Campylobacter combinations only one combination 





2.10 Overall summary – in-vitro log reductions and resistance 
studies 
Studies towards the demonstration of in-vitro log reductions and evaluation of potential resistance to 
the candidate phage cocktail were completed. A two log-reduction was demonstrated in-vitro using 
the universal Campylobacter host, which was the source of all phage isolations, and a phage used in 
farm trials during the CRC proof of concept study. Resistance testing was carried out using two 
approaches (a) development of resistant mutant over time (growth curves in liquid media) and (b) 
plating Campylobacter – phage combinations via soft agar overlay. Using (a) we could not achieve a 
sufficient crash in host numbers with the in-vitro assay to assess the potential development of 
mutants. The second approach (b) however generated some resistant mutants. Among the 15 phage-
host combinations logically selected at a MOI (multiplicity of infection) of 10, only one combination 
(7%) demonstrated the development of true resistant mutants’ in-vitro. Of the remainder, 42% yielded 
resistant colonies sourced from partially lysed lawn (not a representation of true mutants, as the 
former). Among the other combinations 21% yielded sensitive isolates and rest (21%) had merged 
bacterial growth (colonies). To better address the outcomes of the in-vitro resistance encountered in 
the present study and its implication to chicken trials, a brief summary of literature addresses the 
implications of resistance to Campylobacter colonising the chicken gut. In-vivo resistance (in the 
chicken gut), unlike in-vitro is reversible, due to the fitness cost to the bird. Nevertheless both criteria 
addressed via the current milestone were also the focus of the CRC farm trials. During these trials we 
demonstrated a 2-log reduction in the caeca of treated birds and continued sensitivity to isolates tested 
post phage treatment. These outcomes highlight the challenges in comparing in-vivo and in-vitro 
resistance for Campylobacter (where the organism’s main niche is the chicken gut).  
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Table 14 screening of isolates against phage concentrations 106 to 102 
  Phage Concentration 
Source Colony ID 106 105 104 103 102 
2975-677 parental host  FL FL TNTC 17 2 
  Test No: 1 - - - - - 
  Test No:2 - - - - - 
  Test No:3 - - - - - 
  Test No:16 - - - - - 
  Test No:18 - - - - - 
  Test No:19 - - - - - 
  Test No:24 - - - - - 
4356-323 parental host  FL FL TNTC 6 1 
  Test No:4 - - - - - 
  Test No:5 - - - - - 
  Test No:21 - - - - - 
  Test No:22 - - - - - 
  Test No:23 - - - - - 
4352-265 parental host  FL FL TNTC 10 1 
  Test No: 6 - - - - - 
  Test No: 7 - - - - - 
  Test No: 20 - - - - - 
3037-782 parental host  FL FL TNTC 16 1 
  Test No: 8 - - - - - 
  Test No: 9 - - - - - 
2992-431 parental host  FL TNTC 20 2 0 
  Test No: 10 - - - - - 
  Test No: 11 - - - - - 
4346-323 parental host  FL FL TNTC 12 1 
  Test No: 12  - - - - - 
3217-377 parental host  FL FL 60 5 1 
  Test No: 13 - - - - - 
4347-722 parental host  TNTC TNTC 60 5 0 
  Test No: 14 FL TNTC 30 1 0 
2482-232 parental host  FL FL TNTC 12 0 
  Test No: 15 32 3 0 0 0 
3330-726 parental host  FL FL f TNTC 12 
  Test No: 17 FL FL TNTC 33 3 
- No lysis  FL fully lysed; TNTC   too numerous to count 




Table 15 Overall summary of the assessment of in-vitro resistance 
Description of category Percentage 
Bacterial growth emergence within a cleared plaque area “typical resistant mutants”* 7 
Resistant colonies (individual) from partially lysed bacterial lawn (compared to control) 42 
Sensitive colonies (individual) from partially lysed bacterial lawn (compared to control) 21 
No lysis (similar to control) 7 
Grainy – joined bacterial colonies among areas of clearing 21 
# one combination was not tested due to contamination of the control 
*The category highlighted in green was the only category typical of a resistant mutant, all seven isolates tested were resistant 
 
 




2.11 Transmission Electron Microscopy (TEM) of phage images 
Figures 33 and 34 present the TEM images of selected candidates. The phages have isometric heads 
(91-96 nm) and contractile tails (110-115 nm), which places them as members of the Myoviridae 
family and suitable for phage therapy applications. The phage dimensions are typical of group 3 
phage that are now taxonomically classified as Ecampyvirinae Fletchervirus.  
 
 
Figure 33 PH2 phage (head diameter 91 nm, tail 110 nm) 
 
 





2.12 Phage genome sequences 
The complete genome sequences of PH181 (non – cocktail candidate) and cocktail candidates. PH 1 
and PH 2 were determined using the Illumina MiSeq platform, Appendix 2. The genome sequences 
confirm the phage are group 3 phage with genome sizes of 132-135 kb. There are no virulence or 
antibiotic resistance determinants discernible using the available search engines PathFinder and 
CARD. Appendix 3 presents the sequence annotation files (entire coding capacity) of all three phages. 
BlastP searches of the putative phage tail fibre (gp047 homologue in NCTC12673 – Kropinski et al. 
2011) protein encoding genes within the phage PH181, PH 1 and PH 2 genomes were undertaken to 
assess the binding mechanisms and compare these with the host range of these phage. Homologues in 
phages PH181 and PH 2 showed high sequence identity with GP047 (1364 amino acids), whereas a 
stop codon is present after the first 83 amino acids of phage PH 2 due to genetic mutation. The C-
terminal regions of this homologue will be expressed from an internal start codon to create a protein 
missing the N-terminal 219 amino acids. PH 2 shows a broader host range than PH 1. Considering the 
finding from Javed et al. (2015) that the actual binding site of GP047 is located in the C-terminal 
quarter, this may suggest that binding of the shortened tail fibre is less hindered and is available to 
bind a greater variety of Campylobacter types. 
These analyses are work in progress, which will require further work to complete due to time and 
funding limitations. The provisional work demonstrates how detailed analysis can provide a greater 
understanding of phage – Campylobacter binding (in addition to other factors assessed within the 




Chapter 3: Achieve a suitable log 
reduction of Campylobacter with the 
possible inclusion of either “active” or 
“passive” phage therapy strategy, which is 
assessed in-vitro (micro titre plates) 
3.1 Background 
The intestines of poultry become colonised by campylobacters often without noticeable effects on bird 
health but their presence represents a foodborne hazard to humans when transferred to poultry meat 
during processing. Control of Campylobacter is an obvious target for phage therapy because of the 
large proportion of poultry reared for meat harbours these organisms as a part of their intestinal 
microbiota with few practical alternatives for reduction (Connerton et al. 2011). 
Two forms of phage therapy are recognised:  
1. Active therapy, which requires ongoing replication of phage in order that the phage concentration 
reaches or is maintained at levels sufficient to control the bacteria;  
2. Passive therapy, which requires the initial phage dose to inundate the bacteria present to affect a 
reduction bacterial numbers.  
The two modes are not mutually exclusive, and can occur in the same treatment, for example where 
the initial phage dose is large enough to suppress the bacterial population and is maintained at that 
level by phage replication. To understand the basic kinetic properties of phage therapy one must 
appreciate that active therapy can occur only when the concentration of host bacteria exceeds that 
required to productively produce more phage progeny - known as the proliferation threshold, and 
passive therapy can occur only when the initial concentration of phage exceeds the host bacteria such 
that all are bound and killed – known as the inundation threshold. 
Phages have been applied directly to foods and environmental surfaces in processing facilities to 
reduce the numbers of foodborne pathogens, a process that has been termed biosanitization. As 
atmospheric oxygen in these circumstances would normally prevent the growth of Campylobacter and 
replication of phages (since Campylobacter are microaerophilic), the numbers of campylobacters are 
probably reduced through “lysis from without” or by pre-adsorption of phages, which then resume 
their lytic lifecycle when conditions become conducive for Campylobacter growth (Atterbury et al. 
2003). These are examples of passive phage therapy in the absence of replication and are the basis of 
industrial applications for biosanitization. We have examined the survival of Campylobacter treated 
with phage on an inert plastic surface or on chicken skin. 
Active therapy requires phage proliferation that may occur in chickens when host bacterial 
concentrations frequently surpass the phage proliferation threshold (Carrillo et al. 2005). In the 
laboratory the action of phage may be modelled by examining their effect on growing cultures of host 





3.2 Material and methods 
The experimental details for active and passive therapy are presented in the following section 
3.2.1 Passive therapy experiments 
Campylobacter jejuni PT14 was cultured on horse blood agar plates (blood agar base No. 2 
supplemented with 5% defibrinated horse blood), under a microaerobic atmosphere containing 5% 
O2, 5% H2, 10% CO2, 80% N2 at 42 oC for 24 h. Phages PH13, PH19 and PH2 were propagated 
using the soft agar method and enumerated as previously described earlier. Campylobacters were 
applied to microtiter dishes at a range of concentrations and treated at 4 oC with either mock or phage 
suspensions before the mixtures were recovered and diluted to determine the viable count at 42 oC 
under microaerobic conditions. 
Chicken portions were obtained from supermarkets and cut into 2 cm2 sections and transferred to 
square Petri dishes divided into 25 sections at 4 oC. For Campylobacter enumeration skin samples 
were aseptically transferred into individual stomacher bags 10 ml of MRD and stomached in a Seward 
Stomacher 80 Biomaster for 2 min. The suspensions were diluted 1:10 in MRD. Twenty 10 µl 
droplets of both the neat stomachate and the 1:10 dilution were dispensed onto the surface of plates of 
dried mCCDA (2% agar), incubated at 42 oC under microaerobic conditions and the colonies counted 
after 24-72 h. 
 
3.2.2 Active therapy experiments 
One step growth curves for phage against C. jejuni PT14. Overnight cultures of C. jejuni PT14 were 
transferred into 100ml of MH broth with appropriate antibiotics to give a final concentration of 
approximately 7 log10 CFU /ml and incubated at 42°C under microaerobic conditions with 150 rpm 
shaking for 2 hours. The viable counts were measured after incubation as described earlier. Phage 
were diluted and added to bacterial suspension at the titre of 106 PFU/ml. The bacteria/ phage mix was 
further incubated at 42°C under microaerobic conditions with 150 rpm shaking for 3 hours and 
aliquoted samples were taken every 15 minutes. Aliquots were centrifuged at 13,000 x g for 5 minutes 
and the supernatant containing free phages were removed for titration. All measurements were made 
in triplicate and the mean ± standard deviation reported. The adsorption constant was calculated using 
the equation: k = -ln (Pt/P0)/Nt,  
Pt = phage titer at time point t (PFU ml-1), P0 = initial phage titer (PFU ml-1), N = bacterial viable 






3.3.1 Passive therapy 
Campylobacters survive at 4 oC in moist conditions such as those encountered in the processing 
environment and at retail. Similarly, C. jejuni PT14 survived in an aqueous film on plastic (microtiter 
plate) and on chicken skin as indicated by the minimal reductions in the viable count observed in the 
control samples over 24 hours compared to that at time zero, Table 16. 
Figures 35, 36 and 37 present the survival of C. jejuni PT14 at 4 oC in aqueous films in microtiter 
plates. The x-axis indicates the target bacterial count applied in log10 CFU. The controls (blue) were 
administered with SM buffer and the experimental log10 8 PFU phage (as indicated) in SM buffer 
(red). The viable counts were determined immediately post mixing and 24 h later. Triplicate counts 
were performed and are recorded as the mean ± standard deviation. 
 
 
Figure 35 C. jejuni levels with log10 8 PH 13 phage 
 
 




Figure 37 C. jejuni levels with log10 8 PH 2 phage 
The addition of phage reduced the viable count of the bacteria from time zero when mixed in the 
microtiter plates. The reductions were greater after 24 h with the phage achieving 1 to 2 log10 CFU 
reductions in the viable count. The most effective phage treatment under these circumstances was 
phage PH19 with 2 log10 CFU reductions observed at the highest multiplicities of infection (MOI s of 
3,100 and 10,000).  
The decline in Campylobacter jejuni counts after storage of chicken skin at 4 oC were examined. C. 
jejuni PT14 was applied to chicken skin at 5 log10 CFU/cm2 and treated with either 105 or 108 
PFU/cm2 phage. Table 16 shows significant reductions in the viable campylobacters recovered after 
stomaching contaminated chicken skins were recorded compared to controls without phage (MRD 
buffer alone). In this assay phage PH19 achieved the greatest reductions at applications of 105 or 108 
PFU/cm2. Phages PH13 and PH 2 could bring about reductions in the recoverable viable count with 
the greater phage applications. 
Table 16 Mean decline in Campylobacter count (log10 CFU/cm2) on broiler chicken skin (n=10) 
Days post PH13 treatment 105 PFU/cm2 108 PFU/cm2 
 
1 0.8 1.7* 
2 0.9 1.7* 
3 0.9 1.7* 
Days post PH19 treatment 105 PFU/cm2 108 PFU/cm2 
 
1 1.2* 1.8* 
2 1.4* 1.9* 
3 1.4* 1.9* 
Days post PH2 treatment 105 PFU/cm2 108 PFU/cm2 
 
1 0.6 1.5* 
2 0.7 1.6* 
3 0.7 1.6* 
* Significant differences at P= <0.05 by ANOVA 
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3.3.2 Active therapy 
To compare and quantitate the log reductions observable with the phage isolates in actively growing 
cultures a series of growth curves were performed. From these the phage replication parameters were 
calculated, Table 17. Typical of Campylobacter phages the burst sizes are low at ~2 phage per cell 
due to the small size of the host bacterium (3-5 µm in length and 0.2-0.5 µm in width) compared to 
the assembled phage (190-210 nm in length with head diameters of 90-100 nm). 
 
Table 17 Replication parameters for phage on C. jejuni PT14 
Phage Maximum host 
reduction  
(log10 CFU ml-1)_ 
Adsorption constant  
(k) x10-10 (ml min-1) 




PH13 2.1 1.18±0.31 1.9±0.3 70 
PH19 2.3 1.21±0.07 2.2±0.4 70 






The application of phage isolated in this study can reduce the contamination of surface deposited 
campylobacters and on chicken carcass surfaces at refrigeration temperatures by 1-2 log10 CFU. 
However, to achieve these reductions requires high phage numbers and will require the propagation of 
high phage titres for commercial application (109 PFU per application).  
Phage isolated in the course of this project are typical of group 2 and group 3 phage isolated from 
farm environments. Upon active replication when the host bacteria have reached the phage 
proliferation threshold of 7 log10 CFU /ml the phage achieve a reduction of 2 log10 CFU/ml. Of the 
phage investigated PH19 exhibits the greatest adsorption constant, indicating it binds to the host more 
efficiently, which likely contributes to the observation of the greatest Campylobacter host population 
crash. Active therapy requires a greater concentration of target bacteria but requires lower phage titres 




Chapter 4: Based on the knowledge of all 
of the above develop a cocktail of phages 
4.0 Background 
The progression to develop phage cocktails was undertaken in two stages, they included, undertaking 
the preliminary work and the validation of methodologies and the second stage included the 
assembling and analysing of selected phage cocktail activity against the host Campylobacter.  
 
4.1 Preliminary work undertaken towards progressing cocktail 
formulation, Stage 1 
This work was carried out at ESR in New Zealand by Dr Craig Billington and was done through two 
stages. During stage 1 the following was undertaken to initiate and progress the collaborative 
research. The work included and the detailed steps undertaken are listed as follows: 
• Successfully reviving Queensland Campylobacter hosts and phages, Figure 38. 
• Screening and analysis Queensland phages, Figure 39. 
• Using above data picking the most promising phages for cocktail, Figure 40. 
• Making some high titre stocks using the original phage stocks. 
• Testing a 3-phage cocktail on 10 isolates for which the performance was good (100% 
coverage), Figure 41. 
• Establishing high-throughput screening method for phage cocktails to commence screening, 
Figures 42 and 43. 
All the above were successfully achieved to enable progression to the next stage. 
On the initial arrival of Queensland Campylobacter isolates and phages work progressed to revive and 
validate stocks against data generated by the project in Queensland to enable progression of work. 
 
 
Figure 38 Initial testing of shipped frozen stocks 
 
DAF scoring system
host strain ID PH5 PH16 PH19 3 clear
Campylobacter NC2480 0 0 0 2 many plaques / opaque
C.coli NC2905 0 3 0 1 few plaques
C. jejuni NC2981 3 3 3 0 no plaques
C. jejuni NC2992 3 3 3
C.jejuni (sam) PT14 3 3 0





Figure 39 Full screening of Queensland phages 
The phages were narrowed down based on screening against QLD, “NC Campylobacter hosts” 
 
Figure 40 Narrowed down phages (with DAF, NC- hosts) 
This work concluded to start with phage numbers PH5, PH2, PH13, PH8, PH16, PH19 
 
PH5 PH16 PH19 PH1 PH4 PH8 PH11 PH14 PH15 PH17 PH18 PH2 PH3 PH6 PH7 PH9 PH10 PH12 PH13
NC 2480 0 2 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 2
NC 2905 0 0 0 0 0 0 0 0 0 0 0 3 1 0 0 0 0 0 3
NC 2981 2 1 1 0 3 0 0 1 1 0 1 3 3 1 0 0 0 0 3
NC2992 3 1 1 0 3 1 0 0 0 0 1 1 1 0 0 0 0 0 3
PT 14 3 1 0 1 3 1 0 0 0 1 1 ND ND ND ND ND ND ND ND
NC2487 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 3
NC2498 0 1 0 0 0 0 0 0 0 0 0 ND ND ND ND ND ND ND ND
NC 3037 3 1 0 0 3 1 3 0 0 0 0 3 3 0 0 0 1 0 3
NC3548 1 3 0 1 1 0 0 0 0 0 0 3 3 0 0 0 0 0 3
NC3964 1 0 0 0 1 1 0 0 0 0 0 3 1 0 0 0 0 0 3
NC4076 3 1 1 0 3 1 1 0 0 0 0 1 1 0 0 0 0 0 3





Figure 41 Testing 10 hosts with a 3 phage cocktail 
Growth of hosts in various liquid media (for high throughput screen) 
 
Figure 42 outcome when BHI, 42oC, 10% CO2 – combination was used 
 
 
Figure 43 outcome when No2, 42oC, CampyGen (MGS), 100 rpm was used 




4.1.1. High throughput screen initial data 
Some examples of 3-phage cocktail biocontrol on broth are presented in Figures 44 and 45. 
 
 
Figure 44 Lytic activity of cocktail on NC 2981 at 42oC in BHI 
 
Figure 45 Lytic activity of 3 phage Campylobacter cocktail on NC 3037 at 42oC in BHI 
 
4.1.2 Conclusion 
In conclusion, these sequential outcomes demonstrated that a “3-phage cocktail” is exerting good 
performance in liquid media 
This work concluded the validation work undertaken and enabled progression to the next stage i.e. 
carrying out the kinetic assay to screen the phages against different host panels.  
   Host only 
   Host + phage cocktail 
 
   Host only 




4.2 ESR Campylobacter phage characterisation (stage 2 cocktail 
optimisation) 
The aim of this work was to establish kinetic assay for screening different phage combinations against 
Campylobacter host panel. 
 
4.2.1 Modify existing phage kinetic methods to work with Campylobacter (A) 
The Billington lab at ESR is familiar with setting up high throughput screening of phages against host 
bacteria, but this is usually with aerobic bacteria so methods needed to be adapted for use with the 
microaerophilic Campylobacter. Variables tested included media, atmosphere, temperature, agitation, 
incubation and concentrations of phages and bacteria. Data from some of these optimization steps are 
presented below in Figures 46 and 47, where generally NZCYM media performed better than BHI 
media, with No 2. Broth media the poorest performer. 
 
Figure 46 Comparison of growth of Campylobacter in different media - 10 ml tubes 
 
Figure 47 Comparison of growth of Campylobacter in different media – microtitre plate 
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4.2.2 Testing of Campylobacter phage cocktails – (B) 
Host range and qualitative lysis (plaque morphology) data from the Chinivasagam lab were used 
alongside confirmatory data from our own work to establish the phage stocks to be included in the 
cocktails to be used for kinetic screening experiments. Five phages were chosen from Queensland 
stocks: PH13, PH8, PH5, PH2 and PH16 (Table 18). These five phages were made up into 10 
cocktails (Table 19) for testing against 10 Campylobacter hosts (Table 20) selected to be broadly 
representative of Australian isolates from poultry farms. Later, a further phage (PH18) was added to 
make an 11th cocktail.  







PH18 Pig effluent 
 
Table 19 Phage cocktail composition 
Cocktail Phages 
A PH13 PH5 PH2 
B PH13 PH8 PH16 
C PH13 PH8 PH2 
D PH13 PH8 PH5 
E PH13 PH2 PH16 
F PH8 PH5 PH2 
G PH5 PH2 PH16 
H PH8 PH2 PH16 
I PH13 PH5 PH16 
J PH8 PH5 PH16 




Table 20 Campylobacter testing panel 
Strain Identification Origin Isolated 
NC2480 Campylobacter spp. Carbrook  Caeca 
NC2487 C. jejuni Carbrook  Caeca 
NC2498 C. jejuni Carbrook  Litter 
NC2905 C. coli Redland Bay Litter 
NC2981 C. jejuni Redland Bay Caeca 
NC2992 C. jejuni Redland Bay Litter 
NC3037 C. jejuni Redland Bay Litter 
NC3964 C. jejuni Carbrook  Caeca 
NC4076 C. jejuni Moreton Bay No data 
PT14 (NCTC 12662) C. jejuni United Kingdom No data 
 
Phage cocktails were tested by the standard method and relative effectiveness, as measured by 
decrease in optical density, was determined. Representative data from testing of the phage cocktails 
are illustrated in Figures 48, 49, and 50.  
 
 





Figure 49 Comparison of phage cocktails C-E 
 
 




4.2.3 Testing of Campylobacter phage cocktails – combination of Australian and 
New Zealand isolated phages (C) 
Some of the Australian phage cocktails were further tested by addition of New Zealand isolated 
phages to determine if there is any added benefit. The cocktails tested are listed in Table 21, where 
New Zealand Campylobacter phage Cj6 was originally isolated from chicken faeces and phage C62.1 
from chicken feathers. 
 
Table 21 AU-NZ phage cocktail composition 
Cocktail Phages 
L PH13 PH8 PH2 CJ6 
M PH13 PH8 PH5 CJ6 
N PH8 PH2 PH16 CJ6 
O PH13 PH8 PH5 C62.1 
P PH13 PH5 PH16 CJ6 
R PH8 PH5 PH16 CJ6 
S PH13 PH2 PH18 CJ6 
 
The performance of these cocktails (Figures. 51 & 52), which contained four phages rather than three, 
was similar to that observed for Australian only phage cocktails. Note that the total phage titre was 
equivalent in all treatments to eliminate this as a factor. 
 
 





Figure 52 Combined AU-NZ phage cocktails P-S 
An experiment was also performed where the Australian phage cocktail “D” was compared to the 
same cocktail with the addition of either phage Cj6 “M” or phage C62.1 “O” (Figure. 53). For 4/7 
isolates “M” performed better than “D”, and for 5/7 isolates “O” performed better than “D”. This 
indicates there may be value in addition of New Zealand phages to cocktails of Australian phages to 
control Australian Campylobacter. 
 




4.2.4 Overall trend analysis of phage cocktail performance (D) 
The relative efficacy of each cocktail was calculated to determine if there were any trends in 
performance of the different phage cocktails (Figure 54). Cocktail “S” was the best performer, having 
the greatest ability to decrease the concentration of Campylobacter in culture, whereas cocktails “H”, 
“F”: and “G” were the least effective. It is notable that combined Australia-New Zealand isolated 
phage cocktails were amongst the best performing. 
When examining the data on the susceptibility of the Campylobacter isolates tested (Figure. 55), it 
does appear that some strains are more susceptible to the phage cocktails than others. It will be 
interesting to see if there are any genetic determinants which could be linked to these observations – 
this work will be performed later in the project. 
 
 





Figure 55 Overall relative susceptibility of Campylobacter strains to phage cocktails 
 
4.2.5 Conclusions 
Combinations of three and four phages were tested in 18 different formulations (cocktails) for 
efficacy against a panel of Campylobacter hosts. The cocktails all resulted in reductions in 
Campylobacter concentrations in broth. Addition of New Zealand isolated phages to Australian phage 
cocktails may give an added performance benefit. Overall, most phage cocktails were similar in their 
ability to kill Campylobacter. Some strains of Campylobacter had lower reductions in numbers than 




Chapter 5: Generate data to support 
necessary Australian regulatory 
framework for the use of phages as bio-
control agents by the Australian Poultry 
Industry 
Provide the Australian Poultry Industry an 
efficacious environmentally friendly option 
to control Campylobacter that will benefit 
the poultry industry and the consumer.  
5.0 Background 
This section draws outcomes across two previous studies Chinivasagam et al. (2015) and 
Chinivasagam (2017) along with the current study to provide a comprehensive summary in pursuing 
this environmentally friendly option. The initial study (RIRDC funded) provided the basis for the 
isolation of Campylobacter phages and creating a large phage collection which led to the subsequent 
Poultry CRC study to address phage bio-control. The proof of concept (Poultry CRC funded) 
provided previously unavailable outcomes and is only one of the two studies relating to on-farm 
phage bio-control (only one published study exists to date, Kittler et al. 2013, the CRC study is 
accepted for publication). The CRC study provided an understanding of the natural incursion of 
intrinsic phage that co-contributed to Campylobacter reduction along with the cocktail candidate to 
facilitate Campylobacter reduction. This is the first time the need to understand this approach has 
been identified. The current study has thus focused on generating a detailed understanding of phage 
activity both at a laboratory and farm level. Host – phage relationships were furthered by in-vitro 
cocktail development and assessment and detailed molecular understanding of the candidate phages to 
help assess performance. All these outcomes have contributed to  
• Generating data to support necessary Australian regulatory framework for the use of phages as 
bio-control agents by the Australian Poultry Industry 
• Providing the Australian Poultry Industry an efficacious environmentally friendly option to 
control Campylobacter that will benefit the poultry industry and the consumer 




5.1 Conclusions from the “proof of concept trial” with 
consequences to application in Australia 
 
5.1.1 Campylobacter reduction in treated birds 
Managing Campylobacter numbers in the chicken gut, on-farm, is a promising strategy to reduce 
disease burden attributed to human illness from poultry meat consumption. Whilst other options are 
available, one of the reasons that phage therapy has proved successful over treatments such as 
antibiotic therapies is that utilizing a biological agent requires care in selection of the appropriate 
agent and in application. However, the subtlety of being able to target pathogenic species within a 
complex microbiota within the chicken gut with no dysbiosis represents a major advantage. 
Campylobacters are not overt pathogens of chickens thus the ability to target the zoonotic component 
of the microbiota of the chicken is a key advantage to bird welfare, the integrity of the treatment and 
the quality of the product (Richards et al. 2019). 
Two farms, Farm A and B were selected for these trials based on the absence of phage in the caeca of 
the bird one week before application, having a high Campylobacter count in the caeca the 
campylobacters relevant to the cycle being tested being sensitive to two or more members of the 19 – 
phage cocktail panel. Selection of the optimum phages, which are active against the dominant 
Campylobacter in the relevant flock is key to a successful intervention. This occurred in Farm A 
where phage treatment brought about a significant decline of a 2-log reduction in the Campylobacter 
count within the ceca that represents the major reservoir of intestinal contamination, when compared 
to control birds. A strong negative correlation was also observed between the Campylobacter count 
and the phage titre where a high Campylobacter counts in the treated birds represented birds where 
the phages have not attained a great enough titre in the caeca to shift the population.   
As all birds were treated in the similar manner, the failure is likely due to low host concentrations 
encountered in the amplification phase, for example in the intestinal tract prior to reaching the caeca. 
Thus, one of the outcomes of the trial on Farm A was to increase the treatment beyond 24h (as 
adopted in the trial) to allow the phage titre to achieve titre and /or allow time for the required 
dispersion within the intestine. Whilst a statistically significant reduction was achieved on Farm A (at 
the farm), the reductions were not statistically significant following transport. The longer treatment 
period would allow the build-up of sufficient phage numbers to ensure host reduction in the caeca. 
However, in the majority of the phage treated birds on Farm A, the phage did replicate and were 
effective at reducing Campylobacter numbers in the caeca.  
During the current study, a two log-reduction was demonstrated in-vitro using the universal 
Campylobacter host C. jejuni PT 14, which was the source of all phage isolations, and a phage used in 
farm trials during the CRC proof of concept study.   
 
5.1.2 Co-contribution of inherent phages to log reduction 
Indigenous phage can alter Phage – Campylobacter dynamics and outcomes as phage are already 
present in the chicken gut and have been isolated across poultry environments, (as described in 
Chapter 1. During the previously carried out farm trials, Farm B, tested negative a week prior phage 
treatment and the Campylobacter of the relevant cycle was sensitive to two candidates. Following 
phage treatment, the flock was phage positive either as a consequence of the on-going phage 
Campylobacter interactions or the shed environment. These phages most likely reduced the numbers 
of Campylobacter in caecal contents of both control and test birds, either before or concurrently, with 
the phage intervention. Following treatment and subsequent sampling, the average Campylobacter 
number in the caeca was 5.6 log10 CFU/g in contrast to 7.8 log10 CFU/g, when pre-screened, a week 
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earlier, in the absence of phage. This aspect sheds light on the process of co-contribution phages that 
are already a part of the natural Campylobacter – phage interactions occurring in the intestinal tracts 
of farm chickens. This further confirms earlier reports that the presence of phage in broiler flocks can 
reduce caecal Campylobacter population levels (Atterbury et al. 2005). Thus, in addition to the 
contribution to the reduction afforded by the cocktail candidates there is also need to take into account 
the action of concurrent phage infections, which may make phage intervention more effective, if 
optimized correctly. The outcomes from the study Farm B, highlights the need to understand system 
specific phage–host interactions that are likely critical for successful treatment outcomes. 
 
5.1.3 Phage resistance 
Phage resistance is often cited as a barrier to phage treatment. But resistance to the selected phage 
cocktails was not detected on either farm. This was possibly between the time difference between 
phage application and slaughter which was 24 hours. Irrespective of this, one of the key criteria for 
addressing resistance is the use of a cocktail of phages which target different receptors in the host 
bacteria. The short exposure of the birds to the phage cocktail treatment may have contributed to low 
phage titres observed and the strong correlation with the Campylobacter counts observed on Farm A 
in the absence of emerging phage resistant populations. 
In-vitro testing of resistance undertaken by the current study also demonstrated low resistance (7%) as 
demonstrated by the development of true resistant mutants’ in-vitro. Interestingly three of the 
Campylobacter isolates (from farm trial) following phage treatment did not yield any resistance 
colonies, only grainy lawns, during in-vitro testing.   
 
5.1.4 Absence of phage in processed carcass – prior chlorination  
This is a key criterion for consumer acceptance of phage bio-control, i.e. the absence of phage in the 





5.2 Campylobacter phages occur in litter only in the presence in the 
bird 
This was observed during the study that assessed Campylobacter dynamics across four litter practices 
(they were the conventional practice of full-clean-out, conventional litter re-use, free-range – with full 
clean-out and free-range with re-use). This involved the sampling of the birds (caeca) litter, soil and 
carcasses across 17 farms (24 farm samplings) over a two-year period (2012 – 2013). Phages were 
only isolated in conjunction with the host Campylobacter as illustrated in Figure 56.   
 
Figure 56 Levels of Campylobacter (CFU/g) and phages (PFU/g) in caeca of chickens from four 24 farms 





5.3 Survival in water 
The delivery of phages does not require complicated options. They can be delivered via drinking 
water (tap water) as was done with both farm trials. High titre stocks were prepared and assessed over 
time. Figures 57 and 58 illustrate the phage levels in water compared to the common storage media 
SM buffer over time. Thus, high titre stocks can be calibrated to be delivered via the in-shed water 
delivery system. 
 
Figure 57 Storage studies PH18 in tap water and SM buffer at room temperature and 4oC  
 
 





5.4 Additional outcomes from current study 
The current study has provided the Australian Poultry Industry an efficacious environmentally 
friendly option to control Campylobacter that will benefit the poultry industry and the consumer and 
the outcomes are summarised as follows: 
• Provided an expanded set of phage cocktail candidates  
• Evaluated the activity of these candidates on farm basis using previously generated data from the 
Poultry CRC study 
• Expanded the set of Campylobacter isolates by creating a group based on chronological isolation, 
litter practice, source and species to further validate screening undertaken during the previous 
study 
• Evaluated the activity of these candidates against various farm Campylobacter isolates to assess 
activity of candidates 
• Demonstrated the use of select cocktails using both New Zealand and Australian phages 
• Demonstrated the use of select cocktails using both New Zealand and Australian Campylobacter 
isolates 
• Demonstrated the overall relative susceptibility of Campylobacter strains to phage cocktails to aid 
selection and combination of cocktail 
• Demonstrated in-vitro log reduction (also supported by farm trial outcomes) 
• Demonstrated minimum resistance via in-vitro resistance trials (also supported by farm trial 
outcomes) 
• Provided PFGE details to have a detailed understanding of the cocktail candidates 
• Provided detailed genomic data to support suitability for inclusion in cocktails and address 
Australian regulatory framework for the use of phages as bio-control agents by the Australian 
Poultry 
• Demonstrated how detailed genomic analysis can provide a greater understanding of phage – 
Campylobacter binding (in addition to other factors assessed within the project) to enable 
intelligence-based refinement of the phage cocktails, which address both safety and efficiency. 
5.5 Future needs to address commercialisation  
Extensive studies have progressed the outcomes to use Campylobacter phage bio-control to date. The 
studies carried out across three countries has paved the way for successful data sharing, collaborative 
outcomes and previously unavailable data on Campylobacter phage bio-control. This has been 
achieved by both farm and detailed laboratory studies. 
One of the key outcomes that needs to be furthered is the co-contribution of the natural phage – 
Campylobacter interaction which can be harnessed to enhance cocktail contribution. This requires a 
deeper understanding of Campylobacter – phage interactions. 
There is a need to formulate and address selection of cocktails from a scale up perspective to ensure a 
viable commercialisation pathway to market. 
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There is a need to seek potential commercial entities to understand the way forward in providing a 
Australian regulatory frame work for the use of phages as bio-control agents by the Australian Poultry 
Industry.  
There is a need to continue sequence annotation for the rest of the cocktail candidates as demonstrated 




Poultry are a major source of Campylobacter, although a zoonotic pathogen the organism has minimal 
impact on birds. Campylobacteriosis is the most common form bacterial foodborne disease 
worldwide, and the single most important source of Campylobacter is broiler meat (European Food 
Safety Authority 2016). European studies indicate that on-farm interventions can exert effective 
control, with a 2.0 log reduction in faecal Campylobacter counts predicted to reduce human infections 
by 75% or a 1.0 log reduction in faecal count supported by a 1.0 log reduction in contamination of the 
exterior of processed chicken meat a 90% reduction of human infection (Havelaar et al. 2007). Hence, 
the development of an on-farm intervention to control Campylobacter levels by 1.0 to 2.0 logs is of 
significance to industry and policymakers to bring about reductions in human infections from 50,000 
to 5,000 case per year. 
This study represents progress towards delivering a sustainable and low environmental impact option, 
which is likely to gain consumer acceptance for the control of one of the key foodborne pathogens 
responsible for human illness. 
In Summary: 
Implications for relevant stakeholders 
• Poultry are a major source of Campylobacter, with the most important single source of 
campylobacteriosis considered to be broiler meat.  
• Modelling indicates that on-farm poultry interventions can be very effective in reducing human 
infections.  
• Development and validation of on-farm control options for reducing Campylobacter levels by 1.0 
to 2.0 logs can realistically result in a 90% reduction of human infections. 
• This study is progressing towards delivering an environmentally compatible option for the 




Work to develop a Campylobacter bio-control solution for the poultry industry has been significantly 





Appendix 1 Variation to project 
 
Research in Progress Report No. 2 
 
-  Agree work plan and finalise resourcing with international 
collaborators 
-  Data analysis for interim phage resistance experiments 
-  Re-evaluation of original Campylobacter screening panels to optimise 
Campylobacter genome sequencing work 
-  NZ collaborator visit DAF to discuss collaborative work 
Summary Report on Research in 
Progress submitted in Clarity, 
providing an update on the following: 
- Contracts finalised, materials and 
data in place to progress work 
- Data on phage resistance is 
expanded 
- A grouped set of Campylobacter 
isolates selected to progress 
collaborator work 
- Collaborator visit complete, work 
plans in place 
31/5/2018 
Annual Progress Report No. 3 - Undertake kinetic studies to inform phage cocktail formulation 
- Bioinformatics analyses of phage sequences to reveal host receptors 
and determine biosafety 
- Evaluate the potential for overseas phages to improve phage cocktail 
Annual progress report submitted in 
Clarity, reporting on: 
- Formulation of the phage cocktail 
is advanced 
- Initial biosafety analysis complete 
30/11/2018 
Research in Progress Report No. 3 200-word summary report, providing update on project. 
- Cross-reference Campylobacter genome sequence data with phage 
susceptibility data to improve cocktail performance 
- Use in vitro evolution to improve cocktail performance 
- Investigate nature of phage escape mutants 
- Determine commercial potential for cocktail to perform in other 
markets 
Summary report on Research in 
progress to date, submitted in 
Clarity, reporting on  
- In vitro performance of phage 





Please contact AgriFutures Australia's Chicken Meat Extension Officer to 






Appendix 2 Phage genome sequences 
PH 181 
 
CDS_POSITION                       BLAST_HIT                                                                            EVALUE              PRO_SEQ 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
#### region 1 #### 
complement(4..609)                 PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00001; phage(gi100059)         1.17e-132           
MYSKFLNESSENLWVFAKNDIKLRKLILPVIQDNIEYVMFLNDRSIEEGKLKDICLDIEIFGVFEHYNIGNYKKIEPSIVVNVTDLKKDALKSIEDKLKNCKSKDEPVL
SLKLDMITEYNVARLLEKEYYINNFTDIIQNELKSKQFKIVEGNIGESVVELFNDYGESMIFTLKNNKVIKVNGQVGTKYNYLYSSLVIQKI 




complement(1640..2197)             PHAGE_Campyl_CP81_NC_042112: ssDNA binding protein; PP_00003; phage(gi100044)        4.12e-123           
MKLHYYDIYNISNGVFLTFQKNLKEKLLCVSHSKDIMDKKIGFYPLNFSDRGDFILLCVYIMFKHSPSSIYGLCEYLRNYNKTEYEKFKNTIKFYKNMIKKDIALLEE
KYKKPMFKEVMREYSIKQISFVTVYWYLMLYDIKDFNGINNTIICESILNVFKFLKFTDESKDYIKDVFKQIEGEVL 
complement(2210..2470)             PHAGE_Campyl_PC14_NC_031909: ribonucleotide reductase A subunit; PP_00004; phage(gi100062)     1.45e-48            
VESKTELFNKLFEFRKQKDMMDDCILDVIIEFGNHINMDPELIASELSDYAIFRDIVEKDLKKFKFTKYDPNQSDIDISDIDILWE 
complement(2460..2906)             PHAGE_Campyl_PC14_NC_031909: aerobic ribonucleotide reductase B subunit; PP_00005; phage(gi100063)     2.09e-103           
MCVLKTWLEDSNAKLPEISVMGSACYDIFSIEDKTIQPGGFEYVENGVRLIIPDGYYIRFNTRSSLGFIKDLFVYPGILDASWSGNLKVKVYNFGKEPYTIKKGDKYC
QFELLKCNESKIENISKDDFDNITKKLIRGNNGGWGSSGK 
complement(2894..3286)             PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00006; phage(gi100123)     3.60e-83            
MKNIEILNMVEELVKLNPILLISENFSHTYELLKENVRESKSIENKKIKLNCISVKLDDDTKLPCYGTVLSVLMKDNLENIINKNPQSLLEISFKISINVLLDLIDNFVEIY
DFNNESLLLINRIKICVY 







complement(4619..5023)             PHAGE_Campyl_CP81_NC_042112: RegA; PP_00008; phage(gi100039)                         2.63e-90            
MSYSFEQYCNSNNFNEFQRYLITQLGYINNKNVVAIQDSEYIDVFKAIKQEYYKASSCKHSDKEEVIPEHYTKLAIEPIDFIYKNNLNFCEGNIIKYVSRLGSKDDNKS
ELKKIFFYFDYLLHGNYDLTKRTFS 
complement(5027..5203)             PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00009; phage(gi100126)     1.22e-29            
MTIKNKINDINEILQSYVGELVLSDIDTQKIVENLTELETIIKDAISKQLNNSKLILG 
complement(5259..5825)             PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00010; phage(gi100037)         4.14e-127           
MEKLIYIVIFLCIVFTTTSQSVIFHAKYNFEDIIQERLSYLKQNMINHISKYNNKNATEITNYIFEASLKYNINPVFIMSLIQSESYFKHKVKHKYNNVKGISGINYKMW
KIVLAKHNIKHINSLKNQIEATAIIINYIKQKYKTNDDLEILHYYKGRGYDKYLNKSGLDLAQYSYSMYIKNIKIIYN 
complement(5844..6479)             PHAGE_Campyl_CP81_NC_042112: DNA polymerase; PP_00011; phage(gi100036)               1.02e-146           
MKFNCKNFAKALFYSKDINYLIKLFKYAKQEDKKQAMQILLWARDVNGGNIKNSILLLKYIAEKTNNINDMFLASVVKYGCFKDLNEMYKVASDSNKRKILSFYS
NELKLKNQLAAKWAPRKGPLFYALANSLCLKIGDFRRYITSLYISVEAKMCDNMWDSISLDEIPERAIKKYKKVLEKRLKITIYCRSPKQRRLKFKGCEKLLKQY 



























complement(12993..13442)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00016; phage(gi100133)     2.81e-94            
MNIYAKYLNEFTKSSIKLNEADIDFDDFISEVKEIAGTSGDKLHNPRTSPVFRNYMYSLYINDDGISAEKAWRMFEELNIMDSRKIIQYIEEDDDWYVNRLKDEYNIS
LDDFKQMDEYDQIRTFCEIHNCQYIEGTDNKMYVMLPKYYV 
complement(13495..13755)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00017; phage(gi100134)     5.80e-54            
MDKQLIKDITINGLSQFAKGHEIEAITETLQIVQEYNIEHHSHNFEFDVEPITSLEDFIKEINILITYEDLNLFHEVLVESLKYYK 
13810..14211                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00018; phage(gi100076)         2.46e-86            
MTFVEKNMVKELKKTISSKKPLVLCFMSKLLQKEIQKLLKGNKLITIIKIILYAFDKTPVEVKRGVLGYVENEKNIPFQYKYDNTTKTLTFSLDKKSYNFNLCTANEY
IKVLANETNWMILKKNLNNALKNIK 
complement(14229..14747)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00019; phage(gi100077)         2.15e-119           
MAITNYTEFEKLCPKNGEIADQDVLGKPSLQLKRELDTVMSQVNSIIGITDPSNWDTGTTYTQNQIVKYNNYIYVSLSDGNRGNQPDTSPSKWKKISGGSISSSVNIIV
SSSDYNTPVTEVSDNSLSLKPSKVYVNGNLIPTTNYTHDGTLTKITFINGMSVYKNDVVTVEY 
complement(14780..15421)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00020; phage(gi100078)         2.53e-156           
MGILNTAVGAISDFFGGNKTQSAITELAQKIQKAYSTNFDLESLYSIDTFALKNEVPGAGRINILDLPNMDILIQRVSIDPISFAEINEWIGSSWVYTQGRHELQQLTITF
RDSDGGFLYSAFKKLAGHLKDQYPDDQMWIIKIRKRTLRESRNYINQSVQNNEFKNGGHVIIDTQCAMIRSHGGLSLDQNSNGLATFDVTFLFDPFPPQISY 
15467..16120                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00021; phage(gi100027)         1.41e-152           
MELEIWKGKHSILLNKLYNDNNYIYDSDIIDVLVYKCLNQPKYITNDEARFLFFKKYFAEVCSKIDSSFKCPYCNEMNDIKFTNDDISITEYSLKPIEINVDNVIVTMY
FKKELSQDDSLSLITETKNMIDHEKRLLELYYMIDYISINGEELRGNHIIFEKYINELPLSCFNKIFDYFINSIPKHSIIKNCSCKNCNSEINVELKELPESVRRNLF 
16117..16779                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00022; phage(gi100026)         2.40e-156           
LTKDIIINNRHYCLNVWKIKDEIGILHQFIDWIELPLEDQVNKIADILIPQTKDLDYISRLYIMIILSSYANGDYSDILLTCPHCGNPIDTRINIRENLEFIPPKTVEVEINNK
KYTISKQNIELCNELPLKDYNSILNQLNDDGDLKLCAKVKCIMCNNDVLAIRELKDLFENYVIMLDLEWYYSTLKYFISQLGFSKTDFDNLYPFEIELLTNENKDE 
















20544..20897                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00025; phage(gi100083)         5.63e-80            
MNDTQTIQIFDLIGDSQARDYIAIKAYKIGSDVSGIKDSINDILDDDPSKAFDNLLNMAENNISNIINPSNWEAGPRLKPGVPCKYIWILPIPSSLAEAFSHEFNQDEIDPI
GDMIG 




21688..22149                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00027; phage(gi100085)         8.83e-107           
MKNSVLNNKIMVDFNGFSLSPTYSVNIPKLREFMKNNLSMFYVKEMNDNVRFEVLALREYNDSSLWDILMILNFGENGILNFAKGDTWVSDNAENQYKEQQEYFS
PNFKPEDLYNQILSKIQKKNESRRKVIFIKRQFIPQFKESIKDMLNVF 









complement(24041..24382)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00030; phage(gi100147)     1.37e-68            
MFLEDNNKQLSKVLNDNIVIKEDEKNIYIKFKKNIIIESDNNVIFLAKDYIVNSAKEIHLNPDVKISVDDNVDDIIKKIDDKKNEINISVEKLTHNHKHCKIKCFFKKLF
NLN 
complement(24366..24653)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00031; phage(gi100089)         7.88e-64            
MPPVTRLGDIALGHSCYPPSPTIEASSNVFANSIAVHRLGDKIQSHACPDTPPHGRNSSSGSTSVFTNSKATCGIGDAVNCGGIIAQGSNNVFRG 









complement(26272..26718)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00033; phage(gi100014)         3.42e-97            
MEKNYNTFLRKKSVTIKLNDDLKDKLKDTIENINDYDIIKIKLGRTFFNQKRYYKIYARKKFGFYKTLLSENDDSYFFMENTSKIIRRVFNEYDVNCYNLYPNKKYR
YGLSIFILICCSIILIALSLGVGALSYIFKGYFLAFGFSLF 
complement(26778..27350)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00034; phage(gi100092)         3.19e-138           
MGLESGELRNEAQGGYNPPFELSIYKHQVKFTPPNNFESYIKWELLGDIPLHLTINEQTGLITGNIELLSKQPSAKNAIYEYQLMKIDGSNWRHLGILKNGQTFTFNFQ
VKLTYTVQANSGGSRLSNTVTEVSDVTITILQDNDIISTLFCKNYIDEAKFPLKIGDKVYTDAVEFMKNHPNKNNFKINLV 
complement(27367..27894)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00035; phage(gi100012)         1.65e-129           
MPLYTVDKLANALKGGAKSDKYFIEIGTPLGAPEVAFTEEDIILCKTASFPERTLGEVEAFVQGRKLKLPGDSTFDAAWSPVFYQTPDHNIRAKFLTWIDKIDVYKN
NYHTCDPYSLMVTAKVHQVNCNGEPVATYEFFNVWPSKVGEIEVAADKTNSIQEFTVDFTYSHWEKIA 
complement(27923..28501)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00036; phage(gi100094)         1.96e-139           
MSLYNIDRLRSSLKQGGAINSKYKIDIKIPTLLRSLPFFKTVNISGEYLSIMANRTSIPGKSMSTVKVYHRGQPFVIRGAAQFNNTHKITFYNTPDMDIHQLFSDWIYRI
DSFDSTITQSIFLGNYVGFNSVGAGYMSDIIVSQLSSDGRTETEFKLCYTFPIDIAEVELSASGKEISSTEVTFAYTYWERI 
complement(28503..29063)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00037; phage(gi100010)         6.08e-137           
MVESINPPKGYFKIELLDKDRNVIDTFEKHNLVVNGSRPVLASHMAGRSTTPVNKLVLGTRGHIGNNLMMPKTANEGFTAARTQLFAEEEGEFCYHVNFTPPQSDG
QAVVTEDDVGAGSTVEVTNSNNTITYRIELSTTAGNGTLGAVGYTEAGLYAGNDLFCMRTFAVRSKDVSSILRITWTLIF 














complement(32693..33040)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00040; phage(gi100007)         2.88e-75            
VIQYKDINPKNIEKDIINVDTFYVSLKNIVSTTIGDIAGFPEFSNNAQLLFDQYSSVALDAYKTSLKTSIQKFDYRIIVDNINISKGDADNSVYIEIKYRVRDTTISDTASI
KVG 









































complement(42151..42285)           PHAGE_Campyl_PC14_NC_031909: baseplate hub assembly protein; PP_00047; phage(gi100106)     2.63e-21            
MKRDGSIIKSFKREINLQTRFIKNKTKYTRKEKHKKGAIINGFN 
complement(42282..42668)           PHAGE_Campyl_PC14_NC_031909: baseplate hub subunit; PP_00048; phage(gi100107)        1.17e-91            
MDITHSQYEVMVSAYKKDFIPNKNEMNLLNSFMLCRWMSNDIHSVEFANFINNHTDIPINVQYWFARSIMNKVTYMGRPPKEDKLNEYEEAVSKYYNVSFDVAK
QYCSILPKEKQEEVLNMFKGGRIK 
















complement(46765..47112)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00052; phage(gi100180)         1.11e-79            
MNTVYSKYLCESSHYDQYKETRDIETANVEMKNMDRDLEFLKYRIEQKLEKANIEITEPYIEGECIKFALKNYNNEDNKKVKDILYDMRDISWGPISGDYSDMSQG
YEVSLDLED 




complement(47899..48285)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00054; phage(gi100112)         2.17e-85            
MNLISIDYEDKFYRKLLEDELTNFKSYPFKISEDVYWDFRNYGANSIDKPEKEIKLNLSKRKVRFIINRLEYYNENGYWNNVSLIQKHYQEERKLEKLAETHAKTFM
SAVWLCIPIFALLALLKYIFE 


























complement(54648..54995)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00059; phage(gi100007)     7.37e-74            
METKLLNILLNIGEKYGIYFKQNPIEDEYNVEILLWTKESPESWDKIIKDIKTELLVNFTRNIKISSWGKNSVNIKMKLDRLYQVNILYNLEEPKLNITISYPKIINESAY
DNFL 












complement(57328..57456)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00062; phage(gi100010)     9.38e-21            
MTTSGDIATTPSRLTLKRGKIKPKVIKYKQTKTLTLKKLSKN 
complement(57453..57752)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00063; phage(gi100122)         8.28e-63            
MYTKYLYESSLDLQFEVTDQDFDESFLNFNKELPVSLSETLKLKYNIKLSLKFQSKYDDIGILVKLNDNGKYVVYSNSIENIDKFIIFVDTLNQNKGNL 
complement(57742..58242)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00064; phage(gi100012)     3.95e-117           
MANKSKSKGNTFERTVAKMLSDNYADVFNVAQSFQRNISSGSMFGGSNSYRGMNVLDEHTFYAGDIICPSEFKYTVECKHYATAPSFNSLIIQECAQWDKWILQV
EADCEISNKLPMLVVKYDNIKPFVFIKHNFEGFIFKYRDYYAYNFEMFIKEYKKELINNVY 
complement(58259..58636)           PHAGE_Campyl_PC14_NC_031909: cytosine-specific methyltransferase; PP_00065; phage(gi100124)     1.45e-84            
MKVQFINSKELSANVVSTKNLHKLNRKILVPGVVDISGTIYLASPSKELPTIRVEMDAVFKCGECSSFKIKHYVVNKKVYGSNSEIYDGISKFLRKYAKLILVSKDEI
MFFNYTYTGFAKYFKNK 




complement(59543..60124)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00067; phage(gi100126)         2.28e-137           
MVTYEEIQQLIRNCLDVGIKAPASAYSKLLRHGYCVMYGGDAKFNKLEELEDNFDVKQFDRDTWVIKEYKKELTPEEWKDVNSQALYNGGTPDQIAKDIEDGEK
NPILENAFNKLDEAKLKQISKDDLKNIWNENDLETKREKTLKLISELKYKSPSLEKIIDIIKTTKDKNKIDQIITNIMFVGTGDKVIKI 




































complement(68266..68895)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00074; phage(gi100159)         9.26e-153           
MKLIIEEPVKIKGSVELNESKGEKNYYIQGIFATINQQNINGRVYPRPIWESAVNSYQHHITTPTTSSLMEYQHPNRQYVDPLEAVAKIVDLRIEGDYVMGKAKLLDN
PKANQLKNLIDEGISIGVSSRGCGELMNGTVTEYELITFDIVPNPSDRNAHTKGLNESFDNGILKDKNYIKDKNGILVEADESNINNKSITSQFVDLFSQL 
complement(68892..69059)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00075; phage(gi100158)         1.84e-30            
MYNYIKYAERKDMNGLSNVIQKKLQQEYNNHPKVVNHIETIKKNEALIKVLKEYK 























73633..73854                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00080; phage(gi100153)         8.05e-44            
MPPIKHMSVADRIAQKRYRKQPKVKRKLKIRAKKNAKAPSENMSWSSKKRGYVRKDPKLRRTMKLVAKLRRKS 














complement(76778..77074)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00084; phage(gi100144)         8.84e-65            
MDNFDVNSFKIVHPHDVLLEVAYPSEIKSESGIIVTVHPSLIDDRQTQGKVLQIGSEVKDIEIGDTVVFGKQHGIDLHKNDKVKYMLIRDESLMGILR 
complement(77130..77639)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00085; phage(gi100145)         1.27e-115           
MAKLILQRNKEYKDIKWQNSDKIEDSTIGELSLLDDNDNVIFKCASCENIGPSTDESGTDKRIVAREYKLKWCNSSKNGLLSKKYPEWKADNGSNIAIWVVSDEVE
GFNNRLIRIHTGNAPQHTEGCILPGSDLNNGTVGSSVDITHKLFTKIKELGIENIVFEIKEID 
complement(77642..78139)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00086; phage(gi100146)         5.63e-113           
MYYSNVVFPLNEVIPGFTYNVKKSKSNIYIRFVAYGYSVDDLEIVYNNSIITISTIKDYHEVKTDPKFSNNFPQQDKFYIQFWCPKISGINAEYSGNFIKLNCSLGDTSV
NLGVVPIKFINEDNDIDILENTSDDTMNIIQLNGFMDKLEDTKDDFDSEITNNKD 
complement(78174..78317)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00087; phage(gi100146)         5.64e-25            
MVEIIASFFVGGLIGFIAGYFVYHNNKKKASEIGDKIESVKDEIIKK 

















complement(82330..82749)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00090; phage(gi100038)     4.38e-96            
MTIDDLKSFHKKIIEEYDMDSNWNPSTIKHHLTTLSGTIAKYLNYWSRLKHIIIQIDEEYNEKYMILYSHYRENSNINYTVTEIKDLISKDNELCNIRVKKSTAILIMEYI
EKCVDNLNKTRYDLSNYIEIEKFLNGKG 










complement(85798..86442)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00093; phage(gi100134)         2.20e-149           
MILTFDPYYDIKESNEFIKNLKENKINFNTYILSKSPYYWFYEVADKYKPVFLKFNEANSTDLRFMLPKLKELTPSDENYLRRIPKTPSDFERYVSPNIFKKAKYAEYF
CVFRYKNISEINKITETLGIKIYILPKKVKEWNIAFTFNKMIRNFVFGHYILLEKTKKTQFNKVGEIELYLNNKVFVTDKMKFKTRELPFSEDGTYYPLKFQIKQ 











complement(88351..88695)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00096; phage(gi100130)         2.13e-71            
MENIDEFIELKSQKLNVTDFIEKNSINEDELVKNAIKQIFDLEKQKREIDVEIRDIKTKLSKDGINITEFNRVLSTLKNELKMSIDSLSANISMYNSIVSDKELLQNLKDQ
IND 
complement(88752..89366)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00097; phage(gi100157)         5.27e-142           
MKLFEKLEEWLKERHLDKKEYDHLTLLGYLHEEIDEGIKKRDSEHESIDWRCDCIVFLINSLYQDGYNPKICMDECLKEIEERTGEYSESERKFKKHMGAYTYKEA
LDEIIKNYNCRKEDITLHGDHREFWYFLVNGKQIKVKKWYKADYSKSIRDDISNERYITKAYKLGKKIMFRQLNTKNRWKLLRDENLNFKEFDYKVVD 










complement(92544..92933)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00099; phage(gi100161)         5.90e-82            
MKFIECIQILLENNSIGSLSLENDYIKIYKDNDKLKIVDSKDNNVLLSSEHINNENWELNNKLFELILGSMWINDSDIVTKVEDNSFYNNIQYTTFRNMLTNEISILESD
KYYTNYCKNKWFQPEPLKV 
complement(92930..93370)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00100; phage(gi100162)         2.30e-102           
MENISKDLITIYRYGNNFELYNDFYFIFDFDVTSKGFKLEKYLVGNNIIRIPKGFRTDFGSIPQLFQSIISPVGKPTKAYVLHDFLCGKSNKGDIPRALADELFLDAMKL
LGVNVVKRYVVWAWVRVYGIIYKPLAKFFKDIWNKL 
complement(93372..93875)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: recombination endonuclease subunit; PP_00101; phage(gi100052)     2.97e-114           
MIKLIIGPMRSGKSLELLREAEKLHFGRKKYILIRPEIDDREFISRSYKTLHNLNVIKTNNINTIVNEYDYILLDEFQFFDNSITNIIIDNISKNWILCGLNINYESKLFENII
NILPYADRICKLSSICEKCGSEYGNHNISNTGEICIGDDYTILCSTCKLQLKG 
complement(93872..94081)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00102; phage(gi100121)         1.26e-33            
MQIEDVVIDTFKSILILLISAIMLKVYVILFLIISLGVLYYDLTIGIPVTATLMFISIYLANKFEKFIS 






complement(94988..95497)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00104; phage(gi100166)         4.77e-118           
MKKVLCSAVMVAGLMFVGCSTTTPQQQFAKPMLEKYDDLPSWVKEYGDIDTAVGSAMYMGQNYIQQQTEAIAVAKMNLTQKLSSKVDSMIKQYYQNKGVVKT
NNSQVSVQVSSSLVKNVKVVDTYVADDGELFVKIEAYSTNLLETIKNDDSKSLFDELDRRVGNVKSN 
complement(95584..95910)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00105; phage(gi100167)         1.23e-72            
MYFSLKETLEFLSTNSKNGVWEYDDISEADTTVFCSYFSDNSDENDIYIILSNPTGKSDIDLQGNVTDTDSEDGIPDRFSTCIMKVNLAKLNISNFDELGNAIKKYRL 
95996..96451                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00106; phage(gi100117)         2.54e-105           
MNFRNIALNSNIVFRTLLFSDDTQYYCQKVKLPRISLEGQKVGHSTGTLTLGGEVAKFDSITLTLLVDENLEVWKNFVNLINKYNKISTNTGCGIEATSWLEIHDSKN
KYLFKVEFYKSKLDEVSELEYSTTDNNIITLDITLNFDYMKII 
complement(96452..96733)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00107; phage(gi100058)     3.41e-60            
MNYLLELSPIFIVGLICGLSNYLSDEEDTCAGKHIKCILKYIFNSAVLCTIIYCILTSLELPYLTKIGVAGAITYLGIDKAMSLIKEFIHLKK 








complement(98498..99106)           PHAGE_Campyl_PC14_NC_031909: protector from prophage-induced early lysis; PP_00110; phage(gi100001)     2.05e-127           
LQTAINEANKYINYSNKSITIKLISDLVINEYINIVNIHSPFLNIDFNDYSIILNNASYDIGFSMYNSILGHINKLKINCNNKSINTAILLQKNSFCCFYYMKGILNCLGNAF
ALSTNSEAFVSDSTCELSAGSSGYYSKGILSVGSRLLFHTCKFTQNSGTLSQSVETSGIIDNFYTTFSGSVTGKSQVVGTWTKNGYISA 
complement(99091..99216)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: ribonucleotide reductase A subunit; PP_00111; phage(gi100062)     3.96e-14            
MLEYGRSSIKDIIDNSAKLLTSNLEWTVGTGGASSKTCKLL 




complement(100043..100165)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: aerobic ribonucleotide reductase B subunit; PP_00113; phage(gi100063)     1.88e-13            
MINYGNSNIKEIINGSVKILTESKTYTVGRGGGSPNCQML 















complement(103232..103552)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: RNA ligase 1; PP_00116; phage(gi100066)         1.74e-64            
MIINVDKNMFQERMQKQGLSYGASDVLFDYIEQLEDDIGEQIEFDPIAIMSDFSVAEGEDELKDQLETLGYFDMEGDDSDLDDAKQRAINDGVLVYEDDDYYVFKS 













106525..107172                     PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00120; phage(gi100010)         6.98e-158           
MAWNLNNRQNEYQLFGTLSAEIIDMYGFQLTYIKTTRLGHDKVLDDIVNYGTEATYQIFALPENAEMFDERGDILNKFGIFTMDSMNLFVSANTMKRIFQDDSKIPS
AVGDLLLLPSGKYIEITSIEHQVPGANNQFTYSNSKNVYMLRCKSFNYNHDNIPTLEEVNNEEVNESLDEIFNLVGSAENSKDKIKEEQDKESPLVKGTDSVFGYLDS 














110072..110527                     PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00123; phage(gi100100)         1.55e-102           
MKEKAEALGKKLDKINDIFNITEKTIVEVEKSDLVKSNPEENLKFTYLKEDFNLMRESLVNTIKRGQDILEVISNNILADPLSSNQAVMAYSTLVDTINNSTKLLTDIY
KNIVDIQIKIAPKEAEKGSGKQEIMTIAQITKMISKNQQSQN 
complement(110524..111075)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00124; phage(gi100099)         4.96e-112           
MADLKKIEELIALAYGYEYGISHIDESDIDVFIKGFDEKNAEQQLKKADIDLESLLSNNFDKNALIMINYKKYYPIKLYGFNNLIKEFPSLNNINFYGALSGASTIIIKD
DEIMCLVDPNDYEKFKESFDSMLIELMKFIANSNSAEKAMDYLVSNDVGVGSYYNENKELTQMIFNAIELNKA 
complement(111068..111259)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00125; phage(gi100098)         7.00e-26            
MFKKLLNWFMNNFCACILLLYLILLLVIIDGEISLSNVITVIVITGCYIVERIENTIKGNKNG 
complement(111283..111582)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00126; phage(gi100097)         2.60e-62            
MKSSNFKTCKINKKYHCINTKSALVQENYKMEKSKYSVVKEFINLNYNIPIEKIDKETELFFFSIKLLCDIIELCPKHKKEIEDKVGELCDFREYQLES 
complement(111569..111736)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00127; phage(gi100016)         1.02e-29            
MLEYFNCYTSKKELYNYEKLKQELNEHGLNIKDDENSIKEDIDENILKRKNNEIK 
complement(111730..112152)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00128; phage(gi100017)         2.94e-79            
MTNRCFIGILENNNNVKYSFCMYDGNIELAGRILLQNYNKLCELLNIGKDIRFLSNRIDLCNFFEYEYNYNHDVKMNLETFKNIVFDDHYCDIKYIYLFKDGKYYFA
DRNNYKNLLENALEDFICYSMNNEDNLIEEIKC 
complement(112245..112682)         PHAGE_Campyl_PC14_NC_031909: exonuclease A; PP_00129; phage(gi100018)                3.71e-86            
MENYKSVYNDCLLLFLELQKSDDNKKLQIYDLMLKCIKLKLPEITTKENIKKVQEVLKNYKEIETLDKDKTYGTISWYYLLYYIGNVYNIGYKVVFYGTNGRYSYN
DDYFEDIINLYSTITFLKEKLQKGCPDNVSLAVFNKEGN 
complement(112806..113399)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00130; phage(gi100019)         1.36e-72            
MTEIQFNKIKERLTQWREERHLTYENQQAEFFGNVFEKVSEYFRAKDDLEKIDAICDIVIYFFNAFDFKYIAVSSNMYCYTFSDVVVYNIYSLFGARTDNLCVVENE
NDFINLEKNLNLTMFEIEQLYENLDFDFYKCMLEKIKEIESRTGYYDEKLKKFIKDTSDEAKAKWYKADYESCMFEGWEIISKLIKEFKK 
complement(113380..113721)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00131; phage(gi100091)         1.47e-63            
MVSTVFENDYVEVVTRKDAESIVENFIKTCDCDWNDDENCDKCASIDNLKFHLEANRDCNIFVRFKFNKDDKTNLRWSGNLCVNSISEYVENELENDIKVVKYNR
RLNDRNTI 
complement(113765..113968)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00132; phage(gi100022)         1.67e-42            
MNKIKQWTIELMCMFYPIKIKSTAKDNYYISYKFKFNKYYVFGDKGGALFAENYKDALRIVEWMDDN 
complement(113971..114120)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00133; phage(gi100023)         4.33e-28            
MKIEITRDISNVVKKSPEIILNDEFYKLYVKYIGPSEELLFYKNCNKGR 
complement(114347..114823)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00134; phage(gi100084)     5.29e-110           
MYSKFINEAVSDDMLKAINVANWKTGLDFRKDYEEIESHGKKALEILDKLAKGGYNSKQYYNIYSDLRDELWNIHDRLLSYKNKMPWFRDELQSPELKRYREIIK
DYIYEVNQAMKDLKSDYAVVSHISNRNLESIIKAIIDEYERLYEIVEKIALSQ 




complement(115093..115374)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00136; phage(gi100080)         3.56e-57            
MALYKFSVKLYDDKHENIQKFCLIDGKHWHLLKDFRNCLISPDNVYFYDEKDLISISDYEDALKVFKKPIHRRMFIEYGSSYQEPDDKFITEY 
complement(115494..115946)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00137; phage(gi100091)     2.26e-98            
MLLEVVFENFKFCRQDRVEINFDKLYSPDYFKKTFRKVKCKCNPLKSLFFVDCDLPKYILKAIKRDKSLCNEITKDYGVITLTYRQDDFLIDYILKITESEIIQTTDLVY
LDLYLKDENSDCAKTINENTKLKPSEKKALEKVKQFEKIQ 
complement(116057..116371)         PHAGE_Campyl_CP30A_NC_018861: hypothetical protein; PP_00138; phage(gi410493054)     1.39e-68            
MRITFNFEKEYTSTPYARNAEHDKEKNGEDFEKNYLSKWIDEKQETLIKVDNLELPFSDSFVDASFCKLIRQNKKLFYKYIKIDDKTDDEKDLLNTIKEVLARK 
complement(116527..116715)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00139; phage(gi100076)         4.00e-10            
MDKKCRDSYGQIDYLDAYGNYVKTIFESNTERHRNYSGENIRRGNGTKRLEESIKKCKGAKM 
complement(116721..117335)         PHAGE_Campyl_CP81_NC_042112: co-chaperonin for GroEL; PP_00140; phage(gi100075)      6.32e-107           
MIESKFIIKRKLNFKNMEFGYKLFDVSGYFEFVEKPIYPRILEEFKKLDPTMKNKTILNRLRYIDRVRYDLLYDFTFTLAYSKSKLDKTIKNGKDLCEYDLYDLKPDW
LLKMVSDIIDEKTLLKYLPDIFEYMDDIIKSINDNFDLSNNAIFKWFQNVRNYIKLLLDGKIDYKNYCINIDLVIKSNMENALLFEKEVIEELNRC 
complement(117496..117882)         PHAGE_Campyl_PC14_NC_031909: membrane-associated initiation of head vertex; PP_00141; phage(gi100034)     5.89e-75            
MAMILSQEEIDALLECDSRPTNLGIRSIVDKKISELREEHSKLSIKMKAIQGLNLLAHTDDFTIKDYMSIINDLIDCLKYKISHCQSFRDNISNKEAEKEFLKELGSFKLT
LLDFELNMNTGEENGEI 
complement(117961..118116)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00142; phage(gi100072)         2.42e-27            
MRELRGIVFNFYKKYFCKCESCNFREFGKLFKNYFIYLNLFQLYKITDEGI 
complement(118304..118705)         PHAGE_Campyl_CP81_NC_042112: 3'phosphatase, 5'polynucleotide kinase; PP_00143; phage(gi100070)     9.18e-90            
MNNATVISFKFETEQLAFLNNCICYYDDEFYNVKYMCNLSDDEFKRITNFISCMKNNIKYLEINDKNVDIETLINRLGTHIFRYAHTDTPKEHKDTEYMLLKDYLLL
HIKDYGDNELVKQILKKSEELNSKYL 
complement(118756..119199)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00144; phage(gi100038)         2.47e-103           
MPEFKQGFYKPINPEKYIDDVTNIIYRSSWEYKFMLWCDNNAGVLKWASESIVIPYEFLGKKHRYFPDFYIEVKDKDNNIKKYIIEIKPQKDAIFKKPKIITEKNKKRV
VEQALTVSKNQAKWEAAREFCRINNMEFMVLTENELFK 
complement(119199..119582)         PHAGE_Campyl_PC14_NC_031909: RegA; PP_00145; phage(gi100039)                         2.74e-74            
MNESLADYGLDVNGFYKHIDGKESIVETDDFKIKITYDSVNSEFDGDNEELLLKMHCNIELRYIAGIEDAMRVSDEINNKIVEIIEEDLKKYDDVSKYLILVDSGVFID
PDDPDYIQNAYIIIQPKY 
complement(119579..119902)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00146; phage(gi100099)     5.69e-60            
MNIYSIFLNEEVEPQKDLAKKSLDFLGEKLNATHSVSEKGNTLIATYKDKNGNKLCDVNITVNDNNIKVTKVTDNKGKPKQIDLVIHRINDIIGSRMMSYINKVKKQ 
complement(120203..120478)         PHAGE_Weisse_WCP30_NC_031101: DCTP pyrophosphatase; PP_00147; phage(gi100024)        4.39e-05            
MNNKRKNNGTRRFTGYFDKNGNKIYKDDIIIFNDIVHDTNRIGVIIKRQHSGEFRLEFSKDDTLGLKILDESKLLVIGNINENAELLEAKE 
complement(120638..120880)         hypothetical; PP_00148                                                               N/A                 
MKIGTDKNGKEIKIGDVLFCLELVATEVEDEGDEVEYEEFEHYIQVLEKDNEIIVCDLDSDEWWFLHQFSFADYKIVSDY 





complement(121341..121547)         hypothetical; PP_00150                                                               N/A                 
MKEKVQNISIDVNVEELLEQVETEYLLHELSRRPLLYVDITSLIWDTLDEDELKILKKEVHQMIKEKQ 
complement(121882..122052)         PHAGE_Campyl_CP81_NC_042112: aerobic ribonucleotide reductase B subunit; PP_00151; phage(gi100063)     1.03e-30            
MDIKKLKESLEGKDNGKYFCEIFNTNVDILVVDNGMKKSEAIIQVLEDVKELYKND 
complement(122098..122379)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: baseplate subunit; PP_00152; phage(gi100104)     6.97e-53            
MEKVIHKESGKEYSYFKPVLNKTTNEVMICYTDGVNFYVRTKNDFFDKFEILETPEKYDTIKYFHDLVNNKLWALKRQEELLDKVSKFDLSLI 
complement(122386..122628)         PHAGE_Campyl_PC14_NC_031909: ssDNA binding protein; PP_00153; phage(gi100044)        1.85e-46            
MKLIISLLILASMAFSIEVCSFKEPLKRGFFSIDNSIVFLCIDKKLFVRNFPGETDYSYSVTQVFEEGMKPQACSCQAEE 
complement(122625..122792)         PHAGE_Campyl_PC14_NC_031909: loader of DNA helicase; PP_00154; phage(gi100045)       4.14e-21            
MTPKKIQKIFEKVLKEKEKEYTDGRLEEIRKEREYVESIVNEGIQKANNMLKEFK 
















127089..127226                     hypothetical; PP_00158                                                               N/A                 
MSISVYVSNNIVTYSFGFSKCTPTLSNTSKATGKLIKLMIIESTQ 
complement(127254..127625)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00159; phage(gi100111)     6.26e-83            
MKLLVAGSRDFNDYNLLKNKIFELNIQPSTIVCGMTRGADMLGYQYGIDNSLKIEKYKPNWNLYGKSAGPIRNKLMADSLNKETDMAIIFWDGISKGTKNMISILD
DKKINYKIIYYKEKENE 
complement(127622..127828)         PHAGE_Campyl_PC14_NC_031909: recombination endonuclease subunit; PP_00160; phage(gi100052)     4.52e-41            
MFVKIKELICKFVNFKTLQKFITTDRQFIIEGQNGMKYSGDFFFVDEDGCICKISDGSYVGTMVKSSK 













complement(130472..130765)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00163; phage(gi100116)     1.92e-53            
MKRNILLLIFSSFLFIGCSTATKTVTITKKEYLKYPLDEKYIPHKLDVKIMKQKLNGKDYLLILPNDFITIYNQYKHLELNYNNLYDSVEKFNLQIK 




CDS_POSITION                       BLAST_HIT                                                                            EVALUE              PRO_SEQ 
----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- 
 
#### region 1 #### 
complement(4..609)                 PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00001; phage(gi100059)         1.17e-132           
MYSKFLNESSENLWVFAKNDIKLRKLILPVIQDNIEYVMFLNDRSIEEGKLKDICLDIEIFGVFEHYNIGNYKKIEPSIVVNVTDLKKDALKSIEDKLKNCKSKDEPVL
SLKLDMITEYNVARLLEKEYYINNFTDIIQNELKSKQFKIVEGNIGESVVELFNDYGESMIFTLKNNKVIKVNGQVGTKYNYLYSSLVIQKI 






complement(1640..2197)             PHAGE_Campyl_CP81_NC_042112: ssDNA binding protein; PP_00003; phage(gi100044)        4.12e-123           
MKLHYYDIYNISNGVFLTFQKNLKEKLLCVSHSKDIMDKKIGFYPLNFSDRGDFILLCVYIMFKHSPSSIYGLCEYLRNYNKTEYEKFKNTIKFYKNMIKKDIALLEE
KYKKPMFKEVMREYSIKQISFVTVYWYLMLYDIKDFNGINNTIICESILNVFKFLKFTDESKDYIKDVFKQIEGEVL 
complement(2210..2470)             PHAGE_Campyl_PC14_NC_031909: ribonucleotide reductase A subunit; PP_00004; phage(gi100062)     1.45e-48            
VESKTELFNKLFEFRKQKDMMDDCILDVIIEFGNHINMDPELIASELSDYAIFRDIVEKDLKKFKFTKYDPNQSDIDISDIDILWE 
complement(2460..2906)             PHAGE_Campyl_PC14_NC_031909: aerobic ribonucleotide reductase B subunit; PP_00005; phage(gi100063)     2.09e-103           
MCVLKTWLEDSNAKLPEISVMGSACYDIFSIEDKTIQPGGFEYVENGVRLIIPDGYYIRFNTRSSLGFIKDLFVYPGILDASWSGNLKVKVYNFGKEPYTIKKGDKYC
QFELLKCNESKIENISKDDFDNITKKLIRGNNGGWGSSGK 
complement(2894..3286)             PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00006; phage(gi100123)     3.60e-83            
MKNIEILNMVEELVKLNPILLISENFSHTYELLKENVRESKSIENKKIKLNCISVKLDDDTKLPCYGTVLSVLMKDNLENIINKNPQSLLEISFKISINVLLDLIDNFVEIY
DFNNESLLLINRIKICVY 





complement(4619..5023)             PHAGE_Campyl_CP81_NC_042112: RegA; PP_00008; phage(gi100039)                         2.63e-90            
MSYSFEQYCNSNNFNEFQRYLITQLGYINNKNVVAIQDSEYIDVFKAIKQEYYKASSCKHSDKEEVIPEHYTKLAIEPIDFIYKNNLNFCEGNIIKYVSRLGSKDDNKS
ELKKIFFYFDYLLHGNYDLTKRTFS 
complement(5027..5203)             PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00009; phage(gi100126)     1.22e-29            
MTIKNKINDINEILQSYVGELVLSDIDTQKIVENLTELETIIKDAISKQLNNSKLILG 
complement(5259..5825)             PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00010; phage(gi100037)         4.14e-127           
MEKLIYIVIFLCIVFTTTSQSVIFHAKYNFEDIIQERLSYLKQNMINHISKYNNKNATEITNYIFEASLKYNINPVFIMSLIQSESYFKHKVKHKYNNVKGISGINYKMW
KIVLAKHNIKHINSLKNQIEATAIIINYIKQKYKTNDDLEILHYYKGRGYDKYLNKSGLDLAQYSYSMYIKNIKIIYN 
complement(5844..6479)             PHAGE_Campyl_CP81_NC_042112: DNA polymerase; PP_00011; phage(gi100036)               1.02e-146           
MKFNCKNFAKALFYSKDINYLIKLFKYAKQEDKKQAMQILLWARDVNGGNIKNSILLLKYIAEKTNNINDMFLASVVKYGCFKDLNEMYKVASDSNKRKILSFYS
NELKLKNQLAAKWAPRKGPLFYALANSLCLKIGDFRRYITSLYISVEAKMCDNMWDSISLDEIPERAIKKYKKVLEKRLKITIYCRSPKQRRLKFKGCEKLLKQY 





























complement(12993..13442)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00016; phage(gi100133)     2.81e-94            
MNIYAKYLNEFTKSSIKLNEADIDFDDFISEVKEIAGTSGDKLHNPRTSPVFRNYMYSLYINDDGISAEKAWRMFEELNIMDSRKIIQYIEEDDDWYVNRLKDEYNIS
LDDFKQMDEYDQIRTFCEIHNCQYIEGTDNKMYVMLPKYYV 
complement(13495..13755)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00017; phage(gi100134)     5.80e-54            
MDKQLIKDITINGLSQFAKGHEIEAITETLQIVQEYNIEHHSHNFEFDVEPITSLEDFIKEINILITYEDLNLFHEVLVESLKYYK 
13810..14211                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00018; phage(gi100076)         2.46e-86            
MTFVEKNMVKELKKTISSKKPLVLCFMSKLLQKEIQKLLKGNKLITIIKIILYAFDKTPVEVKRGVLGYVENEKNIPFQYKYDNTTKTLTFSLDKKSYNFNLCTANEY
IKVLANETNWMILKKNLNNALKNIK 
complement(14229..14747)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00019; phage(gi100077)         2.15e-119           
MAITNYTEFEKLCPKNGEIADQDVLGKPSLQLKRELDTVMSQVNSIIGITDPSNWDTGTTYTQNQIVKYNNYIYVSLSDGNRGNQPDTSPSKWKKISGGSISSSVNIIV
SSSDYNTPVTEVSDNSLSLKPSKVYVNGNLIPTTNYTHDGTLTKITFINGMSVYKNDVVTVEY 
complement(14780..15421)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00020; phage(gi100078)         2.53e-156           
MGILNTAVGAISDFFGGNKTQSAITELAQKIQKAYSTNFDLESLYSIDTFALKNEVPGAGRINILDLPNMDILIQRVSIDPISFAEINEWIGSSWVYTQGRHELQQLTITF
RDSDGGFLYSAFKKLAGHLKDQYPDDQMWIIKIRKRTLRESRNYINQSVQNNEFKNGGHVIIDTQCAMIRSHGGLSLDQNSNGLATFDVTFLFDPFPPQISY 
15467..16120                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00021; phage(gi100027)         1.41e-152           
MELEIWKGKHSILLNKLYNDNNYIYDSDIIDVLVYKCLNQPKYITNDEARFLFFKKYFAEVCSKIDSSFKCPYCNEMNDIKFTNDDISITEYSLKPIEINVDNVIVTMY
FKKELSQDDSLSLITETKNMIDHEKRLLELYYMIDYISINGEELRGNHIIFEKYINELPLSCFNKIFDYFINSIPKHSIIKNCSCKNCNSEINVELKELPESVRRNLF 
16117..16779                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00022; phage(gi100026)         2.40e-156           
LTKDIIINNRHYCLNVWKIKDEIGILHQFIDWIELPLEDQVNKIADILIPQTKDLDYISRLYIMIILSSYANGDYSDILLTCPHCGNPIDTRINIRENLEFIPPKTVEVEINNK
KYTISKQNIELCNELPLKDYNSILNQLNDDGDLKLCAKVKCIMCNNDVLAIRELKDLFENYVIMLDLEWYYSTLKYFISQLGFSKTDFDNLYPFEIELLTNENKDE 















20319..20672                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00025; phage(gi100083)         5.63e-80            
MNDTQTIQIFDLIGDSQARDYIAIKAYKIGSDVSGIKDSINDILDDDPSKAFDNLLNMAENNISNIINPSNWEAGPRLKPGVPCKYIWILPIPSSLAEAFSHEFNQDEIDPI
GDMIG 




21463..21924                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00027; phage(gi100085)         8.83e-107           
MKNSVLNNKIMVDFNGFSLSPTYSVNIPKLREFMKNNLSMFYVKEMNDNVRFEVLALREYNDSSLWDILMILNFGENGILNFAKGDTWVSDNAENQYKEQQEYFS
PNFKPEDLYNQILSKIQKKNESRRKVIFIKRQFIPQFKESIKDMLNVF 









complement(23816..24157)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00030; phage(gi100147)     1.37e-68            
MFLEDNNKQLSKVLNDNIVIKEDEKNIYIKFKKNIIIESDNNVIFLAKDYIVNSAKEIHLNPDVKISVDDNVDDIIKKIDDKKNEINISVEKLTHNHKHCKIKCFFKKLF
NLN 
complement(24141..24428)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00031; phage(gi100089)         7.88e-64            
MPPVTRLGDIALGHSCYPPSPTIEASSNVFANSIAVHRLGDKIQSHACPDTPPHGRNSSSGSTSVFTNSKATCGIGDAVNCGGIIAQGSNNVFRG 









complement(26047..26493)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00033; phage(gi100014)         3.42e-97            
MEKNYNTFLRKKSVTIKLNDDLKDKLKDTIENINDYDIIKIKLGRTFFNQKRYYKIYARKKFGFYKTLLSENDDSYFFMENTSKIIRRVFNEYDVNCYNLYPNKKYR
YGLSIFILICCSIILIALSLGVGALSYIFKGYFLAFGFSLF 
complement(26553..27125)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00034; phage(gi100092)         3.19e-138           
MGLESGELRNEAQGGYNPPFELSIYKHQVKFTPPNNFESYIKWELLGDIPLHLTINEQTGLITGNIELLSKQPSAKNAIYEYQLMKIDGSNWRHLGILKNGQTFTFNFQ
VKLTYTVQANSGGSRLSNTVTEVSDVTITILQDNDIISTLFCKNYIDEAKFPLKIGDKVYTDAVEFMKNHPNKNNFKINLV 
complement(27142..27669)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00035; phage(gi100012)         1.65e-129           
MPLYTVDKLANALKGGAKSDKYFIEIGTPLGAPEVAFTEEDIILCKTASFPERTLGEVEAFVQGRKLKLPGDSTFDAAWSPVFYQTPDHNIRAKFLTWIDKIDVYKN
NYHTCDPYSLMVTAKVHQVNCNGEPVATYEFFNVWPSKVGEIEVAADKTNSIQEFTVDFTYSHWEKIA 
complement(27698..28276)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00036; phage(gi100094)         1.96e-139           
MSLYNIDRLRSSLKQGGAINSKYKIDIKIPTLLRSLPFFKTVNISGEYLSIMANRTSIPGKSMSTVKVYHRGQPFVIRGAAQFNNTHKITFYNTPDMDIHQLFSDWIYRI
DSFDSTITQSIFLGNYVGFNSVGAGYMSDIIVSQLSSDGRTETEFKLCYTFPIDIAEVELSASGKEISSTEVTFAYTYWERI 
complement(28278..28838)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00037; phage(gi100010)         6.08e-137           
MVESINPPKGYFKIELLDKDRNVIDTFEKHNLVVNGSRPVLASHMAGRSTTPVNKLVLGTRGHIGNNLMMPKTANEGFTAARTQLFAEEEGEFCYHVNFTPPQSDG
QAVVTEDDVGAGSTVEVTNSNNTITYRIELSTTAGNGTLGAVGYTEAGLYAGNDLFCMRTFAVRSKDVSSILRITWTLIF 














complement(32468..32815)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00040; phage(gi100007)         2.88e-75            
VIQYKDINPKNIEKDIINVDTFYVSLKNIVSTTIGDIAGFPEFSNNAQLLFDQYSSVALDAYKTSLKTSIQKFDYRIIVDNINISKGDADNSVYIEIKYRVRDTTISDTASI
KVG 









































complement(41929..42063)           PHAGE_Campyl_PC14_NC_031909: baseplate hub assembly protein; PP_00047; phage(gi100106)     2.63e-21            
MKRDGSIIKSFKREINLQTRFIKNKTKYTRKEKHKKGAIINGFN 
complement(42060..42446)           PHAGE_Campyl_PC14_NC_031909: baseplate hub subunit; PP_00048; phage(gi100107)        1.17e-91            
MDITHSQYEVMVSAYKKDFIPNKNEMNLLNSFMLCRWMSNDIHSVEFANFINNHTDIPINVQYWFARSIMNKVTYMGRPPKEDKLNEYEEAVSKYYNVSFDVAK
QYCSILPKEKQEEVLNMFKGGRIK 
















complement(46543..46890)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00052; phage(gi100180)         1.11e-79            
MNTVYSKYLCESSHYDQYKETRDIETANVEMKNMDRDLEFLKYRIEQKLEKANIEITEPYIEGECIKFALKNYNNEDNKKVKDILYDMRDISWGPISGDYSDMSQG
YEVSLDLED 




complement(47677..48063)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00054; phage(gi100112)         2.17e-85            
MNLISIDYEDKFYRKLLEDELTNFKSYPFKISEDVYWDFRNYGANSIDKPEKEIKLNLSKRKVRFIINRLEYYNENGYWNNVSLIQKHYQEERKLEKLAETHAKTFM
SAVWLCIPIFALLALLKYIFE 


























complement(54426..54773)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00059; phage(gi100007)     7.37e-74            
METKLLNILLNIGEKYGIYFKQNPIEDEYNVEILLWTKESPESWDKIIKDIKTELLVNFTRNIKISSWGKNSVNIKMKLDRLYQVNILYNLEEPKLNITISYPKIINESAY
DNFL 












complement(57106..57234)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00062; phage(gi100010)     9.38e-21            
MTTSGDIATTPSRLTLKRGKIKPKVIKYKQTKTLTLKKLSKN 
complement(57231..57530)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00063; phage(gi100122)         8.28e-63            
MYTKYLYESSLDLQFEVTDQDFDESFLNFNKELPVSLSETLKLKYNIKLSLKFQSKYDDIGILVKLNDNGKYVVYSNSIENIDKFIIFVDTLNQNKGNL 
complement(57520..58020)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00064; phage(gi100012)     3.95e-117           
MANKSKSKGNTFERTVAKMLSDNYADVFNVAQSFQRNISSGSMFGGSNSYRGMNVLDEHTFYAGDIICPSEFKYTVECKHYATAPSFNSLIIQECAQWDKWILQV
EADCEISNKLPMLVVKYDNIKPFVFIKHNFEGFIFKYRDYYAYNFEMFIKEYKKELINNVY 
complement(58037..58414)           PHAGE_Campyl_PC14_NC_031909: cytosine-specific methyltransferase; PP_00065; phage(gi100124)     1.45e-84            
MKVQFINSKELSANVVSTKNLHKLNRKILVPGVVDISGTIYLASPSKELPTIRVEMDAVFKCGECSSFKIKHYVVNKKVYGSNSEIYDGISKFLRKYAKLILVSKDEI
MFFNYTYTGFAKYFKNK 




complement(59321..59902)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00067; phage(gi100126)         2.28e-137           
MVTYEEIQQLIRNCLDVGIKAPASAYSKLLRHGYCVMYGGDAKFNKLEELEDNFDVKQFDRDTWVIKEYKKELTPEEWKDVNSQALYNGGTPDQIAKDIEDGEK
NPILENAFNKLDEAKLKQISKDDLKNIWNENDLETKREKTLKLISELKYKSPSLEKIIDIIKTTKDKNKIDQIITNIMFVGTGDKVIKI 




































complement(68044..68673)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00074; phage(gi100159)         9.26e-153           
MKLIIEEPVKIKGSVELNESKGEKNYYIQGIFATINQQNINGRVYPRPIWESAVNSYQHHITTPTTSSLMEYQHPNRQYVDPLEAVAKIVDLRIEGDYVMGKAKLLDN
PKANQLKNLIDEGISIGVSSRGCGELMNGTVTEYELITFDIVPNPSDRNAHTKGLNESFDNGILKDKNYIKDKNGILVEADESNINNKSITSQFVDLFSQL 
complement(68670..68837)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00075; phage(gi100158)         1.84e-30            
MYNYIKYAERKDMNGLSNVIQKKLQQEYNNHPKVVNHIETIKKNEALIKVLKEYK 























73411..73632                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00080; phage(gi100153)         8.05e-44            
MPPIKHMSVADRIAQKRYRKQPKVKRKLKIRAKKNAKAPSENMSWSSKKRGYVRKDPKLRRTMKLVAKLRRKS 














complement(76556..76852)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00084; phage(gi100144)         8.84e-65            
MDNFDVNSFKIVHPHDVLLEVAYPSEIKSESGIIVTVHPSLIDDRQTQGKVLQIGSEVKDIEIGDTVVFGKQHGIDLHKNDKVKYMLIRDESLMGILR 
complement(76908..77417)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00085; phage(gi100145)         1.27e-115           
MAKLILQRNKEYKDIKWQNSDKIEDSTIGELSLLDDNDNVIFKCASCENIGPSTDESGTDKRIVAREYKLKWCNSSKNGLLSKKYPEWKADNGSNIAIWVVSDEVE
GFNNRLIRIHTGNAPQHTEGCILPGSDLNNGTVGSSVDITHKLFTKIKELGIENIVFEIKEID 
complement(77420..77917)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00086; phage(gi100146)         5.63e-113           
MYYSNVVFPLNEVIPGFTYNVKKSKSNIYIRFVAYGYSVDDLEIVYNNSIITISTIKDYHEVKTDPKFSNNFPQQDKFYIQFWCPKISGINAEYSGNFIKLNCSLGDTSV
NLGVVPIKFINEDNDIDILENTSDDTMNIIQLNGFMDKLEDTKDDFDSEITNNKD 
complement(77952..78095)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00087; phage(gi100146)         5.64e-25            
MVEIIASFFVGGLIGFIAGYFVYHNNKKKASEIGDKIESVKDEIIKK 

















complement(82108..82527)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00090; phage(gi100038)     4.38e-96            
MTIDDLKSFHKKIIEEYDMDSNWNPSTIKHHLTTLSGTIAKYLNYWSRLKHIIIQIDEEYNEKYMILYSHYRENSNINYTVTEIKDLISKDNELCNIRVKKSTAILIMEYI
EKCVDNLNKTRYDLSNYIEIEKFLNGKG 










complement(85576..86220)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00093; phage(gi100134)         2.20e-149           
MILTFDPYYDIKESNEFIKNLKENKINFNTYILSKSPYYWFYEVADKYKPVFLKFNEANSTDLRFMLPKLKELTPSDENYLRRIPKTPSDFERYVSPNIFKKAKYAEYF
CVFRYKNISEINKITETLGIKIYILPKKVKEWNIAFTFNKMIRNFVFGHYILLEKTKKTQFNKVGEIELYLNNKVFVTDKMKFKTRELPFSEDGTYYPLKFQIKQ 











complement(88129..88473)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00096; phage(gi100130)         2.13e-71            
MENIDEFIELKSQKLNVTDFIEKNSINEDELVKNAIKQIFDLEKQKREIDVEIRDIKTKLSKDGINITEFNRVLSTLKNELKMSIDSLSANISMYNSIVSDKELLQNLKDQ
IND 
complement(88530..89144)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00097; phage(gi100157)         5.27e-142           
MKLFEKLEEWLKERHLDKKEYDHLTLLGYLHEEIDEGIKKRDSEHESIDWRCDCIVFLINSLYQDGYNPKICMDECLKEIEERTGEYSESERKFKKHMGAYTYKEA
LDEIIKNYNCRKEDITLHGDHREFWYFLVNGKQIKVKKWYKADYSKSIRDDISNERYITKAYKLGKKIMFRQLNTKNRWKLLRDENLNFKEFDYKVVD 










complement(92322..92711)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00099; phage(gi100161)         5.90e-82            
MKFIECIQILLENNSIGSLSLENDYIKIYKDNDKLKIVDSKDNNVLLSSEHINNENWELNNKLFELILGSMWINDSDIVTKVEDNSFYNNIQYTTFRNMLTNEISILESD
KYYTNYCKNKWFQPEPLKV 
complement(92708..93148)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00100; phage(gi100162)         2.30e-102           
MENISKDLITIYRYGNNFELYNDFYFIFDFDVTSKGFKLEKYLVGNNIIRIPKGFRTDFGSIPQLFQSIISPVGKPTKAYVLHDFLCGKSNKGDIPRALADELFLDAMKL
LGVNVVKRYVVWAWVRVYGIIYKPLAKFFKDIWNKL 
complement(93150..93653)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: recombination endonuclease subunit; PP_00101; phage(gi100052)     2.97e-114           
MIKLIIGPMRSGKSLELLREAEKLHFGRKKYILIRPEIDDREFISRSYKTLHNLNVIKTNNINTIVNEYDYILLDEFQFFDNSITNIIIDNISKNWILCGLNINYESKLFENII
NILPYADRICKLSSICEKCGSEYGNHNISNTGEICIGDDYTILCSTCKLQLKG 
complement(93650..93859)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00102; phage(gi100121)         1.26e-33            
MQIEDVVIDTFKSILILLISAIMLKVYVILFLIISLGVLYYDLTIGIPVTATLMFISIYLANKFEKFIS 






complement(94766..95275)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00104; phage(gi100166)         4.77e-118           
MKKVLCSAVMVAGLMFVGCSTTTPQQQFAKPMLEKYDDLPSWVKEYGDIDTAVGSAMYMGQNYIQQQTEAIAVAKMNLTQKLSSKVDSMIKQYYQNKGVVKT
NNSQVSVQVSSSLVKNVKVVDTYVADDGELFVKIEAYSTNLLETIKNDDSKSLFDELDRRVGNVKSN 
complement(95362..95688)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00105; phage(gi100167)         1.23e-72            
MYFSLKETLEFLSTNSKNGVWEYDDISEADTTVFCSYFSDNSDENDIYIILSNPTGKSDIDLQGNVTDTDSEDGIPDRFSTCIMKVNLAKLNISNFDELGNAIKKYRL 
95774..96229                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00106; phage(gi100117)         2.54e-105           
MNFRNIALNSNIVFRTLLFSDDTQYYCQKVKLPRISLEGQKVGHSTGTLTLGGEVAKFDSITLTLLVDENLEVWKNFVNLINKYNKISTNTGCGIEATSWLEIHDSKN
KYLFKVEFYKSKLDEVSELEYSTTDNNIITLDITLNFDYMKII 
complement(96230..96511)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00107; phage(gi100058)     3.41e-60            
MNYLLELSPIFIVGLICGLSNYLSDEEDTCAGKHIKCILKYIFNSAVLCTIIYCILTSLELPYLTKIGVAGAITYLGIDKAMSLIKEFIHLKK 








complement(98276..98884)           PHAGE_Campyl_PC14_NC_031909: protector from prophage-induced early lysis; PP_00110; phage(gi100001)     2.05e-127           
LQTAINEANKYINYSNKSITIKLISDLVINEYINIVNIHSPFLNIDFNDYSIILNNASYDIGFSMYNSILGHINKLKINCNNKSINTAILLQKNSFCCFYYMKGILNCLGNAF
ALSTNSEAFVSDSTCELSAGSSGYYSKGILSVGSRLLFHTCKFTQNSGTLSQSVETSGIIDNFYTTFSGSVTGKSQVVGTWTKNGYISA 
complement(98869..98994)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: ribonucleotide reductase A subunit; PP_00111; phage(gi100062)     3.96e-14            
MLEYGRSSIKDIIDNSAKLLTSNLEWTVGTGGASSKTCKLL 




complement(99821..99943)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: aerobic ribonucleotide reductase B subunit; PP_00113; phage(gi100063)     1.88e-13            
MINYGNSNIKEIINGSVKILTESKTYTVGRGGGSPNCQML 















complement(103010..103330)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: RNA ligase 1; PP_00116; phage(gi100066)         1.74e-64            
MIINVDKNMFQERMQKQGLSYGASDVLFDYIEQLEDDIGEQIEFDPIAIMSDFSVAEGEDELKDQLETLGYFDMEGDDSDLDDAKQRAINDGVLVYEDDDYYVFKS 













106303..106950                     PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00120; phage(gi100010)         6.98e-158           
MAWNLNNRQNEYQLFGTLSAEIIDMYGFQLTYIKTTRLGHDKVLDDIVNYGTEATYQIFALPENAEMFDERGDILNKFGIFTMDSMNLFVSANTMKRIFQDDSKIPS
AVGDLLLLPSGKYIEITSIEHQVPGANNQFTYSNSKNVYMLRCKSFNYNHDNIPTLEEVNNEEVNESLDEIFNLVGSAENSKDKIKEEQDKESPLVKGTDSVFGYLDS 














109850..110305                     PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00123; phage(gi100100)         1.55e-102           
MKEKAEALGKKLDKINDIFNITEKTIVEVEKSDLVKSNPEENLKFTYLKEDFNLMRESLVNTIKRGQDILEVISNNILADPLSSNQAVMAYSTLVDTINNSTKLLTDIY
KNIVDIQIKIAPKEAEKGSGKQEIMTIAQITKMISKNQQSQN 
complement(110302..110853)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00124; phage(gi100099)         4.96e-112           
MADLKKIEELIALAYGYEYGISHIDESDIDVFIKGFDEKNAEQQLKKADIDLESLLSNNFDKNALIMINYKKYYPIKLYGFNNLIKEFPSLNNINFYGALSGASTIIIKD
DEIMCLVDPNDYEKFKESFDSMLIELMKFIANSNSAEKAMDYLVSNDVGVGSYYNENKELTQMIFNAIELNKA 
complement(110846..111037)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00125; phage(gi100098)         7.00e-26            
MFKKLLNWFMNNFCACILLLYLILLLVIIDGEISLSNVITVIVITGCYIVERIENTIKGNKNG 
complement(111061..111360)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00126; phage(gi100097)         2.60e-62            
MKSSNFKTCKINKKYHCINTKSALVQENYKMEKSKYSVVKEFINLNYNIPIEKIDKETELFFFSIKLLCDIIELCPKHKKEIEDKVGELCDFREYQLES 
complement(111347..111514)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00127; phage(gi100016)         1.02e-29            
MLEYFNCYTSKKELYNYEKLKQELNEHGLNIKDDENSIKEDIDENILKRKNNEIK 
complement(111508..111930)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00128; phage(gi100017)         2.94e-79            
MTNRCFIGILENNNNVKYSFCMYDGNIELAGRILLQNYNKLCELLNIGKDIRFLSNRIDLCNFFEYEYNYNHDVKMNLETFKNIVFDDHYCDIKYIYLFKDGKYYFA
DRNNYKNLLENALEDFICYSMNNEDNLIEEIKC 
complement(112023..112460)         PHAGE_Campyl_PC14_NC_031909: exonuclease A; PP_00129; phage(gi100018)                3.71e-86            
MENYKSVYNDCLLLFLELQKSDDNKKLQIYDLMLKCIKLKLPEITTKENIKKVQEVLKNYKEIETLDKDKTYGTISWYYLLYYIGNVYNIGYKVVFYGTNGRYSYN
DDYFEDIINLYSTITFLKEKLQKGCPDNVSLAVFNKEGN 
complement(112584..113177)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00130; phage(gi100019)         1.36e-72            
MTEIQFNKIKERLTQWREERHLTYENQQAEFFGNVFEKVSEYFRAKDDLEKIDAICDIVIYFFNAFDFKYIAVSSNMYCYTFSDVVVYNIYSLFGARTDNLCVVENE
NDFINLEKNLNLTMFEIEQLYENLDFDFYKCMLEKIKEIESRTGYYDEKLKKFIKDTSDEAKAKWYKADYESCMFEGWEIISKLIKEFKK 
complement(113158..113499)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00131; phage(gi100091)         1.47e-63            
MVSTVFENDYVEVVTRKDAESIVENFIKTCDCDWNDDENCDKCASIDNLKFHLEANRDCNIFVRFKFNKDDKTNLRWSGNLCVNSISEYVENELENDIKVVKYNR
RLNDRNTI 
complement(113543..113746)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00132; phage(gi100022)         1.67e-42            
MNKIKQWTIELMCMFYPIKIKSTAKDNYYISYKFKFNKYYVFGDKGGALFAENYKDALRIVEWMDDN 
complement(113749..113898)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00133; phage(gi100023)         4.33e-28            
MKIEITRDISNVVKKSPEIILNDEFYKLYVKYIGPSEELLFYKNCNKGR 
complement(114125..114601)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00134; phage(gi100084)     5.29e-110           
MYSKFINEAVSDDMLKAINVANWKTGLDFRKDYEEIESHGKKALEILDKLAKGGYNSKQYYNIYSDLRDELWNIHDRLLSYKNKMPWFRDELQSPELKRYREIIK
DYIYEVNQAMKDLKSDYAVVSHISNRNLESIIKAIIDEYERLYEIVEKIALSQ 




complement(114871..115152)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00136; phage(gi100080)         3.56e-57            
MALYKFSVKLYDDKHENIQKFCLIDGKHWHLLKDFRNCLISPDNVYFYDEKDLISISDYEDALKVFKKPIHRRMFIEYGSSYQEPDDKFITEY 
complement(115272..115724)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00137; phage(gi100091)     2.26e-98            
MLLEVVFENFKFCRQDRVEINFDKLYSPDYFKKTFRKVKCKCNPLKSLFFVDCDLPKYILKAIKRDKSLCNEITKDYGVITLTYRQDDFLIDYILKITESEIIQTTDLVY
LDLYLKDENSDCAKTINENTKLKPSEKKALEKVKQFEKIQ 
complement(115835..116149)         PHAGE_Campyl_CP30A_NC_018861: hypothetical protein; PP_00138; phage(gi410493054)     1.39e-68            
MRITFNFEKEYTSTPYARNAEHDKEKNGEDFEKNYLSKWIDEKQETLIKVDNLELPFSDSFVDASFCKLIRQNKKLFYKYIKIDDKTDDEKDLLNTIKEVLARK 
complement(116305..116493)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00139; phage(gi100076)         4.00e-10            
MDKKCRDSYGQIDYLDAYGNYVKTIFESNTERHRNYSGENIRRGNGTKRLEESIKKCKGAKM 
complement(116499..117113)         PHAGE_Campyl_CP81_NC_042112: co-chaperonin for GroEL; PP_00140; phage(gi100075)      6.32e-107           
MIESKFIIKRKLNFKNMEFGYKLFDVSGYFEFVEKPIYPRILEEFKKLDPTMKNKTILNRLRYIDRVRYDLLYDFTFTLAYSKSKLDKTIKNGKDLCEYDLYDLKPDW
LLKMVSDIIDEKTLLKYLPDIFEYMDDIIKSINDNFDLSNNAIFKWFQNVRNYIKLLLDGKIDYKNYCINIDLVIKSNMENALLFEKEVIEELNRC 
complement(117274..117660)         PHAGE_Campyl_PC14_NC_031909: membrane-associated initiation of head vertex; PP_00141; phage(gi100034)     5.89e-75            
MAMILSQEEIDALLECDSRPTNLGIRSIVDKKISELREEHSKLSIKMKAIQGLNLLAHTDDFTIKDYMSIINDLIDCLKYKISHCQSFRDNISNKEAEKEFLKELGSFKLT
LLDFELNMNTGEENGEI 
complement(117739..117894)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00142; phage(gi100072)         2.42e-27            
MRELRGIVFNFYKKYFCKCESCNFREFGKLFKNYFIYLNLFQLYKITDEGI 
complement(118082..118483)         PHAGE_Campyl_CP81_NC_042112: 3'phosphatase, 5'polynucleotide kinase; PP_00143; phage(gi100070)     9.18e-90            
MNNATVISFKFETEQLAFLNNCICYYDDEFYNVKYMCNLSDDEFKRITNFISCMKNNIKYLEINDKNVDIETLINRLGTHIFRYAHTDTPKEHKDTEYMLLKDYLLL
HIKDYGDNELVKQILKKSEELNSKYL 
complement(118534..118977)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00144; phage(gi100038)         2.47e-103           
MPEFKQGFYKPINPEKYIDDVTNIIYRSSWEYKFMLWCDNNAGVLKWASESIVIPYEFLGKKHRYFPDFYIEVKDKDNNIKKYIIEIKPQKDAIFKKPKIITEKNKKRV
VEQALTVSKNQAKWEAAREFCRINNMEFMVLTENELFK 
complement(118977..119360)         PHAGE_Campyl_PC14_NC_031909: RegA; PP_00145; phage(gi100039)                         2.74e-74            
MNESLADYGLDVNGFYKHIDGKESIVETDDFKIKITYDSVNSEFDGDNEELLLKMHCNIELRYIAGIEDAMRVSDEINNKIVEIIEEDLKKYDDVSKYLILVDSGVFID
PDDPDYIQNAYIIIQPKY 
complement(119357..119680)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00146; phage(gi100099)     5.69e-60            
MNIYSIFLNEEVEPQKDLAKKSLDFLGEKLNATHSVSEKGNTLIATYKDKNGNKLCDVNITVNDNNIKVTKVTDNKGKPKQIDLVIHRINDIIGSRMMSYINKVKKQ 
complement(119981..120256)         PHAGE_Weisse_WCP30_NC_031101: DCTP pyrophosphatase; PP_00147; phage(gi100024)        4.39e-05            
MNNKRKNNGTRRFTGYFDKNGNKIYKDDIIIFNDIVHDTNRIGVIIKRQHSGEFRLEFSKDDTLGLKILDESKLLVIGNINENAELLEAKE 
complement(120416..120658)         hypothetical; PP_00148                                                               N/A                 
MKIGTDKNGKEIKIGDVLFCLELVATEVEDEGDEVEYEEFEHYIQVLEKDNEIIVCDLDSDEWWFLHQFSFADYKIVSDY 





complement(121119..121325)         hypothetical; PP_00150                                                               N/A                 
MKEKVQNISIDVNVEELLEQVETEYLLHELSRRPLLYVDITSLIWDTLDEDELKILKKEVHQMIKEKQ 
complement(121660..121830)         PHAGE_Campyl_CP81_NC_042112: aerobic ribonucleotide reductase B subunit; PP_00151; phage(gi100063)     1.03e-30            
MDIKKLKESLEGKDNGKYFCEIFNTNVDILVVDNGMKKSEAIIQVLEDVKELYKND 
complement(121876..122157)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: baseplate subunit; PP_00152; phage(gi100104)     6.97e-53            
MEKVIHKESGKEYSYFKPVLNKTTNEVMICYTDGVNFYVRTKNDFFDKFEILETPEKYDTIKYFHDLVNNKLWALKRQEELLDKVSKFDLSLI 
complement(122164..122406)         PHAGE_Campyl_PC14_NC_031909: ssDNA binding protein; PP_00153; phage(gi100044)        1.85e-46            
MKLIISLLILASMAFSIEVCSFKEPLKRGFFSIDNSIVFLCIDKKLFVRNFPGETDYSYSVTQVFEEGMKPQACSCQAEE 
complement(122403..122570)         PHAGE_Campyl_PC14_NC_031909: loader of DNA helicase; PP_00154; phage(gi100045)       4.14e-21            
MTPKKIQKIFEKVLKEKEKEYTDGRLEEIRKEREYVESIVNEGIQKANNMLKEFK 
















126867..127004                     hypothetical; PP_00158                                                               N/A                 
MSISVYVSNNIVTYSFGFSKCTPTLSNTSKATGKLIKLMIIESTQ 
complement(127032..127403)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00159; phage(gi100111)     6.26e-83            
MKLLVAGSRDFNDYNLLKNKIFELNIQPSTIVCGMTRGADMLGYQYGIDNSLKIEKYKPNWNLYGKSAGPIRNKLMADSLNKETDMAIIFWDGISKGTKNMISILD
DKKINYKIIYYKEKENE 
complement(127400..127606)         PHAGE_Campyl_PC14_NC_031909: recombination endonuclease subunit; PP_00160; phage(gi100052)     4.52e-41            
MFVKIKELICKFVNFKTLQKFITTDRQFIIEGQNGMKYSGDFFFVDEDGCICKISDGSYVGTMVKSSK 













complement(130250..130543)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00163; phage(gi100116)     1.92e-53            
MKRNILLLIFSSFLFIGCSTATKTVTITKKEYLKYPLDEKYIPHKLDVKIMKQKLNGKDYLLILPNDFITIYNQYKHLELNYNNLYDSVEKFNLQIK 





CDS_POSITION                       BLAST_HIT                                                                            EVALUE              PRO_SEQ 
----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- 
 
#### region 1 #### 
complement(4..609)                 PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00001; phage(gi100059)         1.17e-132           
MYSKFLNESSENLWVFAKNDIKLRKLILPVIQDNIEYVMFLNDRSIEEGKLKDICLDIEIFGVFEHYNIGNYKKIEPSIVVNVTDLKKDALKSIEDKLKNCKSKDEPVL
SLKLDMITEYNVARLLEKEYYINNFTDIIQNELKSKQFKIVEGNIGESVVELFNDYGESMIFTLKNNKVIKVNGQVGTKYNYLYSSLVIQKI 






complement(1640..2197)             PHAGE_Campyl_CP81_NC_042112: ssDNA binding protein; PP_00003; phage(gi100044)        4.12e-123           
MKLHYYDIYNISNGVFLTFQKNLKEKLLCVSHSKDIMDKKIGFYPLNFSDRGDFILLCVYIMFKHSPSSIYGLCEYLRNYNKTEYEKFKNTIKFYKNMIKKDIALLEE
KYKKPMFKEVMREYSIKQISFVTVYWYLMLYDIKDFNGINNTIICESILNVFKFLKFTDESKDYIKDVFKQIEGEVL 
complement(2210..2470)             PHAGE_Campyl_PC14_NC_031909: ribonucleotide reductase A subunit; PP_00004; phage(gi100062)     1.45e-48            
VESKTELFNKLFEFRKQKDMMDDCILDVIIEFGNHINMDPELIASELSDYAIFRDIVEKDLKKFKFTKYDPNQSDIDISDIDILWE 
complement(2460..2906)             PHAGE_Campyl_PC14_NC_031909: aerobic ribonucleotide reductase B subunit; PP_00005; phage(gi100063)     2.09e-103           
MCVLKTWLEDSNAKLPEISVMGSACYDIFSIEDKTIQPGGFEYVENGVRLIIPDGYYIRFNTRSSLGFIKDLFVYPGILDASWSGNLKVKVYNFGKEPYTIKKGDKYC
QFELLKCNESKIENISKDDFDNITKKLIRGNNGGWGSSGK 
complement(2894..3286)             PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00006; phage(gi100123)     3.60e-83            
MKNIEILNMVEELVKLNPILLISENFSHTYELLKENVRESKSIENKKIKLNCISVKLDDDTKLPCYGTVLSVLMKDNLENIINKNPQSLLEISFKISINVLLDLIDNFVEIY
DFNNESLLLINRIKICVY 





complement(4619..5023)             PHAGE_Campyl_CP81_NC_042112: RegA; PP_00008; phage(gi100039)                         2.63e-90            
MSYSFEQYCNSNNFNEFQRYLITQLGYINNKNVVAIQDSEYIDVFKAIKQEYYKASSCKHSDKEEVIPEHYTKLAIEPIDFIYKNNLNFCEGNIIKYVSRLGSKDDNKS
ELKKIFFYFDYLLHGNYDLTKRTFS 
complement(5027..5203)             PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00009; phage(gi100126)     1.22e-29            
MTIKNKINDINEILQSYVGELVLSDIDTQKIVENLTELETIIKDAISKQLNNSKLILG 
complement(5259..5825)             PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00010; phage(gi100037)         4.14e-127           
MEKLIYIVIFLCIVFTTTSQSVIFHAKYNFEDIIQERLSYLKQNMINHISKYNNKNATEITNYIFEASLKYNINPVFIMSLIQSESYFKHKVKHKYNNVKGISGINYKMW
KIVLAKHNIKHINSLKNQIEATAIIINYIKQKYKTNDDLEILHYYKGRGYDKYLNKSGLDLAQYSYSMYIKNIKIIYN 
complement(5844..6479)             PHAGE_Campyl_CP81_NC_042112: DNA polymerase; PP_00011; phage(gi100036)               1.02e-146           
MKFNCKNFAKALFYSKDINYLIKLFKYAKQEDKKQAMQILLWARDVNGGNIKNSILLLKYIAEKTNNINDMFLASVVKYGCFKDLNEMYKVASDSNKRKILSFYS
NELKLKNQLAAKWAPRKGPLFYALANSLCLKIGDFRRYITSLYISVEAKMCDNMWDSISLDEIPERAIKKYKKVLEKRLKITIYCRSPKQRRLKFKGCEKLLKQY 





























complement(12993..13442)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00016; phage(gi100133)     2.81e-94            
MNIYAKYLNEFTKSSIKLNEADIDFDDFISEVKEIAGTSGDKLHNPRTSPVFRNYMYSLYINDDGISAEKAWRMFEELNIMDSRKIIQYIEEDDDWYVNRLKDEYNIS
LDDFKQMDEYDQIRTFCEIHNCQYIEGTDNKMYVMLPKYYV 
complement(13495..13755)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00017; phage(gi100134)     5.80e-54            
MDKQLIKDITINGLSQFAKGHEIEAITETLQIVQEYNIEHHSHNFEFDVEPITSLEDFIKEINILITYEDLNLFHEVLVESLKYYK 
13810..14211                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00018; phage(gi100076)         2.46e-86            
MTFVEKNMVKELKKTISSKKPLVLCFMSKLLQKEIQKLLKGNKLITIIKIILYAFDKTPVEVKRGVLGYVENEKNIPFQYKYDNTTKTLTFSLDKKSYNFNLCTANEY
IKVLANETNWMILKKNLNNALKNIK 
complement(14229..14747)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00019; phage(gi100077)         2.15e-119           
MAITNYTEFEKLCPKNGEIADQDVLGKPSLQLKRELDTVMSQVNSIIGITDPSNWDTGTTYTQNQIVKYNNYIYVSLSDGNRGNQPDTSPSKWKKISGGSISSSVNIIV
SSSDYNTPVTEVSDNSLSLKPSKVYVNGNLIPTTNYTHDGTLTKITFINGMSVYKNDVVTVEY 
complement(14780..15421)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00020; phage(gi100078)         2.53e-156           
MGILNTAVGAISDFFGGNKTQSAITELAQKIQKAYSTNFDLESLYSIDTFALKNEVPGAGRINILDLPNMDILIQRVSIDPISFAEINEWIGSSWVYTQGRHELQQLTITF
RDSDGGFLYSAFKKLAGHLKDQYPDDQMWIIKIRKRTLRESRNYINQSVQNNEFKNGGHVIIDTQCAMIRSHGGLSLDQNSNGLATFDVTFLFDPFPPQISY 
15467..16120                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00021; phage(gi100027)         1.41e-152           
MELEIWKGKHSILLNKLYNDNNYIYDSDIIDVLVYKCLNQPKYITNDEARFLFFKKYFAEVCSKIDSSFKCPYCNEMNDIKFTNDDISITEYSLKPIEINVDNVIVTMY
FKKELSQDDSLSLITETKNMIDHEKRLLELYYMIDYISINGEELRGNHIIFEKYINELPLSCFNKIFDYFINSIPKHSIIKNCSCKNCNSEINVELKELPESVRRNLF 
16117..16779                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00022; phage(gi100026)         2.40e-156           
LTKDIIINNRHYCLNVWKIKDEIGILHQFIDWIELPLEDQVNKIADILIPQTKDLDYISRLYIMIILSSYANGDYSDILLTCPHCGNPIDTRINIRENLEFIPPKTVEVEINNK
KYTISKQNIELCNELPLKDYNSILNQLNDDGDLKLCAKVKCIMCNNDVLAIRELKDLFENYVIMLDLEWYYSTLKYFISQLGFSKTDFDNLYPFEIELLTNENKDE 
















20499..20852                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00025; phage(gi100083)         5.63e-80            
MNDTQTIQIFDLIGDSQARDYIAIKAYKIGSDVSGIKDSINDILDDDPSKAFDNLLNMAENNISNIINPSNWEAGPRLKPGVPCKYIWILPIPSSLAEAFSHEFNQDEIDPI
GDMIG 




21643..22104                       PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00027; phage(gi100085)         8.83e-107           
MKNSVLNNKIMVDFNGFSLSPTYSVNIPKLREFMKNNLSMFYVKEMNDNVRFEVLALREYNDSSLWDILMILNFGENGILNFAKGDTWVSDNAENQYKEQQEYFS
PNFKPEDLYNQILSKIQKKNESRRKVIFIKRQFIPQFKESIKDMLNVF 









complement(23996..24337)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00030; phage(gi100147)     1.37e-68            
MFLEDNNKQLSKVLNDNIVIKEDEKNIYIKFKKNIIIESDNNVIFLAKDYIVNSAKEIHLNPDVKISVDDNVDDIIKKIDDKKNEINISVEKLTHNHKHCKIKCFFKKLF
NLN 
complement(24321..24608)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00031; phage(gi100089)         7.88e-64            
MPPVTRLGDIALGHSCYPPSPTIEASSNVFANSIAVHRLGDKIQSHACPDTPPHGRNSSSGSTSVFTNSKATCGIGDAVNCGGIIAQGSNNVFRG 









complement(26227..26673)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00033; phage(gi100014)         3.42e-97            
MEKNYNTFLRKKSVTIKLNDDLKDKLKDTIENINDYDIIKIKLGRTFFNQKRYYKIYARKKFGFYKTLLSENDDSYFFMENTSKIIRRVFNEYDVNCYNLYPNKKYR
YGLSIFILICCSIILIALSLGVGALSYIFKGYFLAFGFSLF 
complement(26733..27305)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00034; phage(gi100092)         3.19e-138           
MGLESGELRNEAQGGYNPPFELSIYKHQVKFTPPNNFESYIKWELLGDIPLHLTINEQTGLITGNIELLSKQPSAKNAIYEYQLMKIDGSNWRHLGILKNGQTFTFNFQ
VKLTYTVQANSGGSRLSNTVTEVSDVTITILQDNDIISTLFCKNYIDEAKFPLKIGDKVYTDAVEFMKNHPNKNNFKINLV 
complement(27322..27849)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00035; phage(gi100012)         1.65e-129           
MPLYTVDKLANALKGGAKSDKYFIEIGTPLGAPEVAFTEEDIILCKTASFPERTLGEVEAFVQGRKLKLPGDSTFDAAWSPVFYQTPDHNIRAKFLTWIDKIDVYKN
NYHTCDPYSLMVTAKVHQVNCNGEPVATYEFFNVWPSKVGEIEVAADKTNSIQEFTVDFTYSHWEKIA 
complement(27878..28456)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00036; phage(gi100094)         1.96e-139           
MSLYNIDRLRSSLKQGGAINSKYKIDIKIPTLLRSLPFFKTVNISGEYLSIMANRTSIPGKSMSTVKVYHRGQPFVIRGAAQFNNTHKITFYNTPDMDIHQLFSDWIYRI
DSFDSTITQSIFLGNYVGFNSVGAGYMSDIIVSQLSSDGRTETEFKLCYTFPIDIAEVELSASGKEISSTEVTFAYTYWERI 
complement(28458..29018)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00037; phage(gi100010)         6.08e-137           
MVESINPPKGYFKIELLDKDRNVIDTFEKHNLVVNGSRPVLASHMAGRSTTPVNKLVLGTRGHIGNNLMMPKTANEGFTAARTQLFAEEEGEFCYHVNFTPPQSDG
QAVVTEDDVGAGSTVEVTNSNNTITYRIELSTTAGNGTLGAVGYTEAGLYAGNDLFCMRTFAVRSKDVSSILRITWTLIF 














complement(32648..32995)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00040; phage(gi100007)         2.88e-75            
VIQYKDINPKNIEKDIINVDTFYVSLKNIVSTTIGDIAGFPEFSNNAQLLFDQYSSVALDAYKTSLKTSIQKFDYRIIVDNINISKGDADNSVYIEIKYRVRDTTISDTASI
KVG 








































complement(42108..42242)           PHAGE_Campyl_PC14_NC_031909: baseplate hub assembly protein; PP_00047; phage(gi100106)     2.63e-21            
MKRDGSIIKSFKREINLQTRFIKNKTKYTRKEKHKKGAIINGFN 
complement(42239..42625)           PHAGE_Campyl_PC14_NC_031909: baseplate hub subunit; PP_00048; phage(gi100107)        1.17e-91            
MDITHSQYEVMVSAYKKDFIPNKNEMNLLNSFMLCRWMSNDIHSVEFANFINNHTDIPINVQYWFARSIMNKVTYMGRPPKEDKLNEYEEAVSKYYNVSFDVAK
QYCSILPKEKQEEVLNMFKGGRIK 
















complement(46722..47069)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00052; phage(gi100180)         1.11e-79            
MNTVYSKYLCESSHYDQYKETRDIETANVEMKNMDRDLEFLKYRIEQKLEKANIEITEPYIEGECIKFALKNYNNEDNKKVKDILYDMRDISWGPISGDYSDMSQG
YEVSLDLED 




complement(47856..48242)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00054; phage(gi100112)         2.17e-85            
MNLISIDYEDKFYRKLLEDELTNFKSYPFKISEDVYWDFRNYGANSIDKPEKEIKLNLSKRKVRFIINRLEYYNENGYWNNVSLIQKHYQEERKLEKLAETHAKTFM
SAVWLCIPIFALLALLKYIFE 


























complement(54605..54952)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00059; phage(gi100007)     7.37e-74            
METKLLNILLNIGEKYGIYFKQNPIEDEYNVEILLWTKESPESWDKIIKDIKTELLVNFTRNIKISSWGKNSVNIKMKLDRLYQVNILYNLEEPKLNITISYPKIINESAY
DNFL 












complement(57285..57413)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00062; phage(gi100010)     9.38e-21            
MTTSGDIATTPSRLTLKRGKIKPKVIKYKQTKTLTLKKLSKN 
complement(57410..57709)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00063; phage(gi100122)         8.28e-63            
MYTKYLYESSLDLQFEVTDQDFDESFLNFNKELPVSLSETLKLKYNIKLSLKFQSKYDDIGILVKLNDNGKYVVYSNSIENIDKFIIFVDTLNQNKGNL 
complement(57699..58199)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00064; phage(gi100012)     3.95e-117           
MANKSKSKGNTFERTVAKMLSDNYADVFNVAQSFQRNISSGSMFGGSNSYRGMNVLDEHTFYAGDIICPSEFKYTVECKHYATAPSFNSLIIQECAQWDKWILQV
EADCEISNKLPMLVVKYDNIKPFVFIKHNFEGFIFKYRDYYAYNFEMFIKEYKKELINNVY 
complement(58216..58593)           PHAGE_Campyl_PC14_NC_031909: cytosine-specific methyltransferase; PP_00065; phage(gi100124)     1.45e-84            
MKVQFINSKELSANVVSTKNLHKLNRKILVPGVVDISGTIYLASPSKELPTIRVEMDAVFKCGECSSFKIKHYVVNKKVYGSNSEIYDGISKFLRKYAKLILVSKDEI
MFFNYTYTGFAKYFKNK 




complement(59500..60081)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00067; phage(gi100126)         2.28e-137           
MVTYEEIQQLIRNCLDVGIKAPASAYSKLLRHGYCVMYGGDAKFNKLEELEDNFDVKQFDRDTWVIKEYKKELTPEEWKDVNSQALYNGGTPDQIAKDIEDGEK
NPILENAFNKLDEAKLKQISKDDLKNIWNENDLETKREKTLKLISELKYKSPSLEKIIDIIKTTKDKNKIDQIITNIMFVGTGDKVIKI 




































complement(68223..68852)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00074; phage(gi100159)         9.26e-153           
MKLIIEEPVKIKGSVELNESKGEKNYYIQGIFATINQQNINGRVYPRPIWESAVNSYQHHITTPTTSSLMEYQHPNRQYVDPLEAVAKIVDLRIEGDYVMGKAKLLDN
PKANQLKNLIDEGISIGVSSRGCGELMNGTVTEYELITFDIVPNPSDRNAHTKGLNESFDNGILKDKNYIKDKNGILVEADESNINNKSITSQFVDLFSQL 
complement(68849..69016)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00075; phage(gi100158)         1.84e-30            
MYNYIKYAERKDMNGLSNVIQKKLQQEYNNHPKVVNHIETIKKNEALIKVLKEYK 













complement(71498..71818)           hypothetical; PP_00078                                                               N/A                 
MLKLPCTVPPNSIACISVGVITKPPGILNPKKPPPLGYIRNVITSEILESNLIFLTPLGRSINSVPFNLPYIANSENFCIVKLIFSSIWKSVSSTVITGEPNIPKI 
71817..72203                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00079; phage(gi100155)         1.42e-89            
MQNVYSVLANMSILDTYFTIIPNYAFNPFTNMLEFFEDITSEKVLLEVRYKYIPEEEDGIYEQPWVKEYALNLCKRTWGSNIGKYDAPLIGGIKANYERIIQEANTELE
RLETVLLENYCEPLPLLRG 






73590..73811                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00081; phage(gi100153)         8.05e-44            
MPPIKHMSVADRIAQKRYRKQPKVKRKLKIRAKKNAKAPSENMSWSSKKRGYVRKDPKLRRTMKLVAKLRRKS 
















complement(76735..77031)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00085; phage(gi100144)         8.84e-65            
MDNFDVNSFKIVHPHDVLLEVAYPSEIKSESGIIVTVHPSLIDDRQTQGKVLQIGSEVKDIEIGDTVVFGKQHGIDLHKNDKVKYMLIRDESLMGILR 
complement(77087..77596)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00086; phage(gi100145)         1.27e-115           
MAKLILQRNKEYKDIKWQNSDKIEDSTIGELSLLDDNDNVIFKCASCENIGPSTDESGTDKRIVAREYKLKWCNSSKNGLLSKKYPEWKADNGSNIAIWVVSDEVE
GFNNRLIRIHTGNAPQHTEGCILPGSDLNNGTVGSSVDITHKLFTKIKELGIENIVFEIKEID 
complement(77599..78096)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00087; phage(gi100146)         5.63e-113           
MYYSNVVFPLNEVIPGFTYNVKKSKSNIYIRFVAYGYSVDDLEIVYNNSIITISTIKDYHEVKTDPKFSNNFPQQDKFYIQFWCPKISGINAEYSGNFIKLNCSLGDTSV
NLGVVPIKFINEDNDIDILENTSDDTMNIIQLNGFMDKLEDTKDDFDSEITNNKD 
complement(78131..78274)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00088; phage(gi100146)         5.64e-25            
MVEIIASFFVGGLIGFIAGYFVYHNNKKKASEIGDKIESVKDEIIKK 















complement(82287..82706)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00091; phage(gi100038)     4.38e-96            
MTIDDLKSFHKKIIEEYDMDSNWNPSTIKHHLTTLSGTIAKYLNYWSRLKHIIIQIDEEYNEKYMILYSHYRENSNINYTVTEIKDLISKDNELCNIRVKKSTAILIMEYI
EKCVDNLNKTRYDLSNYIEIEKFLNGKG 












complement(85755..86399)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00094; phage(gi100134)         2.20e-149           
MILTFDPYYDIKESNEFIKNLKENKINFNTYILSKSPYYWFYEVADKYKPVFLKFNEANSTDLRFMLPKLKELTPSDENYLRRIPKTPSDFERYVSPNIFKKAKYAEYF
CVFRYKNISEINKITETLGIKIYILPKKVKEWNIAFTFNKMIRNFVFGHYILLEKTKKTQFNKVGEIELYLNNKVFVTDKMKFKTRELPFSEDGTYYPLKFQIKQ 









complement(88308..88652)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00097; phage(gi100130)         2.13e-71            
MENIDEFIELKSQKLNVTDFIEKNSINEDELVKNAIKQIFDLEKQKREIDVEIRDIKTKLSKDGINITEFNRVLSTLKNELKMSIDSLSANISMYNSIVSDKELLQNLKDQ
IND 
complement(88709..89323)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00098; phage(gi100157)         5.27e-142           
MKLFEKLEEWLKERHLDKKEYDHLTLLGYLHEEIDEGIKKRDSEHESIDWRCDCIVFLINSLYQDGYNPKICMDECLKEIEERTGEYSESERKFKKHMGAYTYKEA
LDEIIKNYNCRKEDITLHGDHREFWYFLVNGKQIKVKKWYKADYSKSIRDDISNERYITKAYKLGKKIMFRQLNTKNRWKLLRDENLNFKEFDYKVVD 












complement(92501..92890)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00100; phage(gi100161)         5.90e-82            
MKFIECIQILLENNSIGSLSLENDYIKIYKDNDKLKIVDSKDNNVLLSSEHINNENWELNNKLFELILGSMWINDSDIVTKVEDNSFYNNIQYTTFRNMLTNEISILESD
KYYTNYCKNKWFQPEPLKV 
complement(92887..93327)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00101; phage(gi100162)         2.30e-102           
MENISKDLITIYRYGNNFELYNDFYFIFDFDVTSKGFKLEKYLVGNNIIRIPKGFRTDFGSIPQLFQSIISPVGKPTKAYVLHDFLCGKSNKGDIPRALADELFLDAMKL
LGVNVVKRYVVWAWVRVYGIIYKPLAKFFKDIWNKL 
complement(93329..93832)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: recombination endonuclease subunit; PP_00102; phage(gi100052)     2.97e-114           
MIKLIIGPMRSGKSLELLREAEKLHFGRKKYILIRPEIDDREFISRSYKTLHNLNVIKTNNINTIVNEYDYILLDEFQFFDNSITNIIIDNISKNWILCGLNINYESKLFENII
NILPYADRICKLSSICEKCGSEYGNHNISNTGEICIGDDYTILCSTCKLQLKG 
complement(93829..94038)           PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00103; phage(gi100121)         1.26e-33            
MQIEDVVIDTFKSILILLISAIMLKVYVILFLIISLGVLYYDLTIGIPVTATLMFISIYLANKFEKFIS 




complement(94945..95451)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00105; phage(gi100166)         2.51e-115           
MKKVLCSAVMVAGLMFVGCSTTTPQQFAKPMLEKYDDLPSWVKEYGDIDTAVGSAMYMGQNYIQQQTEAIAVAKMNLTQKLSSKVDSMIKQYYQNKGVVKTN
NSQVSVQVSSSLVKNVKVVDTYVADDGELFVKIEAYSTNLLETIKNDDSKSLFDELDRRVGNVKSN 
complement(95538..95864)           PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00106; phage(gi100167)         1.23e-72            
MYFSLKETLEFLSTNSKNGVWEYDDISEADTTVFCSYFSDNSDENDIYIILSNPTGKSDIDLQGNVTDTDSEDGIPDRFSTCIMKVNLAKLNISNFDELGNAIKKYRL 
95950..96405                       PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00107; phage(gi100117)         2.54e-105           
MNFRNIALNSNIVFRTLLFSDDTQYYCQKVKLPRISLEGQKVGHSTGTLTLGGEVAKFDSITLTLLVDENLEVWKNFVNLINKYNKISTNTGCGIEATSWLEIHDSKN
KYLFKVEFYKSKLDEVSELEYSTTDNNIITLDITLNFDYMKII 
complement(96406..96687)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00108; phage(gi100058)     3.41e-60            
MNYLLELSPIFIVGLICGLSNYLSDEEDTCAGKHIKCILKYIFNSAVLCTIIYCILTSLELPYLTKIGVAGAITYLGIDKAMSLIKEFIHLKK 










complement(98452..99060)           PHAGE_Campyl_PC14_NC_031909: protector from prophage-induced early lysis; PP_00111; phage(gi100001)     2.05e-127           
LQTAINEANKYINYSNKSITIKLISDLVINEYINIVNIHSPFLNIDFNDYSIILNNASYDIGFSMYNSILGHINKLKINCNNKSINTAILLQKNSFCCFYYMKGILNCLGNAF
ALSTNSEAFVSDSTCELSAGSSGYYSKGILSVGSRLLFHTCKFTQNSGTLSQSVETSGIIDNFYTTFSGSVTGKSQVVGTWTKNGYISA 
complement(99045..99170)           PHAGE_Campyl_vB_CjeM_Los1_NC_041896: ribonucleotide reductase A subunit; PP_00112; phage(gi100062)     3.96e-14            
MLEYGRSSIKDIIDNSAKLLTSNLEWTVGTGGASSKTCKLL 




complement(99997..100119)          PHAGE_Campyl_vB_CjeM_Los1_NC_041896: aerobic ribonucleotide reductase B subunit; PP_00114; phage(gi100063)     1.88e-13            
MINYGNSNIKEIINGSVKILTESKTYTVGRGGGSPNCQML 













complement(103186..103506)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: RNA ligase 1; PP_00117; phage(gi100066)         1.74e-64            
MIINVDKNMFQERMQKQGLSYGASDVLFDYIEQLEDDIGEQIEFDPIAIMSDFSVAEGEDELKDQLETLGYFDMEGDDSDLDDAKQRAINDGVLVYEDDDYYVFKS 















106479..107126                     PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00121; phage(gi100010)         6.98e-158           
MAWNLNNRQNEYQLFGTLSAEIIDMYGFQLTYIKTTRLGHDKVLDDIVNYGTEATYQIFALPENAEMFDERGDILNKFGIFTMDSMNLFVSANTMKRIFQDDSKIPS
AVGDLLLLPSGKYIEITSIEHQVPGANNQFTYSNSKNVYMLRCKSFNYNHDNIPTLEEVNNEEVNESLDEIFNLVGSAENSKDKIKEEQDKESPLVKGTDSVFGYLDS 














110026..110481                     PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00124; phage(gi100100)         1.55e-102           
MKEKAEALGKKLDKINDIFNITEKTIVEVEKSDLVKSNPEENLKFTYLKEDFNLMRESLVNTIKRGQDILEVISNNILADPLSSNQAVMAYSTLVDTINNSTKLLTDIY
KNIVDIQIKIAPKEAEKGSGKQEIMTIAQITKMISKNQQSQN 
complement(110478..111029)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00125; phage(gi100099)         4.96e-112           
MADLKKIEELIALAYGYEYGISHIDESDIDVFIKGFDEKNAEQQLKKADIDLESLLSNNFDKNALIMINYKKYYPIKLYGFNNLIKEFPSLNNINFYGALSGASTIIIKD
DEIMCLVDPNDYEKFKESFDSMLIELMKFIANSNSAEKAMDYLVSNDVGVGSYYNENKELTQMIFNAIELNKA 
complement(111022..111213)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00126; phage(gi100098)         7.00e-26            
MFKKLLNWFMNNFCACILLLYLILLLVIIDGEISLSNVITVIVITGCYIVERIENTIKGNKNG 
complement(111237..111536)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00127; phage(gi100097)         2.60e-62            
MKSSNFKTCKINKKYHCINTKSALVQENYKMEKSKYSVVKEFINLNYNIPIEKIDKETELFFFSIKLLCDIIELCPKHKKEIEDKVGELCDFREYQLES 
complement(111523..111690)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00128; phage(gi100016)         1.02e-29            
MLEYFNCYTSKKELYNYEKLKQELNEHGLNIKDDENSIKEDIDENILKRKNNEIK 
complement(111684..112106)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00129; phage(gi100017)         2.94e-79            
MTNRCFIGILENNNNVKYSFCMYDGNIELAGRILLQNYNKLCELLNIGKDIRFLSNRIDLCNFFEYEYNYNHDVKMNLETFKNIVFDDHYCDIKYIYLFKDGKYYFA
DRNNYKNLLENALEDFICYSMNNEDNLIEEIKC 
complement(112199..112636)         PHAGE_Campyl_PC14_NC_031909: exonuclease A; PP_00130; phage(gi100018)                3.71e-86            
MENYKSVYNDCLLLFLELQKSDDNKKLQIYDLMLKCIKLKLPEITTKENIKKVQEVLKNYKEIETLDKDKTYGTISWYYLLYYIGNVYNIGYKVVFYGTNGRYSYN
DDYFEDIINLYSTITFLKEKLQKGCPDNVSLAVFNKEGN 
complement(112760..113353)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00131; phage(gi100019)         1.36e-72            
MTEIQFNKIKERLTQWREERHLTYENQQAEFFGNVFEKVSEYFRAKDDLEKIDAICDIVIYFFNAFDFKYIAVSSNMYCYTFSDVVVYNIYSLFGARTDNLCVVENE
NDFINLEKNLNLTMFEIEQLYENLDFDFYKCMLEKIKEIESRTGYYDEKLKKFIKDTSDEAKAKWYKADYESCMFEGWEIISKLIKEFKK 
complement(113334..113675)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00132; phage(gi100091)         1.47e-63            
MVSTVFENDYVEVVTRKDAESIVENFIKTCDCDWNDDENCDKCASIDNLKFHLEANRDCNIFVRFKFNKDDKTNLRWSGNLCVNSISEYVENELENDIKVVKYNR
RLNDRNTI 
complement(113719..113922)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00133; phage(gi100022)         1.67e-42            
MNKIKQWTIELMCMFYPIKIKSTAKDNYYISYKFKFNKYYVFGDKGGALFAENYKDALRIVEWMDDN 
complement(113925..114074)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00134; phage(gi100023)         4.33e-28            
MKIEITRDISNVVKKSPEIILNDEFYKLYVKYIGPSEELLFYKNCNKGR 
complement(114301..114777)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00135; phage(gi100084)     5.29e-110           
MYSKFINEAVSDDMLKAINVANWKTGLDFRKDYEEIESHGKKALEILDKLAKGGYNSKQYYNIYSDLRDELWNIHDRLLSYKNKMPWFRDELQSPELKRYREIIK
DYIYEVNQAMKDLKSDYAVVSHISNRNLESIIKAIIDEYERLYEIVEKIALSQ 




complement(115047..115328)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00137; phage(gi100080)         3.56e-57            
MALYKFSVKLYDDKHENIQKFCLIDGKHWHLLKDFRNCLISPDNVYFYDEKDLISISDYEDALKVFKKPIHRRMFIEYGSSYQEPDDKFITEY 
complement(115448..115900)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00138; phage(gi100091)     2.26e-98            
MLLEVVFENFKFCRQDRVEINFDKLYSPDYFKKTFRKVKCKCNPLKSLFFVDCDLPKYILKAIKRDKSLCNEITKDYGVITLTYRQDDFLIDYILKITESEIIQTTDLVY
LDLYLKDENSDCAKTINENTKLKPSEKKALEKVKQFEKIQ 
complement(116011..116325)         PHAGE_Campyl_CP30A_NC_018861: hypothetical protein; PP_00139; phage(gi410493054)     1.39e-68            
MRITFNFEKEYTSTPYARNAEHDKEKNGEDFEKNYLSKWIDEKQETLIKVDNLELPFSDSFVDASFCKLIRQNKKLFYKYIKIDDKTDDEKDLLNTIKEVLARK 
complement(116481..116669)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00140; phage(gi100076)         4.00e-10            
MDKKCRDSYGQIDYLDAYGNYVKTIFESNTERHRNYSGENIRRGNGTKRLEESIKKCKGAKM 
complement(116675..117289)         PHAGE_Campyl_CP81_NC_042112: co-chaperonin for GroEL; PP_00141; phage(gi100075)      6.32e-107           
MIESKFIIKRKLNFKNMEFGYKLFDVSGYFEFVEKPIYPRILEEFKKLDPTMKNKTILNRLRYIDRVRYDLLYDFTFTLAYSKSKLDKTIKNGKDLCEYDLYDLKPDW
LLKMVSDIIDEKTLLKYLPDIFEYMDDIIKSINDNFDLSNNAIFKWFQNVRNYIKLLLDGKIDYKNYCINIDLVIKSNMENALLFEKEVIEELNRC 
complement(117450..117836)         PHAGE_Campyl_PC14_NC_031909: membrane-associated initiation of head vertex; PP_00142; phage(gi100034)     5.89e-75            
MAMILSQEEIDALLECDSRPTNLGIRSIVDKKISELREEHSKLSIKMKAIQGLNLLAHTDDFTIKDYMSIINDLIDCLKYKISHCQSFRDNISNKEAEKEFLKELGSFKLT
LLDFELNMNTGEENGEI 
complement(117915..118070)         PHAGE_Campyl_CP81_NC_042112: hypothetical protein; PP_00143; phage(gi100072)         2.42e-27            
MRELRGIVFNFYKKYFCKCESCNFREFGKLFKNYFIYLNLFQLYKITDEGI 
complement(118258..118659)         PHAGE_Campyl_CP81_NC_042112: 3'phosphatase, 5'polynucleotide kinase; PP_00144; phage(gi100070)     9.18e-90            
MNNATVISFKFETEQLAFLNNCICYYDDEFYNVKYMCNLSDDEFKRITNFISCMKNNIKYLEINDKNVDIETLINRLGTHIFRYAHTDTPKEHKDTEYMLLKDYLLL
HIKDYGDNELVKQILKKSEELNSKYL 
complement(118710..119153)         PHAGE_Campyl_PC14_NC_031909: hypothetical protein; PP_00145; phage(gi100038)         2.47e-103           
MPEFKQGFYKPINPEKYIDDVTNIIYRSSWEYKFMLWCDNNAGVLKWASESIVIPYEFLGKKHRYFPDFYIEVKDKDNNIKKYIIEIKPQKDAIFKKPKIITEKNKKRV
VEQALTVSKNQAKWEAAREFCRINNMEFMVLTENELFK 
complement(119153..119536)         PHAGE_Campyl_PC14_NC_031909: RegA; PP_00146; phage(gi100039)                         2.74e-74            
MNESLADYGLDVNGFYKHIDGKESIVETDDFKIKITYDSVNSEFDGDNEELLLKMHCNIELRYIAGIEDAMRVSDEINNKIVEIIEEDLKKYDDVSKYLILVDSGVFID
PDDPDYIQNAYIIIQPKY 
complement(119533..119856)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00147; phage(gi100099)     5.69e-60            
MNIYSIFLNEEVEPQKDLAKKSLDFLGEKLNATHSVSEKGNTLIATYKDKNGNKLCDVNITVNDNNIKVTKVTDNKGKPKQIDLVIHRINDIIGSRMMSYINKVKKQ 
complement(120157..120432)         PHAGE_Weisse_WCP30_NC_031101: DCTP pyrophosphatase; PP_00148; phage(gi100024)        4.39e-05            
MNNKRKNNGTRRFTGYFDKNGNKIYKDDIIIFNDIVHDTNRIGVIIKRQHSGEFRLEFSKDDTLGLKILDESKLLVIGNINENAELLEAKE 
complement(120592..120834)         hypothetical; PP_00149                                                               N/A                 
MKIGTDKNGKEIKIGDVLFCLELVATEVEDEGDEVEYEEFEHYIQVLEKDNEIIVCDLDSDEWWFLHQFSFADYKIVSDY 





complement(121295..121501)         hypothetical; PP_00151                                                               N/A                 
MKEKVQNISIDVNVEELLEQVETEYLLHELSRRPLLYVDITSLIWDTLDEDELKILKKEVHQMIKEKQ 
complement(121836..122006)         PHAGE_Campyl_CP81_NC_042112: aerobic ribonucleotide reductase B subunit; PP_00152; phage(gi100063)     1.03e-30            
MDIKKLKESLEGKDNGKYFCEIFNTNVDILVVDNGMKKSEAIIQVLEDVKELYKND 
complement(122052..122333)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: baseplate subunit; PP_00153; phage(gi100104)     6.97e-53            
MEKVIHKESGKEYSYFKPVLNKTTNEVMICYTDGVNFYVRTKNDFFDKFEILETPEKYDTIKYFHDLVNNKLWALKRQEELLDKVSKFDLSLI 
complement(122340..122582)         PHAGE_Campyl_PC14_NC_031909: ssDNA binding protein; PP_00154; phage(gi100044)        1.85e-46            
MKLIISLLILASMAFSIEVCSFKEPLKRGFFSIDNSIVFLCIDKKLFVRNFPGETDYSYSVTQVFEEGMKPQACSCQAEE 
complement(122579..122746)         PHAGE_Campyl_PC14_NC_031909: loader of DNA helicase; PP_00155; phage(gi100045)       4.14e-21            
MTPKKIQKIFEKVLKEKEKEYTDGRLEEIRKEREYVESIVNEGIQKANNMLKEFK 
















complement(126856..127074)         PHAGE_Campyl_CP81_NC_042112: recombination endonuclease subunit; PP_00160; phage(gi100054)     1.92e-41            
MLFETYTDMLIWSFIIICCMLLLVTNKYTTKLYNIVVSLSVVYIMYNFISNCIELYSLYNLIYVEQFFDVNE 
127043..127180                     hypothetical; PP_00159                                                               N/A                 
MSISVYVSNNIVTYSFGFSKCTPTLSNTSKATGKLIKLMIIESTQ 
complement(127208..127579)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00161; phage(gi100111)     6.26e-83            
MKLLVAGSRDFNDYNLLKNKIFELNIQPSTIVCGMTRGADMLGYQYGIDNSLKIEKYKPNWNLYGKSAGPIRNKLMADSLNKETDMAIIFWDGISKGTKNMISILD
DKKINYKIIYYKEKENE 
complement(127576..127782)         PHAGE_Campyl_PC14_NC_031909: recombination endonuclease subunit; PP_00162; phage(gi100052)     4.52e-41            
MFVKIKELICKFVNFKTLQKFITTDRQFIIEGQNGMKYSGDFFFVDEDGCICKISDGSYVGTMVKSSK 













complement(130426..130719)         PHAGE_Campyl_vB_CjeM_Los1_NC_041896: hypothetical protein; PP_00165; phage(gi100116)     1.92e-53            
MKRNILLLIFSSFLFIGCSTATKTVTITKKEYLKYPLDEKYIPHKLDVKIMKQKLNGKDYLLILPNDFITIYNQYKHLELNYNNLYDSVEKFNLQIK 
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A biocontrol option to control a foodborne pathogen; using Campylobacter bacteriophages to 
control Campylobacter in poultry 
Chinivasagam, H.N. 1, Estella, W. 1, Cockerill, S. 1, Maddock, L. 1, Mayer, D. 1., Billington, C. 2, 
Premaratne, A. 2, Liang, L. 3, Connerton, P. L 3, Connerton, I. F3. 
Department of Agriculture and Fisheries, Queensland, Australia1 
Institute of Environmental Science and Research (ESR), New Zealand2 
University of Nottingham, United Kingdom3 
Campylobacter is a leading cause of foodborne illnesses both in Australia and internationally and is a 
commensal in poultry. There is a need for environmentally friendly options to support the current 
farm management strategies that address food-safety. The use of bacteriophages provides a safe 
biocontrol option. A collaborative study by the Department of Agriculture and Fisheries (QLD), the 
University of Nottingham (UK) and the Institute of Environmental Science and Research (NZ) is in 
progress. Campylobacter bacteriophages were sourced from Queensland poultry farms and following 
extensive screening, suitable candidates to be used in cocktails were identified. This followed an on-
farm proof of concept study on a small sample of chickens, using selected cocktail candidates, to 
provide an understanding for practical application. The trial demonstrated a 2-log reduction of 
Campylobacter in the caeca of treated birds (compared to control) (P < 0.05). Another important 
finding of this study was the absence of bacteriophage resistance, a concern with phage therapy.  
Work at ESR has addressed approaches to select and adapt bacteriophage cocktails to particular hosts, 
which included screening against NZ and Australian hosts. This approach enabling the formulation of 
high performing bacteriophage cocktails for Australian and international markets. Work in the UK is 
exploring the understanding of the host-bacteriophage relationships to ensure safety to meet 
regulatory requirements and support potential scale-up options. In summary, the work in progress via 
international collaborations is aimed at delivering a safe biocontrol option that can meet both 
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Campylobacter naturally colonises the chicken gut, where it can 
reach high numbers and potentially contaminate the marketed 
product. A low number of organisms can cause human illness. 
This study explored a biocontrol option using bacteriophages 
(phages) to reduce Campylobacter numbers in chickens. 
Bacteriophages are viruses that infect and kill the target bacteria.  
These specific, Campylobacter-killing phages occur naturally in 
farm chickens, where they are already in a ‘predator–prey 
relationship’ with Campylobacter. The aim of this study is to 
better the outcome of this natural phenomenon.  The study builds 
upon data from previous studies to progress the option of using 
Campylobacter bacteriophages to control Campylobacter levels in 
poultry. 
Campylobacter phages sourced during a previous study were 
narrowed down to a 23-member cocktail candidate panel by 
screening against farm campylobacters. The outcomes of the 
laboratory studies undertaken provided a detailed understanding 
of the phage candidates.  Some phages were subjected to detailed 
molecular analysis. With an understanding, the selected 
candidates were mixed as cocktails, which included all Australian 
phages or Australian candidates with the inclusion of New 
Zealand phages.  The combined Australian and New Zealand 
phages cocktails performed the best against farm campylobacters 
from both countries.  
The work undertaken provided a detailed understanding of 
phages, the approaches adopted demonstrated the potential 
progressing to a more advanced stage in working with these 
phages to develop a biocontrol option to control Campylobacter in 
poultry. 
In summary: 
• Poultry are a major source of Campylobacter, with the most 
important single source of campylobacteriosis considered to 
be broiler meat.   
• Modelling indicates that on-farm poultry interventions can be 
very effective in reducing human infections.   
• Development and validation of on-farm control options for 
reducing Campylobacter levels by 1.0 to 2.0 logs can 
realistically result in a 90% reduction of human infections. 
• This study is progressing towards delivering an 
environmentally compatible option for the industry to achieve 
these reductions in Campylobacter on-farm 
There is need to formulate and address selection of cocktails from 
a scale up perspective to ensure a viable commercialisation 
pathway to market 
There is need to seek potential commercial entities to understand 
the way forward in providing a Australian regulatory frame work 
for the use of phages as bio-control agents by the Australian 
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